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Abstract
The equine pathogens EHV-1 and -4 exert dramatic detrimental effects upon the 
equine population. Infection with either virus can directly or indirectly lead to 
the death of valuable animals although the outcome of EHV-4 infection is 
usually less severe than that of EHV-1 infection. The main consequences of 
EHV-1 associated outbreaks include abortion and/or paralysis. EHV-1 induced 
paralytic disease occurs less frequently than abortigenic disease but can result in 
the direct or indirect loss of animals of any age or sex. It is because of this 
that the paralytic form is most feared since it may lead to the loss of 
established sporting or stud animals. Clinically apparent EHV-4 infections are 
quite common whereas episodes associated with EHV-1 are less frequent. The 
epidemiology of EHV-1 and 4 is inextricably linked from the point of view of 
disease management since the initial stages of infection with either virus are 
similar but result in dramatically different consequences.
The objective of the research carried out in this thesis was to identify molecular 
components of EHV-1 and -4 with a view to the development of diagnostic 
systems for these viruses.
The identification of an EHV-1 paralysis inducing strain-specific marker would 
allow the epidemiological monitoring of such strains in the circulating strain 
population and possibly allow the identification of animals most at risk from this 
potentially devastating condition. Chapter 3 describes the search for such a 
marker in EHV-1 glycoprotein C (gC). This search was initiated by obtaining 
partial DNA sequence data from the gC gene of a number of different strains of 
EHV-1 with different disease associations. The enigmatic nature of this data 
necessitated further investigation, described in chapter 4, of the nature of the 
gC gene and the encoded gC protein from certain EHV-1 isolates.
The ability to distinguish EHV-1 from EHV-4 infected animals on the basis of 
serology has been shown to be of epidemiological and clinical value, especially 
given the need for rapid identification and management of EHV-1 infected horses 
against a background of relatively prevalent EHV-4 infection. Few antibody 
capture reagents have been forthcoming that would be useful for such type- 
specific diagnostic serology. This may seem suprising from a simplified 
perspective given the wealth of data generated in the past 20 years on EHV-1 
and -4 glycoproteins which are the main targets of the equine humoral immune 
response to these viruses. Chapter 5 describes the utilisation of this glycoprotein 
data to identify potentially useful peptides. These peptides were subsequently 
assessed by Pepscan ELISA using sera from naturally and experimentally 
infected horses in order to identify peptides or combinations of peptides that 
would be potentially useful type-specific diagnostic antibody-capture reagents.
Regions of the EHV-1 and -4 glycoprotein G (gG) homologues have previously 
been shown to be valuable serological type-specific diagnostic reagents. Chapter 
6 describes the identification and the assessment of the diagnostic value of 
peptides representing epitopes in these regions.
“The Truth is out there”
Opening credits of The X files.
Chapter One
A General Introduction to the Herpesviridae,
EHV-1 and EHV-4
Chapter One: General Introduction to the Herpesviridae, EHV-1 and EHV-4
1.1 A SUMMARY OF HERPESVIRUS CHARACTERISTICS
1.1.1 STRUCTURE OF A TYPICAL HERPESVIRUS VIRION
All herpesviruses have very similar morphology (see figure 1.1). The size of 
the herpesvirus particle was shown to range from 120-300nm in diameter as
determined by electron microscopic techniques (Roizman and Furlong, 1974).
Considering the virion from the outside in, the first entities encountered are
heterogeneous spike-like structures formed by viral glycoproteins and possibly other 
virus encoded proteins that contain membrane spanning domains (MacLean et al., 
1991; Baines et al., 1991). These structures extend from the surface of the virus 
particle and are rooted in the viral envelope (Stannard et al., 1987). The envelope, 
a lipid bilayer derived from host cell membranes, is separated from the virus 
nucleocapsid by the tegument, a proteinaceous layer that is not well defined. Until 
recently variations in the size and shape of each virion were attributed to 
differences in the envelope and tegument; however, refinements of electron 
microscopic procedures for visualising virus particles have shown these structures to 
possess greater uniformity than originally thought (Rixon, 1993). The nucleocapsid 
consists of protein structures called capsomeres which are arranged to give the 
nucleocapsid a distinct icosahedral shape (Schrag et al., 1989; Baker et al., 1990). 
The icosahedron contains the virus nucleic acid, a large linear dsDNA molecule. 
Although still contentious most recent evidence (Puvion-Dutilleul et al., 1987; Booy 
et al., 1991) suggests that for HSV-1 at least, the viral genome fills the capsid 
interior and is most likely not structurally associated with any protein as purported 
by earlier studies (Furlong et al., 1972).
Variations of this basic structure, the most notable being light particles 
(Szilagyi and Cunningham, 1991), can arise during the life-cycle of some 
herpesviruses but these generally do not interfere with the identification of a 
herpesvirus.
Once a virus has been tentatively identified as a herpesvirus attempts are 
made to place it in one of the herpesvirus sub-families.
1
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Figure 1.1 Schematic representation of a herpesvirus virion.
(Kindly provided by Prof. D.E. Onions)
Chapter One: General Introduction to the Herpesviridae, EHV-1 and EHV-4
1.1.2 HERPESVIRUS CLASSIFICATION
In 1995 herpesvirus-like DNA was discovered in homosexual men with 
Karposis sarcoma and infectious virus subsequently isolated (Renne et a l, 1996). 
This highly publicised discovery represents the eighth herpesvirus identified in 
humans thus far. It is likely that more will be discovered which will add to the
long list of this virus family, the Herpesviridae, that affects many different species
(Roizman and Baines, 1991). Given the potential enormity of this family which has
over 100 members, separating them into well defined groups would be of
academic, medical and environmental importance.
Classification remains a formidable task, the perfect system being one that 
allows a new member to be rapidly classified on the basis of genetic and biological 
relatedness to well characterised members of the Herpesviridae. A system was 
devised that divided the Herpesviridae into three sub-families namely the a, p, and 
y herpesvirinae (see table 1.1) (Roizman, 1982). A herpesvirus is defined as a 
member of one of the sub-families mainly on the basis of its in vitro and in vivo 
growth characteristics. The availability of viral DNA sequence may also aid in 
classification. Although the classification system is essentially quite simple 
complications can arise in that a virus, an example being Marek's disease virus 
(MDV), may have the growth characteristics of a y herpesvirus while DNA 
sequence information and genome organisation may indicate an a  herpesvirus 
classification (Buckmaster et al., 1988). Such anomalies reinforce the idea that a 
reductionist classification system would not suffice in that the concerted action of 
genes in giving rise to a given characteristic must be considered e.g. with reference 
to MDV, divergent groups of genes in y and a  herpesviruses have similar 
phenotypic effects.
1.1.3 PROPERTIES OF HERPESVIRUS GENOMES
In a herpesvirus virion the viral genome consists of a single linear double 
stranded DNA molecule of molecular weight 80-150 x 10^ daltons. Herpesvirus 
DNAs range in size and percentage GC base composition from approximately 120 
to 235 kilobase pairs (Kbp) and 32 to 75% respectively. Technological advances of
2
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Chapter One: General Introduction to the Herpesviridae, EHV-1 and EHV-4
the last fifteen years have made the task of completely sequencing herpesvirus 
DNAs possible. As alluded to earlier, partial sequence data has aided in 
classification in that it has been possible to calculate evolutionary relationships 
among herpesviruses by comparing specific protein sequences. The availability of 
more extensive data has seen the application of complex mathematical methods for 
comparing herpesvirus DNA sequences. The application of such methods have 
yielded interesting results with regard to the anomalies of the biological 
classification system (see Karlin et al., 1994).
An alternative method for separating herpesviruses into distinct groups is 
based on the structure of the viral nucleic acid (Roizman, 1990). There are six 
types or groups of herpesvirus genomes labelled A through to F which differ from 
each other with respect to the presence, type, number, size, and position of repeat 
sequence elements (see figure 1.2).
The structure of a type A genome consists of a large sequence from one 
terminus directly repeated at the other terminus. Group B genomes differ from 
those of group A in that the group B terminal sequence is shorter and is directly 
repeated a variable number of times at the genomic termini. Group C genomes are 
typified by multiple reiterations of one set of sequences in the same orientation at 
both ends of the genome. Tandem reiterations of other sets of sequences are found 
within the type C genome. Group D genomes consist of two covalently linked long 
(L) and short (S) segments. L consists of a unique sequence (UL) and S is a
unique sequence (Us) bordered by inverted repeats, an internal repeat (IRS) and a
terminal repeat (TRS). The L segment is generally in fixed orientation whereas the 
S segment can invert relative to L which gives rise to two isomeric forms of the 
genome. Type E genomes comprise of sequences from both ends of the genome 
that are repeated in an inverted orientation and juxtaposed internally. The L and S 
segments formed by this genome arrangment are flanked by inverted repeats and 
therefore can invert relative to each other giving rise to four potential isomers of 
the genome. One other genome type has been identified that is totally dissimilar 
from the other types in that it consists of a unique long sequence bordered by
non-identical terminal sequences that have no internal counterparts.
One of the most interesting aspects of herpesvirus genome structure is the 
presence of these repeat regions. It is because of recombination within and between
3
Group S eq u en ce  Arrangement
LTR RTR
Isomer Example 
1 CCV, HHY -6
B 1 HVS
R4 R3 R2 R1
c — ------ {inrmfl===a i E3V
D
UL IR U<= TR
3- -2 VZV
an b
H u s
UL
, # t /  . «b an c Us c a
4  HSV-1
1 Tupaiid HV-1
Figure 1.2 Different types of herpesvirus genome s tru c tu res  
(adapted from Roizman, 1990).
Chapter One: General Introduction to the Herpesviridae, EHV-1 and EHV-4
these regions that the structure and size of the genome of a given virus varies 
within a population. Whether these repeat driven changes have any functional 
significance remains to be seen.
1.1.4 THE MULTIPLICATION PROCESS OF AN a-HERPESVIRUS
The mechanisms via which HSV-1 infects and multiplies within a cell (see 
figure 1.3) are being studied in detail. Much of what is known can loosely be 
extended to the other viruses in its sub-family, including EHV-1 and -4.
The attachment and entry of HSV-1 into host cells involves the virus 
envelope glycoproteins. The virus first binds to heparin sulphate moieties on the 
surface of a potential host cell (WuDunn and Spear, 1989; Shieh et al., 1992). 
This function is mediated by the viral glycoprotein gC and possibly independently 
by gB (Herold et al., 1991 and 1994). This attachment is reversible.
The formation of a stable attachment of the virus to its host cell is probably 
linked to the viral entry process. Evidence is accumulating for the interaction of gD 
with a cell surface receptor to initiate irreversible attachment. Recently potential 
candidate cell surface receptors were identified (Montgomery et al., 1996; Geraghty 
et al., 1998). gD, gB, gH and gL have all been implicated in the associated 
penetration process. Two processes, namely receptor mediated endocytosis and 
membrane fusion, were proposed as methods of viral entry into the cell but the 
balance of evidence suggests that only the latter results in a productive viral 
infection (Campadelli-Fiume et al., 1988; Wittels and Spear, 1991).
The fusion process results in the loss of the viral envelope allowing the 
release of the nucleocapsid and associated tegument proteins into the cell. Host 
protein synthesis is switched off via degradation of mRNA by the virion host shut- 
off (VHS) protein which normally resides in the tegument. Interestingly this shut- 
off does not occur in EHV-1 infected cells although the virus does encode a 
functional VHS protein (Feng et al., 1996). The capsid and tegument proteins are 
transported to the nucleus into which the viral DNA is released where it circularises 
via ligation of the terminal repeats. The a-TIF, a viral encoded transcripitional 
activator contained in the tegument, induces with the aid of host co-factors
4
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(McKnight et al., 1987) the first round of viral gene expression (Campbell et al.,
1984). Viral genes are expressed in an ordered fashion depending mainly on when 
they are required during the lytic-cycle (Honess and Roizman, 1974).
a-TIF induces the first round of transcription of viral genes namely the a  or 
immediately early genes. The protein products of these genes are involved in either 
self-regulation or induce subsequent rounds of transcription which result in the 
production of the p / early and y / late genes, p proteins are required for the 
synthesis and replication of viral DNA. The late genes which encode mainly 
structural proteins can be further subdivided into yi and y i  genes in that DNA 
replication is a prerequisite for the initiation of 72 but not yi gene transcription.
In the nucleus replication products i.e new virus genomes are packaged into 
recently constructed capsids. The capsids bud from the inner nuclear membrane 
where the newly synthesized precursor glycoproteins have been inserted and are
subsequently transported to the cell surface. The transportation pathway is unclear 
but probably involves some interaction with the golgi-apparatus where the precursor 
glycoproteins are most likely glycosylated. A recent report suggests that the
extracellular virions have envelopes which differ from the nuclear membranes with 
respect to phospholipid composition. The envelope phospholipid composition reflects 
either a golgi or plasma membrane origin (Van Genderen et al, 1994).
Release of the virus from the cell is thought to involve a number of virus
glycoproteins including gD, gH and gK.
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1.2 EHV-1 and EHV-4
Eight distinct herpesvirus have been isolated from members of the Equidae. 
These viruses have been designated EHV-1 to -8 (See table 1.2). Not all these 
viruses have a definitive disease association. Given the detrimental effects of EHV-1 
and -4 associated diseases particularly with regard to profitable industry based on 
the equids, it is not surprising that these equine herpesviruses have been singled 
out for much attention by the virology research community.
The following is a review of the aspects of the biology of EHV-1 and -4 
which are relevant to this thesis and is intentionally an incomplete review. 
Reference to other herpesviruses will be made where insufficient information is 
available regarding the aforementioned EHVs.
1.2.1 THE DISEASE SPECTRUM OF EHV-1 AND -4
Historically EHV-1 and -4 were considered to be a single entity, equine 
rhinopneumonitis virus (Dimock and Edwards, 1936). Subsequently serological and 
clinical observations led to the conclusion that this virus was not a single entity but 
two sub-types of the same virus, namely EHV-1 sub-types 1 and 2 (Burrows and 
Goodridge, 1973). Finally, in 1981, the results of a number of restriction enzyme 
analysis studies prompted Studdert to suggest that these viruses should be 
considered as distinct entities.
The most frequently quoted reason for studying these viruses is their 
detrimental impact on industries associated with the equid. Horses assembled in 
relatively large groups frequently succumb to EHV-1 and -4 infections. The 
outcome of an infection with either virus cannot be accurately predicted but may 
lead to death under certain conditions. Both viruses are respiratory pathogens but 
generally differ with regard to the diseases they cause.
Infection by EHV-1 and -4 is normally contracted by the inhalation and to a 
lesser extent ingestion of material contaminated with virus. Common sources of 
infectious material include the secretions of infected in-contact animals, aborted
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foetuses and material i.e. fomites e.g. bedding that has been directly or in-directly 
in-contact with affected animals. It has also been proposed that infection may also 
occur from within as a result of reactivation of latent virus. Both viruses replicate 
in the respiratory epithelium and infection can spread via the lymphatic system to 
local lymph nodes. EHV-4 causes a relatively mild respiratory infection, the risk 
associated with this virus being that it may make affected animals, particularly 
foals, susceptible to potentially life threatening secondary infections. Affected 
competition animals are not allowed to compete which has obvious financial 
consequences. In young horses EHV-1 respiratory infection can have extremely 
serious consequences.
EHV-1 establishes a viraemic infection. The virus multiplies in the local 
lymph nodes (Prickett, 1970) where it most likely initiates a cell associated 
viraemia, the vehicle by which it spreads to other tissues (Scott et a l, 1983). The 
consequences of EHV-1 associated viraemia are multiple.
Experimental infections have shown that EHV-1 can replicate at a number of 
sites within the uterus of a pregnant mare (Smith et al., 1993). Pregnant mares can 
abort as a result of EHV-1 infection of the placenta and foetus or the placenta 
alone, the latter giving rise to abortion of a virus negative foetus (Smith et al., 
1992). The devastating effects of the abortigenic potential of EHV-1 can be seen 
on stud-farms with a large population of pregnant mares, where after the initial 
index case of EHV-1 infection practically all the mares sequentially abort in what is 
referred to as an abortion storm (Allen and Bryans, 1986). EHV-1 induced abortion 
can occur at any time during the gestation period. In some cases abortion does not 
occur but the foals are still-born or bom alive but die due to complications arising 
from a severe EHV-1 infection (Dixon et a l . 1978). Isolated incidents of abortion 
are not uncommon.
EHV-1 infected horses regardless of gender can develop paralytic symptoms. 
Animals can recover from mild cases of paralysis but in some instances horses that 
are severely affected have to be euthanased. In some cases of EHV-1 induced 
paralysis, the eye can also be affected (Platt et al, 1980). Apart from paralysis of 
the eye direct tissue damage has been observed in the retina and cornea of EHV-1 
affected animals (Slater et al., 1992). Pathological examination indicates that
7
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paralytic symptoms are due to damage of the blood vessels supplying the affected 
areas of the CNS (Edington et al, 1986).
Although EHV-1 infection results in pathology of a number of different body 
organs the culmination of a number of studies indicates a unifying pathological 
mechanism with regard to abortion and neurological disease elicited by certain EHV- 
1 strains (Edington et a l, 1991; Smith et a l, 1992 and 1993). Virus induced 
damage of endothelial cells lining blood vessels supplying the nervous system and 
uterus seems to be a major contributory factor in the pathogenesis of EHV-1. It is 
unclear if endothelial cell damage is directly or indirectly a result of virus 
replication in these cells. This mechanism of CNS induced damage is atypical of 
other alphaherpesviruses which normally multiply within the CNS thus inducing 
disease. There is very little evidence for productive replication of EHV-1 in the
CNS of the horse although reactivatable latent virus has been demonstrated in the
trigeminal ganglion (Slater et al, 1994).
It has been assumed that EHV-4 does spread from the site of infection,
however the virus has been associated with isolated cases of abortion (Allen and
Bryans, and references therein 1986) and paralysis (Meyer et a l . 1987). EHV-4 
was recently isolated from endothelial cells and synovial epithelium of a pony foal 
suffering from pneumonia (Blunden et a l . 1995). Furthermore EHV-4 has also 
been demonstrated as a latent presence in widely disseminated tissues including the 
CNS (Edington et a l, 1994; Borchers et a l, 1997). It seems likely that under 
favourable conditions infection of horses with certain strains of EHV-4 may result 
in a viraemia.
8
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1.3 THE MOLECULAR BIOLOGY OF EHV-1 AND -4
1.3.1 VIRION AND GENOME STRUCTURE
The virions of EHV-1 and -4 are as that described for a typical herpesvirus
(O'Callaghan et al., 1978; Baker et al., 1990).
Restriction endonuclease analysis played a central role in the elucidation of the 
structures of the genomes of these viruses and led to the conclusion that they were 
distinct species and not sub-types of the same virus which confused many early 
scientific studies of EHV-1 and -4 (Sabine et al., 1981; Studdert et al., 1981; 
Turtinen et al., 1981). Both viruses have a group D genome structure (see figure 
1.2). Extensive restriction enzyme maps have been constructed for three EHV-1 and
two EHV-4 strains (Whalley et al., 1981; Henry et al., 1981; Baumann et al.,
1986; Cullinane et al., 1988; Nagesha et al., 1992; Kirisawa et al., 1993a).
The entire DNA sequences of the AB-4 strain of EHV-1 and EHV-4 strain 
NS80567 were determined. The EHV-1 genome is 150,224bp in size and the G+C 
content is 56.7% (Telford et al, 1992). The EHV-4 genome is 145,597 bp in size 
(Telford et al., 1998). Partial sequence data is available for other strains of EHV-1 
and EHV-4. These data have proved extremely valuable and attempts are now being 
made to identify the function of the products of the genes sequenced and their 
contributions to the viruses life cycles and pathogenicity.
1.3.2 VIRION GLYCOPROTEINS
The virions of EHV-1 and -4 contain at least twelve glycoproteins. The 
presence of glycoproteins in these viruses was initially demonstrated by glycoprotein 
specific staining techniques and by utilising tritiated glucosamine as a sugar source 
for virus infected cells which results in the metabolic labelling of sugar-containing 
proteins within the cells (Turtinen et al., 1981; Turtinen and Allen, 1982; Meredith 
et al., 1989; Crabb and Studdert, 1990). Two different EHV glycoprotein 
nomenclature systems were proposed the first based on glycoprotein electrophoretic 
mobility in SDS polyacrylamide gels and the second on the apparent molecular
9
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weight of the glycoproteins (Turtinen and Allen, 1982; Meredith et al., 1989). Both 
systems have not been universally accepted since they are prone to misinterpretation 
based on technical differences between laboratories studying these viruses and their 
glycoproteins (see table 1.3). The advent of molecular techniques has allowed a 
direct comparison of glycoprotein genes between HSV-1, other a  herpesviruses and 
EHV-1 and -4. Subsequently the HSV glycoprotein nomenclature system is now 
commonly employed, whenever possible, for the glycoproteins of EHV-1 and -4.
Five approaches have been utilised in order to identify the genes encoding 
some of these glycoproteins.
1. Glycoprotein specific monoclonal antibodies (Mabs) have been used to 
probe Xgtll EHV-1 and -4 genomic DNA expression libraries in order to identify 
clones containing partial sequence data (Allen and Yeargen, 1987; Whittaker et al.,
1991; Cullinane et al., 1993; Wilson et al., 1994). An alternative yet similar
approach is to clone part of a suspected glycoprotein gene into a bacterial 
expression vector and subsequently develop an antiserum against the bacterially 
expressed protein which should then react with one of the virion glycoproteins 
(Crabb et al, 1992).
2. On the basis of colinearity between EHV-1 and -4 and utilising 
glycoprotein genes from other a  herpesviruses, namely HSV-1, as low stringency 
probes to screen EHV-1 and -4 genomic DNA plasmid libraries, it has been 
possible to identify EHV glycoprotein genes (Riggio et a l, 1989; Bonass et al.,
1990; Nicolson et al., 1990; Nicolson and Onions, 1990).
3. Sequencing of relatively large regions of virus genome and subsequent 
comparison of identified ORFs with glycoprotein gene homologues of other 
herpesviruses (Audonnet et al., 1990; Elton et al., 1991a and b; Telford et al.,
1992 and 1998). Those genes thought to encode potential glycoproteins but with no 
homology to existing glycoproteins can be examined at the amino acid level for the 
presence of sequence traits common to herpesvirus glycoproteins, namely a N- 
terminal signal sequence, a membrane spanning domain and glycosylation sites.
4. Deletion of a specific gene from the viral genome and the subsequent 
absence of a specific glycoprotein from the mutant virus (Sun et al, 1994).
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5. None of the aforementioned approaches definitively link a particular protein 
with a particular gene unlike the fifth and final approach which requires the 
purification of the glycoprotein of interest followed by N-terminal protein 
sequencing of the purified product in order to relate amino acid sequence to DNA 
sequence (Wellington et al, 1996a).
The available glycoprotein gene sequences have been exploited mainly for the 
purposes of vaccine development and as yet very little is known of the functional 
significance of their gene products.
gC
The gC gene homologues sequences of three strains of EHV-1 (Allen and 
Coogle, 1988; Telford et al, 1992; B.S. Crabb, Personal communication) and two 
strains of EHV-4 (Nicolson and Onions, 1990; Telford et al., 1998) have been 
determined. All genes have partial homology with their HSV-1 counterpart. The first 
EHV-1 gC gene to be sequenced was initially identified using method one above 
(Allen and Yeargen, 1987). The EHV-4 homologues were identified on the basis of 
colinearity between the EHV-1 and -4 genomes (Nicolson and Onions, 1990) or by 
sequencing the entire EHV-4 genome (Telford et al., 1998).
gC of HSV-1 is a multifunctional envelope glycoprotein. It is involved in the 
adsorption of vims to host cell heparin sulphate moeities and is known to bind the 
C3b component of the complement cascade system when expressed on the surface 
of infected cells and on the virion envelope (Herold et al., 1991; Hidaka et al., 
1991; Friedman et al., 1984). No evidence as yet exists for the participation of the 
gC homologues of EHV-1 and -4 in the adsorption process, although some anti-gC 
Mabs against the EHV-1 homologue were shown to neutralise viral infectivity but 
only in the presence of complement (Sinclair et al., 1989). Furthermore unpublished 
data suggests that heparin may have a limited role in the adsorption of wild-type 
strains of EHV-1 to cells in culture suggesting that the role of the EHV-1 gC 
homologue in adsorption may be somewhat different from that of its HSV-1 
counterpart (see Sugahara et a l, 1994). EHV-1 infected bovine cells express a 
complement binding activity (Bielefeldt-Ohmann and Babiuk, 1988). That anti-EHV-1
11
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and -4 gC Mabs can inhibit the agglutination of equine complement coated 
erythrocytes is indirect evidence of the complement binding activity of these 
glycoproteins. Direct evidence for the complement binding activity of gC of EHV-1 
and -4 was obtained by showing that gC purified from EHV infected cell lysates 
could bind C3 and cells transfected with a plasmid encoding gC under the control 
of a eukaryotic promoter could bind complement (Huemer et al, 1995).
gD
An identical situation exists between gD and gC as regards the availability of 
EHV-1 and -4 sequence information (Audonnet et al., 1990; Elton et a l, 1991b; 
Flowers et al, 1991; Whalley et al, 1991; Telford et a l, 1992; Cullinane et a l, 
1993; Telford et al ., 1998).
The gD homologues of other a-herpesviruses are the focus of much attention 
because they play an essential role in the infectivity process. Antibodies against a 
peptide derived from the EHV-1 gD homologue were shown to neutralise virus 
infectivity in the absence of complement (Flowers and O'Callaghan, 1992). Anti-gD 
Mabs inhibit penetration but not adsorption of EHV-1 thus showing that EHV-1 gD 
functions in a similar fashion to other gD homologues (Whittaker et a l, 1992a). 
The HSV-1 gD homologue is also thought to be involved in virion egress from 
infected cells and the ability of the virus to spread from cell to cell without release 
into the extracellular environment. These properties are probably mediated in part by 
the viruses ability to cause cell-cell fusion, a process known to involve gD (Noble 
et a l, 1983). No evidence to date suggests that EHV-1 gD is involved in cell 
fusion elicited by EHV-1 infection although this glycoprotein does promote cell 
fusion when expressed in cell lines (Wellington et al, 1996b).
Little is known about the EHV-4 gD homologue.
gB
The gB homologue of EHV-1 is structurally similar to that of other 
herpesviruses with the exception of HSV-1 in that it is cleaved at two sites
12
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(Wellington et al., 1996a) to form a heterodimeric complex of processed proteins 
all initially derived from cleavage of precursor gB (Meredith et a l, 1989). The 
amino acid sequence of the EHV-4 gB homologue derived from the gene sequence 
predicts that it would be processed in a similar fashion (Riggio et al, 1989).
gB of HSV-1 is involved in the penetration process (Cai et a l, 1988). 
Neubauer and colleagues (1997) have demonstrated a role for the EHV-1 gB 
homologue in penetration and cell-cell spread. Also anti-EHV-1 gB Mabs have been 
shown to inhibit cell-cell fusion thus suggesting a possible function for this 
glycoprotein in cell to cell spread and egress (Wellington et al, 1996c).
gE and gl
The gene homologues of these glycoproteins have been identified for EHV-1 
and -4 (Cullinane et al, 1988; Audonnet et al, 1990; Elton et a l, 1991a; Telford 
et al, 1992 and 1998). These glycoproteins function together to form Fc receptors 
for immunoglobulin G (IgG) complexes, and gE alone can act as a receptor for 
IgG in HSV-1 infected cells (Dubin et a l, 1990). EHV-1 infected bovine cells 
bind the Fc portion of immunoglobulins (Bielefeldt-Ohmann and Babiuk, 1988).
V P13/14
The VP 13/14 and VP 14 glycoproteins of HSV-1 and -2 respectively are 
located in the tegument and for HSV-1 at least may have some involvement in 
gene control. An anti-EHV-1 gplO Mab was shown to cross-react with VP13/14 
and VP 14. This Mab was used to isolate the gene encoding an EHV-4 VP 13/14 
homologue (Whittaker et a l, 1991). The EHV-1 homologue has also been 
sequenced (Telford et al, 1992).
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gp2 (gp300)
This glycoprotein was initially characterised by Whittaker et al (1992b). It 
differed from other previously characterised herpesvirus glycoproteins in that it 
contained a large amount of O-linked carbohydrate as opposed to N-linkages 
although it was also modified in this way (Whittaker et al., 1990). Also tentative 
evidence suggested that it may cross the membrane a number of times. The EHV-1 
gene encoding this glycoprotein was identified as the HSV-1 UL32 gene homologue 
and was confirmed by an anti-EHV-1 gp2 Mab which recognised a procaryotic 
fusion protein expressed from this gene. However controversy has arisen in that 
another gene the EHV-1 homologue of HSV-1 gene US5 has been proposed to 
encode gp2 (Sun et al, 1994).
Both studies have found common ground with regard to the possible role of 
gp2 in promoting cell to cell fusion.
It is now accepted that gp2 is encoded by gene 71 of EHV-1 (Wellington et 
al., 1996c). Apart from a role in inducing cell fusion deletion mutant studies also 
suggested a role for this glycoprotein in virus maturation and envelopment. The 
EHV-4 gene homologue has been characterised (Nagesha et al, 1993).
gM
The EHV-1 gM homologue is encoded by gene 52. In contrast to the HSV- 
1 homologue gM of EHV-1 is a major constituent of the envelope of EHV-1. It 
has been proposed that this glycoprotein may also span the membrane a number of 
times (Pilling et al, 1994). Mutation of the gene has demonstrated a potential role 
for the EHV-1 gM homologue in virus penetration and cell-cell spread but it is not 
an ion channel as first suggested by Pilling and coworkers (1994) (Osterrieder et 
al, 1996). An EHV-4 homologue has recently been identified (Telford et a l, 
1998).
14
Chapter One: General Introduction to the Herpesviridae, EHV-1 and EHV-4
gG
The DNA sequences of the EHV-1 and -4 gG homologues have been 
determined (Crabb et al., 1992; Telford et al., 1992; Telford et al., 1998). Their 
functions remain to be elucidated, however like the PRV homologue, both the 
EHV-1 and -4 gG homologues are secreted (Crabb et al., 1992; Drummer et al., 
1998).
gH, gL, and gK
Sequencing of the EHV-1 genome has revealed genes with homology to 
HSV-1 gH, gL and gK (Robertson et al., 1991; Telford et al, 1992; Zhao et al., 
1992). The EHV-4 gH (Nicolson et al., 1990; Telford et a l, 1998), gL and gK 
(Telford et al., 1998) gene homologues have also been sequenced. Very little 
information regarding the protein products of these genes is available.
1.3.3 IMMUNITY TO EHV-1 and EHV-4
Immunity to EHV-1 and -4 generally does not last very long and horses may 
be reinfected every three to six months. Young horses are infected by 1 year of 
age and tend to be particularly susceptible to reinfection (Allen and Bryans, 1986).
The envelope glycoproteins of EHV-1 and -4 are obvious targets for the host 
humoral immune response. A number of studies using a variety of approaches have 
identified gp2, gC, gB, gD, gp21/22a and possibly the gplO complex to be targets 
(Allen and Bryans, 1986; Crabb et al., 1991; Ahmed et al., 1993). Ostlund and 
co-workers (1992) have shown that gB followed by gC are the major target 
antigens for the equine humoral immune response. Antibodies to gG have also been 
detected in EHV-1 and -4 infected horses as well as experimentally infected animals 
(Crabb et al, 1992; Crabb and Studdert, 1993). There is also preliminary evidence 
that the EHV-1 membrane glycoproteins are targets for cell-mediated immune 
responses (CMI) (Bridges et al., 1988).
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The sensitivity of new-born foals to infection could be due to several factors 
including their tendency not to develop sufficient levels of circulating anti-virus 
antibodies (Coignoul et a l, 1984a and references therein) and the insufficient
protection conferred by the passive immunity provided by the mares colostrum 
(Higgins et al, 1987). In contrast, as outlined previously, older animals tend to 
develop good adaptive responses to EHV glycoproteins and other virion 
polypeptides which can neutralise virus infectivity in vitro. One of the most 
perplexing questions in EHV-1 and -4 biology is why, when given a good
adaptive response, animals are reinfected with such frequency.
The answer may come from studies of innate immunity to EHVs which were 
initiated in the late 1970s. It was demonstrated that foals could evolve a CMI 
response to infection; however EHV-4 infection can result in defective neutrophil 
function in young horses (Coignoul et a l, 1984b). Subsequent studies illustrated 
that EHV-1 infection could derail a number of aspects of the innate immune 
response (Bridges and Edington. 1986; Hannant et a l, 1991; Lunn et a l . 1991). 
Recent data has suggested that elevated levels of the cytokine TGF-P in EHV-1 
affected animals may be responsible for the immunosuppressive effect of that virus 
(Charan et al, 1997). It remains to be seen exactly how the viruses elicit these 
alterations in immune function and if these changes contribute to the frequency at
which horses are reinfected.
1.3.4 STRAIN VARIATION
The ability to detect differences between strains of either EHV-1 or -4 is of 
great epidemiological importance for two reasons. Firstly it should allow the 
assessment of the contribution of infection with particular strains to the morbidity 
and mortality rates in a given equine population. Secondly it may allow strains to 
be grouped according to their pathogenic potential. Such information may ultimately 
lead to the elucidation of factors which determine virus pathogenicity and allow the 
determination of the best treatment or preventative measures for a given horse
population.
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Phenotypic/growth characteristics and protein structure
EHV growing in cell culture showed inconsistent variation in plaque size and 
morphology (Holmes et al., 1979).
Patel et al (1982) noted that abortigenic and paralytic isolates have different in 
vivo cellular tropisms. These differences may not necessarily reflect inherent 
differences between the strains in that the study involved observations of natural 
infections and therefore host factors may be involved.
Minor undesignated differences in the protein profiles of different strains of 
EHV-1 and -4 were identified (Turtinen et al., 1981).
Epitope content
Initial attempts to serologically characterise strains of EHV-1 and -4 involved 
the use of crude polyclonal antiserum. The serum neutralisation tests utilised were 
prone to variation and although inter-strain antigenic variation was purported to be 
detected the data were considered unreliable (Allen and Bryans, 1986 and references 
therein).
In the ensuing years the development of monoclonal antibody (Mab) 
technology had a major impact on serology. Consequently a number of studies 
aimed at characterising EHV specific Mabs and their utilisation in diagnostic tests 
revealed potential antigenic variation between EHV strains. The reactivity of different 
strains of EHV-1 and -4 with pools of Mabs was shown to vary in enzyme 
immunofiltration assays and indirect immunofluorescence (DF) tests (Yeargen et al.,
1985). Edington noted what were termed as inconsistent differences in reactivity of 
EHV strains with specific Mabs in IIF tests (Edington et al, 1987). Both enzyme 
immunofiltration assays and IIF tests rely on detection of cell surface expression of 
virus proteins and therefore the aforementioned results are not necessarily indicative 
of strain specific antigenic variation.
An extensive study revealed that 72 strains of EHV-1 differed from each 
other with respect to anti-gC Mab reactivities in direct ELIS As (Allen et al, 1988). 
Japanese strains of EHV-1 differed with regard to neutralisation by Mabs in the
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presence of complement (Shimizu et al., 1989). Sinclair and co-workers noted 
variability in the reactivity of EHV-4 strains with a Mab against a virion 
polypeptide and an anti-gC Mab in immunofluorescence assays (Sinclair et al., 
1989; Sinclair and Mumford, 1992).
Genome variation
Restriction fragment length polymorphism (RFLP) analysis has revealed 
variation in the genomic structure of EHV-1 and -4 strains (Sabine et al., 1981; 
Studdert et al., 1981; Allen et al., 1983a). Earlier RFLP-based studies may have 
been compromised by the fact that many of the strains analysed were passaged in 
cells that were not of equine origin. Subsequent studies revealed that handling the 
viruses in this way could alter their genomic structure (Allen et al., 1983b; 
Studdert et al, 1983; Studdert et al, 1986; Meyer et al., 1987; Sugahara et a l, 
1994). The most extensive RFLP analyses were performed on strains of EHV-1 
and -4 by Allen and co-workers (1983a). That study confirmed earlier ambiguous
findings that both viruses could be placed into defined groups on the basis of loss
or gain of restriction enzyme sites. It was demonstrated that greater genomic 
variability existed between EHV-4 strains relative to that of EHV-1 (Allen et a l, 
1983a).
The epidemiological value of RFLP analysis was illustrated in two separate 
studies where in one it was possible to identify which were the dominant
abortigenic strains in Kentucky (Allen et a l, 1985), and in the second it was
possible to distinguish an abortigenic from a paralytic isolate during a single 
outbreak on the same farm (Studdert et al, 1984). However, it must be stated that 
the latter study did not indicate whether the RFLPs identified were located in the 
repeat regions of the EHV-1 genome which can be inherently unstable.
The availability of the genomic map of a variety of EHV-1 strains and the
entire DNA sequence of one EHV-1 strain should allow the retrospective 
localisation of these variable regions. Indeed recent studies involving Australian, 
Japanese, and British isolates revealed that many RFLPs of EHV-1 isolates are due
to differences in the number of copies of repeated regions located at a number of
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sites in the EHV-1 genome (Studdert et al, 1992; Kirisawa et al., 1993a; Bonass 
et al, 1994; Matsumura et al, 1994; Binns et al, 1994; McCann et a l, 1995). 
These studies revealed that the genomes of the EHV-1 strains examined were quite 
conserved. However the latter RFLP study (McCann et a l, 1995) using restriction 
enzymes with 4bp recognition sites was able to separate EHV-1 strains into defined 
groups of epidemiological use, with the added bonus that all paralytic isolates 
resided in a single group.
Although RFLP analysis reflects variation at the DNA sequence level it cannot 
be expected to reveal all sequence variation between strains of EHV-1 and -4. In
the paper describing the EHV-1 strain AB4 DNA sequence, variation was detected
in different coding and non-coding regions between strain AB4 and other strains
sequenced (Telford et a l, 1992). Similarly a comparison of the gene sequences 
from EHV-4 strains reveals inter-strain sequence variation (Telford et a l, 1998). It 
is worth noting that a few of the EHV-1 and-4 strains from which sequence data 
has been derived were passaged several times in non-equine cells.
Another study suggested sequence variation between EHV strains could affect 
detection of specific virus genes via PCR. Sharma and colleagues (1992) noted that 
the failure of some EHV-4 isolates and possibly some EHV-1 isolates to be
detected by a gC gene specific PCR may be due to sequence variation across the 
primer sites in some isolates. Again it should be noted that the EHV-4 strain from 
which the primer sequences were derived i.e 1942, was passaged in non-equine 
cells.
1.3.5 DIAGNOSIS
After the initial clinical diagnosis of an EHV-1 or 4 infection confirmatory 
tests involving virus isolation, complement fixation (CF) tests and/or IIF are 
routinely employed. Recent advances in immunological and molecular techniques 
have resulted in a plethora of diagnostic methods for these viruses which may 
circumvent some of the disadvantages of older tests.
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Immunological methods
Antibody to EHV-1 and -4 is routinely measured by CF, immunoflourescence 
(IF), and virus neutralisation (VN). A measurable rise in antibody titre as 
determined by CF is thought to be a sign of recent EHV infection. These tests 
suffer from three main disadvantages:
1 . changes in antibody titre may be slow and not necessarily measurable, 
especially in older horses which have experienced a number of prior 
infections. McCartan and co-workers (1995) also demonstrated that foals 
infected with a highly virulent strain of EHV-1 did not develop significant 
increases in antibody titre,
2. the tests do not necessarily distinguish between EHV-1 and -4 infections, and
3. depending on the reagents used antigenic variants may not be detected 
(Thomson et al, 1976).
The two latter disadvantages were overcome by employing pools of type- 
specific Mabs to detect either virus in IIF or enzyme immunofiltration assays 
(Yeargen et al., 1985). A disadvantage of these types of tests is the requirement 
that the virus be grown and its antigens expressed in cell culture which may be 
time consuming or impossible.
An antigen capture system using uncharacterised Mabs was used to detect 
virus antigen in nasal swabs. The test although not particularly sensitive was fast 
and did not rely on the presence of infectious virus. Strain variation was not a 
problem with respect to EHV-1 detection but only a limited number of samples 
were examined (Sinclair and Mumford, 1992).
A recombinant GST fusion protein derived from EHV-1 gB was used as an 
antibody capture system in an ELISA. The recombinant protein contained an 
immunodominant domain and cross-reacted with serum from EHV-4 infected animals 
(Sinclair et a l, 1993a). Crabb and co-workers (1992 and 1995) used a similar 
system to express recombinant proteins derived from gG of both viruses which 
were of value in serologically distinguishing EHV-1 from EHV-4 infected horses. 
Retrospective analysis of EHV-1 infection in the Australian horse population
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revealed the epidemiological value of this test (Crabb and Studdert, 1993). However 
its clinical usefulness remains to be determined especially in countries where 
widespread anti-EHV-1 vaccination of thoroughbred horses takes place. GST fusion 
proteins containing truncated forms of EHV-1 gC were also demonstrated to have 
diagnostic potential not unlike that of gG (Crabb and Studdert, 1995).
An immunoperoxidase assay was used to detect viral antigen in wax- 
embedded tissues (Whitwell et al., 1992). This test is particularly useful for post­
mortem diagnosis especially in cases where it is difficult to isolate the virus e.g 
from the CNS (Whitwell and Blunden, 1992).
A radial immunodiffusion enzyme assay was proposed as a potential field test 
for EHV-1 antibody by Gradil and Joo (1988).
M olecular methods
The first generation of molecular diagnostic techniques for detection of EH Vs 
are not applicable to routine diagnosis because of the specialised techniques 
involved.
Morris and Field (1988) used cloned fragments of EHV-1 DNA to detect 
virus DNA in Southern and dot blots of tissue and cellular DNA. They could 
detect >1 genome/cell. Cross reaction between cellular DNA and the probes, 
particularly with dot blot analysis, could lead to erroneous results. The authors 
suggested that it might be possible to estimate the concentration of viral load and 
to detect the form of the viral DNA with their system.
A rapid method for isolating whole cellular DNA and subsequent analysis 
with labelled virus DNA allowed the detection and screening of a large number of 
isolates for RFLPs. The presence of replication intermediates could confuse results 
(Chowdhury et al, 1986a).
In situ hybridisation with non-radioactive probes could detect EHV-1 DNA 
directly in infected tissue. This approach could not detect viral DNA in the CNS of 
horses with paralytic symptoms (Schmidt et a l . 1994). This may be due to the
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insensitivity of the technique or the fact that the study was not extensive since 
antigen was detected in the CNS in separate studies using different techniques.
The second generation of molecular diagnostic techniques are based on the 
polymerase chain reaction (PCR). These because of their sensitivity, speed, and 
relatively simple applicability may replace virus isolation as the standard diagnostic 
method for the EH Vs and other viruses. However, it must be stressed that if PCR 
is to become the gold standard in diagnosis extreme care will have to be taken 
during its execution to avoid contamination.
A number of groups have favourably compared PCR and virus isolation with 
regard to sensitivity (Ballagi-Pordany et al, 1990; Sharma et al., 1992). The 
technique has been used to detect the virus in nasal secretions and a variety of 
tissues. A single tube PCR has been developed that can distinguish between EHV-1 
and -4 (Kirisawa et al., 1993b). Others have used the extremely sensitive technique 
of nested PCR to detect latent EHV-1 and EHV-4 in the CNS and lymphoid tissue 
(Welch et al., 1992; Borchers and Slater, 1994; Slater et al., 1994; Borchers et 
al., 1997). PCR diagnosis may have limitations relative to virus isolation under 
certain circumstances. Firstly the small starting sample used for PCR may result in 
insensitivity especially if the clinical sample has a relatively large volume and is 
dilute in terms of virus concentration. Secondly PCR does not necessarily detect 
infectious virus which would require further specialisation of the procedure and thus 
make it less attractive as a clinical diagnostic tool.
1.3.6 LATENCY
Recent studies using PCR have definitively demonstrated latent EHV-1 and -4 
infections in lymphoid tissue and to a lesser extent in the peripheral blood 
leukocytes (PBL) and trigeminal ganglion (TG) of ponies (Welch et al., 1992). 
Subsequent studies demonstrated that the trigeminal ganglion is also a major site of 
EHV-1 and EHV-4 latency (Slater et al., 1994; Borchers et al., 1997). The authors 
of the latter study suggest that for EHV-1 at least the trigeminal ganglion is a 
more important source of reactivatable virus (Slater et a l, 1994). It must be 
stressed however that there were some key differences between both studies, in
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particular the presence and potential role of EHV-2 in reactivating EHV-1 or -4 
from cells of lymphoid origin. A survey of healthy animals at slaughter 
demonstrated a very high prevalence of latent EHV-1, -2 and -4 in both lymphoid 
tissue and to a lesser extent the trigeminal ganglion (Edington et al., 1994). Indeed 
the presence of latency associated transcripts has been detected in PBLs but not the 
TG of horses with latent EHV-1 (Chesters et al., 1997). However Borchers and 
colleagues (1997) utilised RT-PCR to demonstrate the presence of the EHV-4 gB 
transcript in some of the TG latently infected with EHV-4. It remains to be seen if 
the gB transcript actually is a product of virus reactivation and expression of late 
genes, low-level late gene transcription during latency or a left-over residual 
transcript from a lytic infection.
Latency is a source of great concern for the prevention and treatment of 
herpesvirus diseases, not least the EHVs. Induction of immunosuppression by the 
use of high doses of corticosteroids was initially used to demonstrate the presence 
of reactivatable latent/persistent EHV-1 and -4 infections (Edington et al., 1985; 
Browning et al., 1988). Previous to this circumstantial evidence suggested that as 
with other herpesviruses stress could lead to reactivation (Burrows and Goodridge, 
1978). Thus latency represents a potentially important epidemiological source of 
infection which is made all the more serious by the findings that reactivated virus 
may be shed from the host in the absence of viraemia and overt clinical symptoms 
(Browning et al, 1988; Slater et al., 1994).
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2.1 M ATERIALS
2.1.1 VIRUSES AND MAMMALIAN CELLS
Strains of EHV-1 utilised in this thesis were kindly provided by Prof. G. 
Allen • (University of Kentucky, Lexington, USA) and Dr. M. Binns (Animal Health 
Trust, Newmarket, UK). EHV-1 strain AB4 was generously supplied by Dr. A. 
Davison of the Institute of Virology, Glasgow.
NBL-6 cells, a primary cell line derived from equine dermal cells were 
purchased from ICN Flow, High Wycombe, Buckinghamshire.
2.1.2 BACTERIA, NUCLEIC ACIDS, AND MOLECULAR WEIGHT MARKERS
E.coli strains JM109 and Invitrogen a  F  were obtained from Promega, UK 
and Invitrogen, UK respectively.
Bluescript M13+ and lambda/HindUl, pUC19/TaqI, pUC19/Sau3AI molecular 
weight markers were obtained from Stratagene, UK.
High range protein molecular weight marker was supplied by Promega.
A BamHI library of EHV-1 strain HVS25A in pBR322 was kindly provided 
by Dr. J.M. Whalley (Macquarie University, Australia).
2.1.3 CHEMICALS AND EQUIPMENT
Chemicals and equipment for molecular biology were obtained from B.D.H 
chemicals Ltd, Sigma Chemical Co., Promega, LKB Pharmacia, or Applied 
Biosystems.
Radiochemicals were purchased from Amersham or ICN.
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Immunochemicals were obtained from Dynatech labs. Ltd., Dako Ltd., or 
Novabiochem.
2.1.4 GROWTH MEDIA AND VESSELS
Medium and supplements for the propagation of mammalian cell lines were 
supplied by Gibco BRL Ltd. Tissue culture flasks were purchased from Costar.
Bacteriological media was expertly prepared by the Bacteriology section of the 
Department of Veterinary Pathology, University of Glasgow Veterinary School. Petri 
dishes were obtained from Sterilin Ltd.
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2.2 METHODS
The following general techniques were an integral part of the experiments 
described in subsequent chapters of this thesis.
2.2.1 MAMMALIAN CELL CULTURE
Propagation of NBL-6  cells
Medium was decanted from the vessel in which the monolayer of cells was 
growing. A sufficient amount of lx trypsin-EDTA was added to the vessel such 
that the monolayer was completely covered. The trypsin was removed and an 
identical volume of lx trypsin-EDTA was added to the cells and left in contact
with the monolayer until the cells had detached from the surface of the culture
vessel. The trypsin was then inactivated by adding an equal volume of cell growth
medium (table 2.1). Trypsinised cells were removed to a 20ml or 50ml conical
centrifuge tube and centrifuged at lOOOrpm for 5 mins. in a Beckman GPR 
centrifuge. The supernatant was removed and the cell pellet resuspended in cell 
growth medium. Appropriate fractions of the cells were added to new culture 
vessels as was a volume of cell growth medium such that the monolayer was 
covered by lcm^ of medium. The new cell cultures were then placed in a 
humidified atmosphere containing 5% CO2 at 37°C. Confluent monolayers were 
attained in approximately four days.
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2.2.2 BASIC VIROLOGICAL TECHNIQUES
Estimation of virus titre
A 50% tissue culture infective dose (TCID50) assay was used to determine 
virus titre. 200ul of the virus stock to be titrated was added to 1.8ml of virus 
titration medium (see table 2 .1). 200ul of this dilution was transferred to another 
tube containing 1.8ml of virus titration medium. Ten fold serial dilutions of the 
virus stock down to 10"8 were made in this way. 1ml of each of these dilutions 
was transferred to separate tubes containing 2 .2ml of cell growth medium, therefore 
the virus was also diluted from 10“1*5 down to 10"8-5. A 96 well flat bottomed 
microtitre dish was seeded by adding 150ul of NBL6 cells at a concentration of 
105 cells/ ml of medium to each well. lOOul of each dilution was added to separate 
wells and this was done in quadruplicate i.e. four wells per dilution. The dish was 
covered and placed at 37°C in a humidified incubator containing 5% CO2 . The 
plates were monitored over a period of five days for cytopathic effects (CPE) of 
the virus. A score representing the number of wells per dilution exhibiting CPE 
was assigned to each dilution and the TCID50 calculated using the Karber formula 
(Karber, 1931).
Preparation of virus stocks
Strains of EHV-1 were supplied either as tissue culture supernatants or in a 
freeze dried form. Those which were freeze dried were reconstituted by 
resuspension in 0.5ml of sterile distilled water. These master virus stocks were 
then aliquoted into sterile 1.5ml eppendorf tubes and stored at -70°C. Secondary 
virus stocks were prepared by infecting a monolayer of NBL6 cells in a 75cm^ 
flask with primary virus stocks at a M.O.I of 0.005 TCID50 units per cell. The 
cells were monitored daily until 100% CPE was evident at which point the medium 
covering each monolayer was decanted into separate 30ml centrifuge tubes and 
clarified by spinning in a JA 21 rotor at 8000g for 10 mins. in a Beckman J2-21 
centrifuge. The supernatants from each tube were aliquoted and stored as previously 
described for the master virus stocks.
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A number of precautions were employed in the preparation of the virus 
stocks in order to prevent contamination of individual virus strains with other 
strains or with nucleic acids routinely manipulated within the laboratory. Only one 
virus strain was handled in a laminar flow safety cabinet at any given time. All 
instruments and surfaces were swabbed with 70% ethanol and left for 10 mins. 
prior to the handling of another virus. During this 10 min. period a sentinel 
control i.e an open microcentrifuge tube containing 20ul of H2O was placed in the 
safety cabinet. The H2O was then analysed by PCR (see section 2.2.5) in order to
detect potential aerosol contamination. After the safety cabinet and instruments had
been cleaned new latex gloves and disposable laboratory aprons were put on. 
Finally all viruses were aliquoted with positive displacement pipettes.
2.2.3 BACTERIOLOGICAL METHODS
Transformation of bacterial cells
There are many methods available for introducing DNA into bacteria-however 
commercially competent cells were routinely used. If commercially available 
competent bacteria were unobtainable for transformation then bacterial cells were 
made competent by electroporation.
One litre of L-broth was innoculated with 10ml of an overnight culture of the 
strain of E. coli to be transformed. The diluted culture was incubated at 37°C with 
vigourous shaking until the O.D^qo was between 0.5 and 1.00. The culture was 
placed in JA-15 centrifuge buckets and chilled on ice for 15 minutes. The cells 
were harvested by centrifugation at 4000g for 15 minutes in a pre-cooled 
centrifuge. As much as possible of the medium was removed and the cells 
resuspended in 1 litre of cooled sterile water and centrifuged as before. The water
was removed and the cells resuspended in 500ml of cold water and again
centrifuged as before. The cells were resuspended in 20ml of cold 10% glycerol 
and centrifuged. Finally the cells were resuspended in 2ml of cold 10% glycerol. 
At this stage the cells were snap frozen in a dry ice ethanol bath and stored in 
aliquots at -70°C or used directly for electrotransformation.
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DNA which was to be transformed into bacterial cells by electroporation was 
first precipitated, washed twice with 70% ethanol, and resuspended in Milli-Q 
reverse endo-osmosis grade water in order to reduce the salt concentration of the 
DNA sample.
Cells if frozen were thawed on ice. 40ul of the cells were mixed with no 
more than 4ul of DNA in a polypropylene tube and left on ice for at least a 
minute. The Biorad gene pulser apparatus was set at 25uF and 2.5kV. The pulse 
controller also from Biorad was set at 200 ohms. The DNA and cells were placed 
between the electrodes at the bottom of a 0 .2cm electroporation cuvette which had 
been prechilled on ice. Excess moisture was wiped from the cuvette prior to 
placing it in a safety chamber slide which was then pushed into the chamber such 
that the cuvette electrodes made contact with the electrodes of the gene-pulser. A 
pulse with a time constant of 4-5msec was delivered to the cells and DNA. The 
cuvette was removed from the chamber and the cells immediately resuspended in 
lml of cold L-broth. The cell suspension was transferred to a 15ml polypropylene 
tube and then incubated for 1 hour at 37°C with vigorous shaking. 50ul, lOOul, 
and 200ul aliquots of cells were plated on medium selective for the transformed 
phenotype. In most cases the phenotype was ampicillin resistance encoded by 
plasmid cloning vectors routinely transformed into the bacteria. Transformations 
were therefore plated on to L-agar containing 50ug/ml of ampicillin and left to 
grow overnight at 37°C.
Storage of bacterial clones
Bacteria containing plasmid clones were grown overnight at 37°C with 
vigorous shaking in L-broth containing 50ug/ml of ampicillin. lml of the overnight 
culture was mixed with lml of 25% glycerol solution made up in L-broth. The 
mixture was vortexed and aliquoted into eppendorf tubes. The tubes were snap 
frozen in a dry ice ethanol bath and then immediately transferred to -70°C where 
they were stored until required.
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2.2.4 PURIFICATION AND SEPARATION OF NUCLEIC ACIDS
Small scale preparation of plasmid DNA
Plasmids were isolated from E.coh using a method described by Jones and 
Schofield (1990).
3ml of L-broth containing 50ug of ampicillin per ml was inoculated with a 
single colony harbouring the plasmid of interest, and incubated at 37°C overnight 
in an orbital incubator shaking at 225rpm. The next day 1.5ml of the overnight 
culture was decanted into an eppendorf tube and spun at 14,000rpm for 2min. The 
clarified broth was carefully and completely removed from the bacterial pellet. The 
pellet was resuspended in 150ul of solution one (table 2.1). Freshly prepared 
solution two (300ul) (table 2.1) was then added, and the contents of the tube 
gently mixed by inversion before placing it on ice for 5 minutes. Solution three 
(table 2.1) (225ul) was then added, the contents mixed as before, and then placed 
on ice for a further 5 minutes. The precipitate formed was pelleted by 
centrifugation at 14,000rpm for 5 minutes. The clarified supernatant was removed 
to a clean tube and the pellet discarded. An equal volume of absolute alcohol was 
added to the supernatant which was then briefly shaken prior to centrifugation at 
14,000rpm for 5 minutes. The ethanol was then removed and the pellet washed 
with 70% ethanol before a final centrifugation at 14,000rpm for 2 minutes. The 
supernatant was discarded and the pellet was dried briefly in a vacuum dessicator.
The pellet was resuspended in 30ul of sterile distilled water.
Direct purification of PCR products
The Promega Magic™ PCR DNA purification system was used for
purification of PCR products directly from PCR reaction mixes. The protocol
recommended by the manufacturer is outlined here.
The PCR reaction was brought to a final volume of 300ul with H2O and 
lOOul of direct purification buffer was then added. After the addition of lml of the 
purification resin, the complete mixture was vortexed. The mixture was then loaded
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into a 2ml syringe that was attached to a magic minicolumn. The syringe plunger 
was inserted and the liquid was slowly pushed through the minicolumn. The 
minicolumn was then washed with 2ml of 80% isopropanol. Residual isopropanol 
was removed by spinning the minicolumn at 14,000rpm for 20 seconds before 
leaving it to air dry at room temperature for 10 minutes. 50ul of H2O was placed 
on the resin bed in the minicolumn and left for at least 1 minute. The nucleic acid 
eluted into the H2O was removed from the minicolumn by centrifugation at 
14,000rpm for 30 seconds and collected in a microcentrifuge tube.
PCR products purified in this way were suitable for most molecular 
manipulations.
Agarose gel electrophoresis of nucleic acids
Routine molecular manipulations of nucleic acids were visualised by horizontal 
agarose gel electrophoresis. The concentration of agarose and the dimensions of the 
gel used were determined by the size range and, to a lesser extent, the 
concentration of nucleic acids being separated.
The desired quantity of electrophoresis grade agarose was dissolved in lxTBE 
(table 2.2) by heating in a microwave oven. When all the agarose had dissolved 
ethidium bromide was added to a concentration of 0.5ug/ml. The agarose was 
allowed to cool to approximately 60°C with periodic agitation. Preformed moulding 
trays were used to cast the gel slabs, some of which had open sides which 
required sealing with autoclave tape. Cooled agarose was poured into cleaned trays. 
Combs were inserted into their slots on the trays and bubbles removed using a 
pipette tip. The gel was left undisturbed to solidify after which it was submerged 
in lxTBE in the electrophoresis chamber. The combs were carefully removed. 6x 
loading dye (table 2 .2) was diluted with nucleic acid samples to lx and the 
samples were then loaded into the wells formed by the combs. A molecular weight 
marker was also loaded into one of the wells. A voltage was then applied to the 
chamber such that the nucleic acids migrated through the longest portion of the gel 
towards the anode electrode. Gels were run for 1.5 to 3hrs at 50-80mA such that
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sufficient separation of the nucleic acids was achieved. Gels were then viewed 
under a UV transilluminator and a photograph taken if desired.
The concentration of electrophoresed DNA was estimated by comparing the 
intensity of the DNA band of interest with a band of similar size in the molecular 
weight markers which were normally run in parallel with the DNA of interest. 
Since a known concentration of M.W marker is electrophoresed the quantity of the 
DNA in the sample can be extrapolated from this.
Purification of DNA from agarose gels
Three different methods of purification methods were used:
1. The Promega Magic prep system.
2. The Bio 101 geneclean system.
3. The Pharmacia sephaglass bandprep system.
Although all systems were routinely used the latter was preferable since it 
gave the most consistent results in my hands. Subsequently it is described here in 
more detail. Detailed protocols for the other methods can be found in the 
manufacturer's literature.
The band of interest was cut from the agarose after electrophoresis with a 
sterile scapula and transferred to a microcentrifuge tube. A pipette tip was used to 
mash the agarose plug into smaller pieces. The weight of the excised agarose plug 
was estimated and lul of gel solubilizer/mg of agarose was added to the plug. 
After vigourously vortexing the contents of the tube it was placed at 60°C for 5- 
10 minutes in order to melt the agarose. 3ul of sephaglass was then added and the 
tube gently agitated for 5 minutes. The tube was spun at high speed for 1 minute 
in a microcentrifuge and the supernatant carefully removed so that the sephaglass 
pellet was undisturbed. The pellet was resuspended in 200ul of wash buffer and 
centrifuged as before. This was repeated twice in order to clean the pellet. The 
tube was inverted over a paper towel and left to dry for 10 minutes. The pellet 
was resuspended in 15ul of elution buffer and the tube agitated for 5 minutes.
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After centrifugation for 1 minute the supernatant was removed to a clean tube and 
the pellet subjected to an identical elution process. The supernatants were pooled 
and the quantity of recovered DNA estimated by agarose gel electrophoresis of a 
small aliquot.
Denaturing polyacrylamide gel electrophoresis
The products of sequencing reactions described in the next section are 
separated by denaturing PAGE. The LKB macrophor system was employed for the 
assembly and operation of denaturing PAGE. A detailed description of this system 
is described in the manufacturer's (Pharmacia) literature. The following is a general 
outline of the protocol.
The plates, combs, spacers and wedges were cleaned with detergent followed 
by 70% alcohol in order to ensure the removal of as much dust as possible. The 
thermostatic plate was then treated with repel silane and the back plate with bind 
silane. The spacers, wedges, and thermostatic plate were assembled together. A 
denaturing gel solution (table 2 .2) containing 6% acrylamide was freshly prepared. 
After addition of TEMED and 10% APS to the acrylamide the back plate was 
brought into contact with the spacers and thermostatic plate and the gel poured 
according to the manufacturer's instructions. The combs were inserted to the desired 
level and the gel left to polymerise for 15 minutes.
The gel sandwich was clipped in a vertical position to the macrophor 
apparatus such that the back plate was flush against the buffer reservoirs and the 
thermostatic plate tubing was then attached to the thermostatic circulator. The buffer 
chambers were filled with lxTBE and the combs were carefully removed. Excess 
gel was trimmed away from the top of the wells formed by the combs. 
Unpolymerised acrylamide was flushed from the wells and the entire apparatus was 
checked for leaks prior to application of a voltage. The circulator was switched on 
and set such that the gel was maintained at a constant temperature of 55°C. A 
constant voltage of 2000V was applied and the gel allowed to pre-run for 15-30 
minutes before loading samples.
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Sequencing reactions were placed at 75°C for 3 minutes prior to placing them 
on ice. Reactions were then quickly loaded into respective wells and electrophoresed 
at 2000V for 1.5-3 hours. After electrophoresis the system was dismantled and the 
plates eased apart. The gel adhering to the plate previously treated with bind-silane 
was fixed in 10% acetic acid / 10% methanol, dried, and exposed overnight to 
autoradiographic film. The film was developed in an X-omat automatic developer.
Elution of oligonucleotides
Oligonucleotides were synthesised on an in-house DNA synthesizer and 
provided on a column. The following is the protocol used for elution of an 
oligonucleotide from a column and removal of protecting side chains from an 
oligonucleotide.
2ml of 30% ammonia solution were drawn into a 3ml syringe. This syringe 
was attached to one end of the column and an empty syringe to the other end. 
The column was flushed four times over a period of one hour by repeatedly 
pushing the ammonia back and forth through the column with the syringes. When 
flushing was not in progress the ammonia solution was left in contact with the 
column. The ammonia solution was aliquoted into screw cap microcentrifuge tubes 
after the final flush. The caps were screwed tightly on to the tubes and sealed 
with parafilm. Side chains on the oligo were removed by incubating the eluted 
oligonucleotide overnight at 55°C.
The deprotected oligonucleotide was then placed on ice for ten minutes. One 
tenth the volume of 5M NaCl and 2.5 volumes of ethanol were added and the 
oligonucleotide precipitated at -70°C for 10 minutes. The precipitated DNA was 
collected by centrifugation at 14,000rpm for 15 minutes and washed with 70% 
ethanol. The DNA was resuspended in a total volume of lml of sterile d t^O .
The concentration of the purified oligonucleotide was estimated by UV 
spectrophotometry. The oligonucleotide was diluted 1/100 in a total volume of 
500ul of dH2 0  and the O.D of this dilution measured at 260nm. The absorbancy 
value was multiplied by a factor of 2 to give the concentration of oligonucleotide 
in ug/ul.
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2.2.5 ENZYMATIC MANIPULATIONS OF NUCLEIC ACIDS
Restriction enzyme digestion of DNA
Most digestions were carried out in a total volume of 20ul. The required 
amount of DNA was added to a microcentrifuge tube. Water was added such that 
the final reaction volume was 20ul when all the reactants were present. One tenth 
the volume of the appropriate lOx restriction enzyme buffer was added. In the 
case of plasmid preparations (see section 2.5) 0.5ul of RNase one was added. The 
contents of the tube were mixed and briefly centrifuged. Restriction enzyme(s) (5- 
10 units) were added and the contents of the tube mixed and spun as before. 
Digestions were incubated for 1-2 hrs at the appropriate temperature after which 
time one fifth of the reaction was examined by agarose gel electrophoresis. If 
digestion was not complete more restriction enzyme was added and the reaction 
was left to incubate overnight.
Ligation of plasmid DNA with insert DNA
Plasmid DNA which had been suitably modified for cloning was mixed with 
insert DNA at a molar ratio of 1:100. 50-200ng of plasmid DNA was normally 
used. lOx ligation buffer (lul) was added and the entire reaction volume was 
brought to 9ul with water. The contents of the tube were mixed and centrifuged 
then left on ice for 5 mins. T4 DNA ligase (10 units) was added and the contents 
of the tube mixed as before. The ligation was incubated at 12°C overnight. Part of 
the ligation reaction was transformed into commercially competent E.coli Invitrogen 
a  F' cells according to the manufacturer's instructions.
Nucleotide sequence analysis
The DNA sequences of plasmid DNAs were determined using the dideoxy 
chain termination method (Sanger et al., 1977).
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Single stranded DNA (ssDNA) was prepared from plasmid DNA by 
incubating 9ul of plasmid prepared as outlined in section 2.2.4 with lul of 2M 
NaOH for 15 mins at 37°C. After neutralisation with 3ul of solution three (table 
2.1) 80ul of 100% ethanol was added and the ssDNA precipitated at -70°C for 10 
mins. ssDNA was collected by centrifugation, washed with 75% ethanol, and 
vacuum dried. The DNA was sequenced with either the Sequenase or T7 DNA 
polymerase kits. The latter is described in more detail here since it was the 
preferred DNA sequencing system, however both are essentially the same.
ssDNA was resuspended in lOul of H2O. 2ul of primer at 5pmol/ul was
added to the ssDNA as was 2ul annealing buffer. This annealing reaction was
incubated at 37°C for 15 mins.
The annealed primer/template complex was radioactively labelled by the 
addition of 3ul of labelling mix, lul of [a-^^S]dCTP (370MBq/ml), and 2ul of 
diluted enzyme containing 3.2 units of T7 DNA polymerase. The labelling reaction 
was allowed to proceed for 5 minutes at room temperature. As the labelling 
reaction proceeded 2.5ul of each of the four chain termination mixes were aliquoted 
and prewarmed to 37°C. The labelling reaction was terminated by adding 4.5ul 
aliquots of it to each of the four termination mixes which were then left at 37°C 
for 5 minutes. The termination reactions were stopped by adding 5ul of stop 
solution. Sequencing reactions were analysed by denaturing PAGE (section 2.2.4).
PCR amplification
Saiki et al (1988) described the amplification of specific DNA sequences from 
a complex and heterogenous biological sample by the PCR. In this thesis much of 
the PCR was performed on clarified virus particles.
All PCR reaction mixes were prepared outside the laboratory in an EHV free
area. Perkin Elmer geneamp kits were the source of the main reaction components. 
A reaction typically contained lxPCR reaction buffer, 1.5mM M g C ^  50pmoles of 
each of the primers, 50uM of each of the dNTPs, and 2 units of amplitaq DNA 
polymerase in a total volume of 40ul. lOul of virus containing approximately 1(P 
TCID50 units of virus was boiled for 10 minutes in order to release viral DNA
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from the particles. Virus was added to the reaction mix which was then overlayed 
with mineral oil. The assembled PCRs were subjected to the following thermal 
cycle on a Hybaid thermal block; 95°C for 30 seconds, 48°C for 10 seconds, and 
72°C for 60 seconds, repeated 25 times and followed by 72°C for 5 minutes. 
Variations in any of these parameters are alluded to throughout the thesis.
When the cycles were completed the overlay was removed and an aliquot of 
the PCR examined by agarose gel electrophoresis.
Because of the extreme sensitivity of this technique great effort was made to 
reduce the possibility of contamination. As referred to earlier, reaction mixes were 
prepared in a separate laboratory free from potential sources of contaminaton. 
Positive displacement pipettes were routinely used and gloves were changed between 
samples. Since reaction mixes were prepared in bulk a primer control was included 
which consisted of virus/target free water being added to one of the PCRs prior to 
the addition of virus to the others. A positive primer control PCR would indicate 
inadvertent contamination of reaction mixes with target DNA during preparation. 
Sentinel controls were included when multiple samples were being processed for 
PCR. These controls consisted of an aliquot of virus free water, one for each 
sample being processed. They were handled between each sample and the next in a 
manner identical to the manipulation of each sample before, during, and after the 
PCR. Positive sentinel control PCRs indicated cross contamination of samples. In 
general positive controls were avoided unless PCRs failed. The target in this case 
was normally lOng of plasmid cloned target DNA.
Radiolabelling of DNA
The chosen method for labelling DNA was the random priming method 
developed by Feinberg and Vogelstein (1983). The Pharmacia Oligolabelling kit 
which incorporated this method was used.
25-50ng of DNA was heat denatured at 100°C for 2-3 minutes and then 
placed on ice for a further 2 minutes. The following was added to the denatured 
DNA-lOul of reagent mix, 5ul of a-P^^dCTP(3OOOCi/mmol), and sterile dF^O 
such that the final reaction volume was 50ul. lul of Klenow fragment of E.coli
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DNA polymerase I was added and the reaction mixed and centrifuged briefly. The 
labelling was allowed to proceed at 37°C for 60 minutes. The labelled DNA was 
used directly as a probe (see section 2 .2 .6) without any further purification.
2.2.6 SOUTHERN TRANSFER AND HYBRIDISATION ANALYSIS OF DNA
Southern transfer of DNA
DNA was transferred to nylon membranes by a modification of a method first 
described by Southern (1975).
After the desired degree of separation of DNA was achieved by agarose gel 
electrophoresis the nucleic acid was denatured in situ by immersing the gel in a 
solution of 0.4M NaOH/0.6M NaCl for 30 minutes. The membrane was soaked in 
this solution and placed on a glass plate. All air bubbles were removed from 
between the plate and membrane before the gel was placed on the membrane. Air 
bubbles were removed from between the gel and membrane. Prior to preparing the 
membrane and gel the following assembly was constructed. A glass plate was 
placed on an even surface. A wad of tissue paper was placed on the glass plate. 
Finally 5 pieces of 3mm whatman paper of slightly larger surface area than the gel 
was placed on the tissue. The gel and membrane were allowed to slide carefully 
from the glass plate on to the whatman paper such that no air bubbles became 
trapped between the membrane and whatman paper. The glass plate was then 
placed on top of the gel and a 200g weight placed on the glass plate. This 
assembly was left overnight such that the DNA was drawn down onto the 
membrane by capillary action.
The filter was neutralised by rinsing it extensively in 50mM Sodium 
Phosphate buffer (pH 6.5) (table 2.2). The membrane was placed briefly on 3mm 
whatman paper to remove excess liquid and then allowed to air dry. The membrane 
was wrapped in aluminium foil and baked at 80°C for 2 hours in order to fix the 
DNA to the membrane.
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Hybridisation of radiolabelled DNA to membrane bound DNA
QuickHyb solution from Stratagene was used as the hybridisation medium 
since it has the advantage of allowing quick hybridisations to be performed.
QuickHyb solution (4ml) was placed in a hybridisation bottle and heated to 
68°C in a hybridisation oven. The membrane containing the fixed DNA was rinsed 
in deionised H2O, placed in the bottle containing the QuickHyb and prehybridised 
at 68°C for 20 minutes.
Radiolabelled probe (5ul) was added to lOOul of salmon sperm DNA 
(lOmg/ml) and boiled for 2 minutes, lml of the prehybridisation solution was 
removed from the bottle and the denatured probe mixed with it before returning it 
to the bottle. Hybridisation was allowed to proceed at 68°C for 1 hour.
After hybridisation the membrane was removed from the bottle and rinsed 
with 2xSSC buffer containing 0.2%SDS. The bottle was also rinsed with the same 
buffer in order to remove the hybridisation solution. The membrane was returned to 
the bottle and washed twice for 15 minutes at room temperature with the 
aforementioned buffer. If required a high stringency wash for 30 minutes at 60°C 
with O.lxSSC buffer containing 0.1%SDS was performed.
The membrane was wrapped in saran wrap and exposed to an 
autoradiographic film with an intensifying screen at -80°C overnight. The film was 
developed in an X-omat automatic processor and reexposed if necessary.
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Tables
REAGENTS FOR GROWTH AND PROPAGATION OF ANIMAL 
CELLS, VIRUSES AND BACTERIA
Cell growth medium Virus titration medium L-broth
MEM containing 10% FCS, 
2mM Glutamine, lx MEM 
non-essential amino acids, 
Pencillin/Streptomycin and 
fungizone.
Identical to cell growth 
medium except FCS is at a 
concentration of 2 %.
20g Tryptone
20g NaCl
lOg Yeast extract 
Add dH20  to 21
Adjusted to pH 7.0 with 
NaOH. Autoclaved.
Ampicillin
0.5g of ampicillin dissolved in 10ml of sterile dH2 0  and filter sterilized through a 0.2 
micron filter, aliquoted and stored at -20°C.
SOLUTIONS FOR PLASMID MINIPREPARATIONS
Solution one
25mM Tris HCL pH 8.0 
lOmM EDTA 
50mM Glucose 
The Tris HCL/ EDTA 
solution was autoclaved, 
the required amount of 
glucose was added and the 
solution filter sterilised with 
a 0.2 micron filter.
Solution two
This solution was prepared 
fresh by mixing equal 
volumes of 0.4M NaOH 
and 2% SDS.
Solution three
60ml 5M Potassium Acetate
11.5ml glacial acetic acid 
28.5ml sterile dH2 0 .
Table 2.1: Solutions for cell culture and plasmid minipreps.
ELECTROPHORESIS REAGENTS
lOx TBE 6x Loading dve Sequencing gel mix
216g Tris base 
llOg Boric acid 
100ml 0.5M EDTA 
Added dH2 0  to 21
0.25% BPB
0.25% Xylene cyanol FF 
30% Glycerol
8 .8ml 38% Acrylamide:2%
Bisaciylamide
25.2g Urea
6ml lOx TBE
When the Urea had
dissolved the solution was
brought to 60ml with 
dH20
SOUTHERN BLOT ANALYSIS SOLUTIONS
50mM Sodium Phosphate pH 6.5 20xSSC
4.45g Na2HP04  in 800ml 
Adjusted to pH 6.0 with conc. H3PO4 
Added dH20  to 11
173g NaCl
88.2g Sodium Citrate, trisodium salt.
Adjusted pH to 7.0 with HC1. Added 
dH20  to 11
Table 2.2: Solutions for electrophoresis and Southern blotting.
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3.1 INTRODUCTION
Chapter one described the disease manifestations associated with EHV-1 
infection of the horse. Of the possible outcomes of EHV-1 induced pathology, 
paralytic disease remains one of the most enigmatic as the following summary of 
research in this area will demonstrate.
Saxegaard (1966) was the first to isolate EHV-1 from a horse with paralysis. 
However, this study and others (Thorsen and Little, 1975; Charlton et al., 1976; 
Little and Thorsen, 1976; Thein, 1981; Meyer et al., 1987) describing successful 
virus isolation from the CNS may have been compromised by the fact that CNS 
samples were derived from viraemic animals and therefore may have been 
contaminated at slaughter by virus from the blood vessels supplying the CNS (Platt 
et al, 1980). Furthermore, it has not been possible to reproduce paralytic disease 
by direct innoculation of the virus into the CNS (Prickett and Bryans, 1969), in 
contrast to results obtained via systemic infection which resulted in the fulfilment of 
Koch's postulates in that EHV-1 is an aetiological agent of paralytic disease in the 
horse (Jackson and Kendrick, 1971; Jackson et al, 1977). Subsequent studies have 
demonstrated viral antigen, and to a lesser extent infectious virus, to be present in 
a few vascular endothelial cells within the CNS of affected animals (Jackson et a l, 
1977; Edington et al, 1986; Whitwell and Blunden, 1992; Blunden and Whitwell, 
1993).
Pathological examination of experimentally induced and natural EHV-1
associated paresis in the equid has demonstrated that damage to the vasculature of 
the blood vessels supplying the CNS is the most common feature (Jackson et a l,
1977; Platt et a l, 1980; Edington et al, 1986; Whitwell and Blunden, 1992;
Blunden and Whitwell, 1993). This may be accompanied by thrombosis and is 
thought to lead ultimately to oxygen starvation of the surrounding tissues (Platt et 
al, 1980; Edington et al, 1986). Although direct damage to nervous tissue, which 
can vary in extent and location, is seen post-mortem (Allen and Bryans, 1986 and 
references therein) it is always associated with vasculitis and is most likely
preceeded by it (Jackson et al, 1977).
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Outbreaks of EHV-1 associated paresis can occur in isolation or can be 
associated with outbreaks of abortigenic or respiratory disease (Allen and Bryans,
1986). Given the relatively rare and sporadic occurrence of the disease two theories 
have been postulated as to how and why it happens. The first theory suggests the 
existence of a spectrum of virulence in the natural population of circulating strains 
of EHV-1 i.e highly virulent strains which may not be common induce high rates 
of abortion and severe neurological symptoms, while those at the other end of the 
virulence scale rarely cause abortion or paralysis and are mainly associated with 
respiratory disease. The second theory purports that host factors may determine a 
given horse's or horse population's predisposition to paralytic disease regardless of 
the infecting virus (Allen and Bryans, 1986; Meyer et al., 1987).
Two studies have suggested that mares that have recently given birth present 
symptoms of greater severity relative to other animals in a given outbreak 
(Greenwood and Simpson, 1980; McCartan et al., 1995). Jackson et a l, (1977) 
suggested that in mares pregnancy may be a predisposing factor to EHV-1 induced 
paralytic disease. Hormonal immunosuppression was not considered to be a 
contributory factor since all of the affected mares were at an advanced stage of 
pregnancy when immunosuppressive hormones return to pre-pregnancy levels 
(Jackson et al, 1977). Indeed evidence suggests that the immune system plays an 
active role in neurological disease associated with EHV-1. Inflammation of affected 
areas in the CNS led Jackson and Kendrick (1971) to propose an 
immunopathological mechanism. Previous exposure to virus is thought to result in a 
faster and potentially stronger response to reinfection which might predispose 
immunologically experienced animals to neurological symptoms (Dinter and 
Klingebom, 1976). Of relevance to this theory is the demonstration that some 
newborn foals with CNS pathology do not present with clinical signs of disease 
(Whitwell and Blunden, 1992) and that SPF foals demonstrated clinical 
manifestations only after reactivation of latent virus (Gibson et a l, 1992a). 
Conversely, neurological disease has been demonstrated in foals aged two to 
nineteen weeks. In this study mild symptoms of disease were seen in five out of 
twenty five foals. Most foals tested positive for EHV-1 neutralising antibodies 
(Greenwood and Simpson, 1980).
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Failure to isolate virus from affected tissue has been attributed to the presence 
of high levels of antibodies leading to the suggestion that the lesions were a 
consequence of immune complex deposition (Jackson et al., 1977; Platt et al., 
1980). Immune complexes were demonstrated in animals with EHV-1 associated 
paresis but were detected at high levels only after the onset of pathological changes 
(Edington et al., 1986). Indeed the role of immune factors in the development of 
CNS disease remains unclear in that it is yet to be unequivocally established 
whether or not they are a cause or an effect.
Further evidence for the involvement of host factors in the development of 
CNS disturbances came from the singular isolation of EHV-4 from the brain of an 
animal that had neurological disease (Meyer et al., 1987). It may have been that 
the animal was unusually susceptible to neurological disease or that the virus in 
this case was a highly virulent strain of EHV-4, or conversely that the virus in 
question had nothing to do with the clinical symptoms.
The relatively rare occurrence of EHV-1 induced neurological disease has led 
to the suggestion that the ability to induce paralytic disease is a property of some 
strains of EHV-1 but not of others. Potential experimental support for this 
assumption came from a single study in which RFLP analysis distinguished 
between an isolate from a horse with paralysis and an isolate from a mare which 
aborted during an outbreak of EHV-1 disease on the same farm (Studdert et a l ., 
1984). This study however cannot be considered as definitive evidence for the 
existence of specifically neurovirulent strains since (1) one isolate may have been 
reactivated from latency by the superinfecting virus and may have had nothing to 
do with the observed pathologies, or (2) the infecting virus may have altered its 
genomic structure on in vivo passage thus giving rise to the different isolate or (3) 
the infecting inoculum may have contained more than one strain of virus. The two 
isolates differed with respect to the mobility of certain restriction fragments with at 
least two of the restriction enzymes utilised. This would suggest that the differences 
between the isolates noted within this study were confined to regions containing 
repetitive elements. Matsumara and colleagues (1994) demonstrated that repetitive 
regions were unstable on in vivo passage. One study has distinguished between 
two abortigenic isolates from the same farm on the basis of RFLP analysis. Two 
of the polymorphic sites used to distinguish the isolates resided in reiterated
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sequences. The authors suggest that recrudescence of a latent strain or mixed 
inoculums may account for the observed differences between the isolates (McCann 
et al., 1995).
A singular study has given credence to the possibility that a spectrum of 
pathogenicity may indeed exist in the natural EHV-1 population. This study 
demonstrated that a low-passage EHV-1 isolate had reduced pathogenic potential in 
that it has not been associated with paralytic disease and has a relatively weak 
abortigenic potential (Mumford et al, 1994). The isolate, V592, was isolated from 
a foetus during an abortion storm and passaged twice on equine embryonic lung 
cells prior to analysis. This isolate is not endotheliotropic and does not induce the 
same level of non-specific immunosuppression in ponies as that induced by more 
virulent strains of EHV-1 (Hannant et al, 1991). Obviously, more EHV-1 isolates 
would have to be assessed in this way i.e in the equid, in order to extend these 
findings.
There is evidence to suggest that wild-type HSV-1 isolates have different 
neuropathogenic abilities in animal model systems. Obviously the neuropathogenic 
potential cannot be assessed in the natural host and it is difficult to draw parallels 
between the natural situation and animal models. A similar situation exists with 
respect to EHV-1 in that EHV-1 strains which are neurovirulent in available animal 
models are not necessarily so in the horse and vice-versa (Chowdhury et al., 
1986b; Palfi and Christensen, 1995). Van Woensel et a l . (1995) have developed a 
reliable mouse model system based on EHV-1 induced weight loss in mice for 
determining the pathogenic potential of a given virus in the horse. Whether it is 
also a reliable indicator of pathogenic potential with regard to the CNS remains to 
be seen.
A clear picture does not emerge from the data regarding EHV-1 induced 
paralysis. The research described in this chapter concentrated on the possibility of 
identifying a marker which could distinguish between paralysis-inducing and non- 
paralysis-inducing strains of EHV-1. In contrast to HSV-1 and other a  
herpesviruses it has not been possible to consistently demonstrate productive viral 
replication in the CNS of affected horses or animal models. Certainly studies of 
EHV-1 latency and reactivation would suggest that this virus is indeed neurotropic 
and has the ability to multiply in the CNS, but pathological examination of animals
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with EHV-1 induced paralytic syndrome, as summarised in the preceding 
paragraphs, suggests that EHV-1 neurovirulence is not as a direct result of viral 
multiplication in neuronal tissue. It follows that EHV-1 is not an example of classic 
a  herpesvirus neurovirulence, therefore focusing on previously identified HSV/PRV 
neurovirulence factors was considered inappropriate for this study.
This chapter describes the DNA sequence analysis of the gC gene of isolates 
associated with neurological disease and potentially non-neuropathogenic isolates of 
EHV-1.
An anti-EHV-1 gC monoclonal antibody was initially used to locate the region 
encoding the gC gene in a Xgtl 1 EHV-1 expression library (Allen and Yeargen,
1987). Detailed analysis of this region led to the elucidation of the coding sequence 
of the EHV-1 gC gene (Allen and Coogle, 1988). The open reading frame (ORF) 
contains 1404bp which encode a protein containing 468 amino acids. However the 
predicted size of this protein i.e. 50.8K does not correlate with the 87-96K protein 
recognised by anti-gC Mabs. Indeed further analysis of the translated gene indicated 
that the protein would undergo extensive post-translational modifications. 
Hydropathic analysis of the amino acid sequence illustrated features typical of a 
membrane inserted glycoprotein. These features include (1) a signal sequence 
contained within the first 30 amino acids followed by (2) a region 397 amino acids 
long of extended hydrophobic and hydrophilic regions corresponding to the 
transmembrane domain, which contains 9 potential N-linked glycosylation sites, (3) 
a short region containing a potential hydrophobic membrane insertion site and (4) a 
positively charged cytoplasmic tail.
A comparison of EHV-1 and -4 gC protein sequences indicated that the 
positions of 9 glycosylation sites and 6 cysteine residues were conserved. However 
a comparison of all the herpesvirus gC sequences that have been determined to date 
revealed that it is quite an evolutionary divergent protein (see figure 3.1) (Nicolson 
and Onions, 1990 and references therein). The level of homology between the 
EHV-1 and -4 gC homologues is 79% (Nicolson and Onions, 1990). At the onset 
of this study, gC was considered to be second most divergent glycoprotein of 
EHV-1 and -4, gG being the first (Crabb et al., 1992). Indeed Allen and co­
workers (1988) extended the scope of this divergence by suggesting that 85% of 
the gC epitopes on EHV-1 and -4 also show sequence divergence. The divergent
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N-terminus of the EHV-1 gC homologue was shown to contain an 
immunodominant region in addition to six other distinct epitope containing regions.
The aforementioned data, together with the high degree of interstrain antigenic 
variation identified in EHV-1 gC, led Allen et al (1988) to propose that this 
glycoprotein "contributes to the adaption of the particular EHV-1 subtype (EHV-1) 
to its unique ecological niche within the horse". Thus the N-terminal coding region 
of the EHV-1 gC gene became the focus of this study as it was thought that if 
gC did indeed reflect the unique internal environments that EHV-1 encountered 
within the horse, then determination of interstrain sequence variation, particularly 
within the N-terminal coding region of the gC gene, might reveal markers of a 
given strains pathogenicity since strains of differing pathogenicity may have 
experienced different internal environments.
Other reasons led to the supposition that the gC gene may contain a potential 
EHV-1 neurovirulence marker.
In vivo observations suggested that neuropathogenic EHV-1 isolates may 
preferentially infect endothelial cells of blood vessels supplying the CNS of affected 
animals. gC might be a determinant of endotheliotropism since the gC homologue 
of HSV-1 may determine the ability of certain HSV-1 strains to infect the apical 
surface of bi-polar cells in vitro (Sears et al., 1991; Griffiths et al., 1998). Of 
relevance to this is the finding that the gC homologue of PRV can determine
whether or not PRV can infect a given cell type (Zsak et al., 1992). Limited
variation was detected in the protein and DNA sequences of the gC homologue of 
epidemiological distant strains of PRV (Ishikawa et al., 1996) and HSV-2 (Terhune 
et al., 1998) however these differences could not be correlated with differences in 
pathogenicity.
HSV-1 has been implicated as a potential co-factor in the development of 
atherosclerosis in humans, a condition which ultimately leads to thrombosis in the 
affected blood vessels. gC may focus the complement and coagulation cascades at
affected areas and so ultimately lead to thrombosis (For a review see Hajjar,
1991). The pathology of EHV-1 induced CNS disease is thought to involve 
thrombosis in the blood vessels supplying the nervous system.
45
Chapter Three: Inter-strain sequence analysis o f the N-terminal coding.
As referred to earlier, Allen et a l . (1988) described antigenic variation in gC 
of EHV-1 strains but no linkage between antigenic variation and neurovirulence was 
observed. It is unlikely that Mab typing will detect all possible inter-strain 
variations in gC and therefore a potential marker may not be identified. As a result 
the DNA sequencing approach may be considered superior to RFLP and Mab 
typing analysis because all possible variations in the region analysed will be 
detected. The nucleotide sequence of the entire gC gene of four EHV-1 strains AB- 
4 (Telford et al., 1992), KyA (Matsumura et al.t 1993), T431 (Allen and Coogle. 
1988; Guo et al., 1989) and HVS25A (B. Crabb. Personal communication) has 
been determined independently by other groups and has been shown to contain 
DNA sequence variation (see figure 3.2). KyA is relatively divergent from the other 
strains but this is most probably due to the passage of the virus in non-equine 
cells. HVS25A differs from AB-4 by at least two nucleotides, one of which results 
in a conserved amino acid change; however the passage history of this virus is 
unclear, although it is known that it is a low passage isolate. T431 differs from 
AB-4 at two nucleotide positions but neither of these differences results in an 
amino acid change.
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3.2 EXPERIMENTAL APPROACH
So as to generate comparitive sequence data for the gC gene of EHV-1 
strains a PCR assay was developed in order to amplify the first 700bp of the N- 
terminal coding region of the EHV-1 gC gene. After surmounting initial difficulties 
PCR products were obtained for nine EHV-1 isolates. A TA-cloning vector was 
generated for the purposes of subcloning the PCR products for sequencing analysis. 
At least three cloned PCR products were sequenced for each strain. All strains 
except T431 had identical DNA sequences. The entire gC gene of one strain, 
T373, was sequenced using a similar PCR based strategy in order to determine if 
any C-terminal sequence variation could explain anomalies concerning that strain.
A stringent control system was applied throughout this study to guard against 
the possibility of contamination at the different stages of virus preparation for and 
during PCR.
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3.3 MATERIALS
3.3.1 VIRUS ISOLATES
The virus isolates utilised in this chapter were kindly provided by Professor 
George Allen and Dr. Matthew Binns of the University of Kentucky, U.S.A and 
the Animal Health Trust, U.K. respectively (see table 3.1).
3.3.2 OLIGONUCLEOTIDE PRIMERS
PCR primers were obtained from Applied Biosystems, U.K. and sent directly 
to Dr. E. Hall, Stirlingshire for the preparation of master mixes in an EHV-1 free 
area described in chapter 2 section 2.2.5. Sequencing primers were synthesized at 
the MRC retrovirus laboratory, University of Glasgow Vet School by Mr. T 
McPherson. See table 3.2 for a list of the primers and their sequence. The 
approximate position and orientation of these primers in the EHV-1 gC is shown in 
figure 3.3.
3.3.3 RECIPES
IPTG
A 50mM solution of IPTG was prepared in water and this was added to 
molten L-agar at a final concentration of 0.5mM.
X-G al
A 40mg/ml solution of X-Gal in DMF was prepared and added to molten L- 
agar at a final concentration of 40ug/ul.
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3.4 METHODS
3.4.1 PCR AMPLIFICATION OF EHV-1 ISOLATES
In order to amplify the N-terminal coding region of the gC gene of EHV-1 
isolates two oligonucleotide primers PC-3 and PC-5 (fig 3.3 and Table 3.2) were 
obtained. Optimal amplification conditions were initially established using a plasmid 
containing the EHV-1 HVS25A gC gene as starting template. The thermocycling 
parameters for these primers were 25 cycles of denaturation at 94°C for 20 secs., 
annealing at 48°C for 20 secs., and extension at 72°C for 60 secs. A final 
extension at 72°C for 5 mins. was also included. Each reaction contained 2.0 units 
of Taq DNA polymerase. All sentinel controls associated with the growth and 
preparation of these isolates for PCR (see chapter 2 sections 2.2.2 and 2.2.5) were 
amplified with primers PC-3 and PC-5. Likewise a control containing 10^ 
uninfected cells used for the propagation of viruses was subjected to PCR analysis. 
Primers PC-5 and PC-7 were utilised to amplify the entire gC coding sequence, 
using identical thermocycling parameters as for PC-5 and PC-3 with the exception 
that the extension times were increased to 90 secs (fig. 3.3 and table 3.2). The 
products of three independent amplifications for each virus were then pooled and 
precipitated prior to analysis by agarose gel electrophoresis.
3.4.2 AGAROSE GEL ELECTROPHORESIS AND PURIFICATION OF PCR 
PRODUCTS
PCR products were separated on 0.7% agarose gels or LMP gels. Individual 
bands of the correct size were excised from the gels with a clean scalpel blade and 
the DNA extracted from the gel segment using geneclean or sephaglass band prep, 
kits. The PCR products were eluted in 30ul of T.E or water. The yield of nucleic 
acid was estimated spectrophotometrically prior to storage of the purified PCR 
product at -20°C until it would be required for further analysis.
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3.4.3 CONSTRUCTION OF A TA CLONING VECTOR
Bluescript M l3+ vector was modified according to the method of Marchuck et 
al (1991), to generate a T-tailed vector for the direct cloning of PCR products. 
5ug of vector were digested to completion with EcoRV. The digest was phenol 
chloroform extracted and the nucleic acid precipitated with ethanol. The blunt-ended 
vector was resuspended in a PCR reaction containing IX PCR buffer, 1.5mM 
MgCl2 , 2mM dTTP, and 5 units of amplitaq enzyme. The reaction was incubated 
at 70°C for 2 hours, after which time the modified vector was phenol extracted 
and precipitated. The vector was resuspended in a final volume of water such that 
the nucleic acid concentration was 20ng/ul. Aliquots of the vector named pBSTA 
were stored at -20°C.
3.4.4 CLONING AND SEQUENCING OF PCR PRODUCTS
PCR products were ligated with pBSTA and transformed into commercially 
competent Invitrogen a -F  cells or electrocompetent JM109 cells. Clones were 
selected by plating the transformations on LB agar containing IPTG, X-Gal, and 
50ug of ampicillin per ml of agar.
Plasmid DNA was extracted from white colonies and the presence of a cloned 
PCR product verified by digesting the plasmids with EcoRI and Hindlll which 
flank the cloning site.
At least three cloned PCR products derived from each virus were sequenced. 
Potential discrepancies between the sequences were resolved by sequencing a fourth 
clone. Cloned PCR products derived using primers PC-3 and -5 were sequenced 
with primers PC-3, -5, -4, and -6 (figure 3.3 and table 3.2). The cloned PCR 
products derived from PC-5 and -7 were sequenced with primers PC-5, -7, -3, -4, 
-6 , -8 , -9 and -10 in order to derive sequence data across the entire cloned PCR 
product.
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3.4.5 SOUTHERN BLOT ANALYSIS OF PCR CONTROLS
All control PCRs were precipitated, resuspended in lOul of water, and run on 
0.7% agarose gels along with lpg and O.lpg of purified PCR products. The gel 
was first stained with ethidium bromide and viewed under UV. DNA was 
transferred to a nylon membrane and then probed with a PCR product labelled with 
32p_dATP by random priming. The membrane was exposed overnight to 
autoradiographic film at -80°C with an intensifying screen in place.
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3.5 RESULTS
3.5.1 AMPLIFICATION OF THE gC GENE OF NINE EHV-1 ISOLATES
The amplification parameters for PCR using primers PC-3 and -5 were 
initially established using plasmid DNAs as targets. However, when these 
conditions were employed for the PCR with vims as a source of template, a 
number of problems were encountered which are illustrated in figure 3.4.
No amplification products were detected with either the Animal Health Trust 
(figure 3.4 lane 5) or University of Kentucky (figure 3.4 lane 9) vims isolates 
when using one unit of Taq polymerase in PCRs. Increasing Taq polymerase to 
two units per reaction resulted in products for AHT isolates (figure 3.4 lane 7) but 
not for those supplied by the University of Kentucky (figure 3.4 lane 11). A 
distinct difference between the isolates supplied was that those obtained from 
Kentucky were freeze dried while those from the AHT were supplied as tissue 
culture supernatants. Secondary stocks of all isolates were made as described in 
chapter two, and when used as sources of target template successful amplification 
occurred at the elevated enzyme concentration (figure 3.4 lanes 13 and 15). A PCR 
product of approximately 700bp corresponding to the N-terminal coding region of 
the gC gene was obtained for each isolate.
Isolate T373 was used as a template for PCR amplification with primers PC- 
5 and -7 under the conditions established for primers PC-3 and -5, with the 
exception that a longer extension time was employed with regard to the expected 
size of the PCR product. A product of approximately 1.5kbp was obtained (figure
3.5 lanes 5 and 7).
3.5.2 CLONING AND SEQUENCING OF PCR PRODUCTS
Initial attempts were made to sequence dsPCR products directly using a 
number of previously published techniques; however in my hands, these methods 
proved inconsistent and unsuitable for comparative sequence analysis (data not
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shown). It was decided to adopt a more conventional approach of cloning and 
sequencing.
Bluescript M l3+ was modified for cloning PCR products and proved quite 
successful in that excellent cloning efficiencies with low backgrounds were obtained. 
The vector remained stable for two years after which time the cloning efficiency 
was spontaneously reduced, possibly because of the loss of the T tails. All PCR 
products were cloned with this vector (figure 3.5 lanes 8 and 9) with the exception 
of that derived from strain 82244 which was cloned using the Invitrogen TA 
cloning kit according to the manufacturer's (Invitrogen) protocol.
Sequencing of the plasmid cloned PCR products revealed that all isolates had 
gC N-terminal coding sequences identical to EHV-1 AB-4 (table 3.3) with the 
exception of strain T431, the sequence of which was identical to that obtained by 
Allen and Coogle (1988) (see figure 3.2). The sequence of the PCR product 
representing the entire gC gene of T373 was identical to that of strain AB-4.
In the case of four strains T373, T632, AHT50592 and AHT91320 at least 
one mutation was detected, relative to the consensus sequence for each strain, in a 
plasmid cloned PCR product (table 3.4 and figure 3.6). Initially these were 
assumed to be PCR artifacts on the basis that a fourth clone sequenced through the 
area thought to contain the mutation was identical to EHV-1 AB-4. In the case of 
T373 a further 6 clones were sequenced in the region of interest and were shown 
to have an AB-4 like sequence in this region (table 3.4).
3.5.3 SOUTHERN BLOT ANALYSIS OF EXPERIMENTAL CONTROLS
All the controls involved in the preparation of the viruses for PCR were 
initially PCR amplified using primers PC-3 and -5. The PCRs, when run on 
ethidium bromide stained gels, revealed no contaminating template in these controls. 
Southern blot analysis of these gels detected the presence of as litde as 0.1-1 pg 
of PCR product in the positive control lanes, whereas all the preparative control 
lanes were negative (figure 3.7).
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Figure 3.1: Alignment of selected a-herpesvirus gC amino acid
sequences. gC homologues were aligned using a clustal program. Each virus 
is indicated at the beginning of each row of the corresponding gC amino acid 
sequence and the number of the last amino acid in each row is indicated at the 
end of each row. Amino acids are represented by single letters. Regions of 
100% identity are boxed.
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Figure 3.2: Alignment of the published gC DNA sequences o f
three EHV-1 strains. The EHV-1 strain is indicated at the beginning of each 
row of its corresponding gC DNA sequence. Nucleotides are represented by 
single letters and the number of the last nucleotide in each row is indicated at 
the end of each row. Regions of 100% identity are shaded.
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TCXACXAl^ OX^ ACSG GCAOXiAGIATCATITGX'C: GOVIAGCCA&a&^^
^AGCATAGAGPGGTACAG GGAOG^AGIMtXSTIGXC 0CATAGDCAAAGC2XXAACA GCXnXXSIUmGIT
GxxxAAcaTrcjrcaTFi’ix: gtiataagxcxagagggcci vtcixii’accicx'1 aaaixxgta  ccgj q^gagcxixgig
OU'ZTAAlXXJ'GI'COGi'riG XXrAGAAGACGT-AGACGGCCi TGIUrAOGCXXWj'IXXXTI'A CGCACXACXX3XX71G 
GXOTAACOTIXXCOGrTTC GTmGAAXCGGXGATGXG TCTGrAOXXXAAATGOTrA i'CXJG^GGAOOGSGGTG
PC-5 PC-6 PC-8 PC-9
PC-4 PC-3 PC-10 PC-7
= Forward primer 
= Reverse primer 
—  = non-coding region 
Q  = gC coding region
| =  linear antigenic domain (Allen et  a l 1992) 
ATG = start codon (124)
TAG = stop codon (1531)
Figure 3.3: Schematic representation of the EHV-1 gC gene indicating the 
approximate position of various primers
Figure 3.4: PCR analysis of virus isolates with primers PC-3 and
PC-5. Negative image of an ethidium bromide stained 1% agarose gel
electrophoresis analysis of PCR reactions containing various virus isolates/stocks and 
different Taq polymerase concentrations. Lanes (1) X HindHI/EcoRI M.W marker.
Molecular weights are given on the left hand side of the gel. (2) Example of a
negative control. (3) Example of a sentinel control. (5) Primary stock AHT82244 
with 1 unit of Taq. (7) Primary stock AHT82244 with 2 units of Taq. (9) 
Primary stock T632 with 1 unit of Taq. (11) Primary stock of T632 with 2 units
of Taq. (13) Secondary stock T632 with 2 units of Taq. (15) Secondary stock
AHT 82244 with 2 units of Taq. (19) and (20) 1 pg of positive control plasmid 
DNA.
21 ,266
1 2 3 . 5
5149,4973
426
3530
1 9 2 0
2027,1904 m
1 584 
1 375
5 6 4
■ 7 0 0 B p
Figure 3.5: TA cloning of PCR product generated with primers PC -5
and PC -7. Negative image of an ethidium bromide stained 0.7% agarose gel. 
Lanes (1) X HindIII/pucl9 Taql/pucl9 Sau3A I M.W marker. Molecular weights 
of selected bands are listed on the left hand side of the gel. (2) Negative control 
i.e. PCR with no template (5) PCR with PC-5 and -7 using T373 as template. 
(7) Purified T373 PCR product. (8) pBSTAT373-1.5 linearised with EcoRI. (9) 
pBSTAT373-1.5 digested with Hindin and EcoRI. No samples loaded in lanes (3), 
(4) and (6 ).
4 
44TA clone pBSTA
PCR product\insert
Figure 3.6 DNA sequence of cloned m utant PCR products:
Autoradiographs of sequencing gels illustrating the DNA sequence of non-mutant 
(First four lanes of each autorad from left to right) and mutant (last four lanes of 
each autorad from left to right) PCR products derived from (A) T373 (B) T373 
(C) AHT50592 (D) T632 and (E) AHT91320. The location of the mutated 
sequences on the autoradiograph and the type of nucleotide change are indicated on 
the right hand side of each autoradiograph. The number in brackets indicates the 
position of each mutation in the EHV-1 gC coding sequence (Allen and Coogle. 
1988).
T373 (587) T373 (335)
50592
T A-►AT
Figure 3.7: Southern blot and hybridisation analysis of PC R
controls: Two examples of autoradiographs showing the signals obtained from
varying quantities of PCR product and thus the sensitivity of the probe used for 
hybridisation. These positive controls were loaded and electrophoresed on the left 
hand side of the gel which was then subjected to Southern transfer and 
hybridisation analysis. All other lanes contained a selection of either negative or 
sentinel controls from PCR analysis of the various isolates. All were negative in 
that no signal was detected.
1 pg PCR p ro d u ct-^ li
0.1 pg PCR product-►
Isolate Observed clinical 
manifestations
Supplier Citations
T431 Abortigenic GA Allen et al., 1988
T373 Abortigenic GA Allen et al., 1988
T654 Abortigenic GA None
T672 Paralytic GA Binns et al., 1994
T632 Abortigenic/Paralytic GA None
T629 Paralytic GA Binns et al., 1994
A H T91320 Paralytic MB McCann et al., 1995
AH T82244 Paralytic MB McCann et al., 1995
AH T50592 Abortigenic MB Mumford et al., 1987 
Hannant et al., 1991 
Mumford et al., 1994 
McCann et al., 1995
Table 3.1: List of EHV-1 isolates analysed, their d isease
association and the supplier. GA= Professor G. Allen and MB= Dr. M. 
Binns. The column headed citations lists references containing details of 
experiments involving these isolates.
Primer Sequence Location (Numbered 
according to Allen 
and Coogle 1988)
Application
PC-3 5'-gacggtaacgctggtac-3' 765-749 PCR and sequencing
PC-4 5'-aatggggtgcgctggtt-3' 470-454 sequencing
PC-5 5'-tctccgaccagtggagtt-3' 61-78 PCR and sequencing
PC-6 5'-aaccagcgcaccccatt-3' 454-470 sequencing
PC-7 5'-aggttgtttgggggaga-3' 1557-1541 PCR and sequencing
PC-8 5'-gtaccagcgttaccgtc-3' 749-765 sequencing
PC-9 5'-cagtcttcgctgtagca-3' 1114-1130 sequencing
PC -10 5'-tgctacagcgaagactg-3' 1130-1114 sequencing
Table 3.2: Details of primers used for sequencing and PCR
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Chapter Three: Inter-strain sequence analysis o f the N-terminal coding,
3.6 DISCUSSION
All virus isolates initially proved to be unsuitable sources of PCR template 
when 1 unit of Taq polymerase was used in the PCR to amplify the N-terminal 
coding region of the EHV-1 gC gene. Raising the concentration of Taq polymerase 
to 2 units/reaction resulted in successful PCR amplification from AHT but not from 
University of Kentucky isolates. Since the latter were supplied as freeze-dried 
stocks it was assumed that some aspect of the freeze-drying process introduced 
elements to these stocks that were inhibitory to the PCR process regardless of the 
concentration of Taq polymerase utilised. Secondary stocks for both the AHT and 
University of Kentucky isolates proved to be suitable sources of PCR template at 
elevated Taq polymerase concentration. Retrospective examination of supplied stock 
virus titres may explain unsuccessful amplification at lower enzyme concentrations. 
All isolates supplied had titres ranging from Kp-lO^ infectious virus particles/ml, 
implying that between 10-100 virus particles were used as templates in each PCR 
if the genome contribution of non-infectious viruses is ignored. This may have 
been insufficient template to produce a visible PCR product at the lower polymerase 
concentrations. All secondary stocks had titres ranging from 10^-10^ infectious 
particles/ml. As these stocks were not subjected to PCR at the lower enzyme 
concentration it was not demonstrated that low virus titre was the reason for
unsuccessful PCR amplifications at lower enzyme concentrations.
The sequencing of the N-terminal coding region of the gC gene of nine
isolates revealed that they all had identical amino-acid and, with the exception of
T431, DNA sequences. Although the study cannot be considered extensive since 
only nine isolates were analysed, the sequence conservation observed is surprising 
in that all isolates are epidemiologically distant from each other with regard to 
origin, disease symptoms, or time. The results are believed to be accurate for two
reasons. Firstly, a stringent control regime was in operation and this revealed that 
no contamination occurred during the preparation of viruses for PCR. Secondly, 
isolate T431 can be considered as an internal control because it was known to 
contain sequence variation in relation to strain AB-4 which was detected in this 
study.
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Obviously the work of Allen and colleagues (1988), their study detecting a 
very high degree of inter-strain antigenic variation in EHV-1 gC, is in direct 
conflict with this study. Likewise, complement dependant neutralising anti-gC Mabs 
detected antigenic variation in EHV-1 isolates from Japan (Shimizu et al., 1989). 
Similar studies detected inter-strain antigenic variation in the gC homologue of PRV 
and HSV-1 (Pereira et al., 1982; Ben-Porat et al ., 1986). Studies of HSV-2
glycoproteins other than gC also revealed limited inter-strain antigenic variation 
(Bhattarakosol et al., 1990; Bhattarakosol et al, 1991). However, Bhattarakosol and 
co-workers (1990) noted that with the ELISA assay they employed to determine 
antigenic variation, the optical density values inexplicably varied between strains 
over a broad range of values which were independent of the viral protein 
concentration present in the ELISA. In addition, each of the aforementioned PRV 
and HSV studies analysed strains that were grown in cells derived from animals 
which are not the natural host of the virus under study. Changes in the coding 
region of the EHV-1 gC gene homologue have been observed after passage of the 
virus in cells which were not of host origin (Matsumura et al., 1993; Sugahara et 
al, 1994). However other studies (Kirisawa et a l, 1994; McCann et al., 1995) 
noted that strains of EHV-1 were quite stable in terms of genomic structure after in 
vitro passage and concluded that the instability observed by others may depend on 
the cell type utilised for virus propagation (Kirisawa et al, 1994).
It is likely that these variations in the epitope content of glycoproteins are due 
to inter-strain sequence variations in the encoding genes. Indeed, this has been 
demonstrated for HSV-1 and members of the other families of the herpesviridae. 
On the other hand, there is evidence accumulating that the EHV-1 genome is 
extremely stable and that the majority of inter-strain genomic variation is not due to 
genetic mutation but rather to differences in copy number of repetitive sequences 
(Allen et al, 1983a; Studdert et a l, 1992; Kirisawa et a l, 1993b; Binns et a l, 
1994; Bonass et al.., 1994; Matsumura et a l, 1994). Studdert et al (1992) 
demonstrated that there was no antigenic variation in Australian EHV-1 isolates 
which were found to diverge at the genomic level. The Mabs used in the 
Australian study had also been used in the studies of Allen et al (1988). No 
antigenic variation in gC was noted among a small number of English isolates 
(Sinclair et a l, 1989). It might be argued that these studies are insensitive,
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epidemiologically different, or not sufficiently extensive to detect the same level of 
variation as that detected in the study of Allen et al (1988).
A consideration of the biology of EHV-1 does not resolve the apparent 
disparity of the studies described above. gC has been shown to be a major target 
of the equine humoral immune response (Allen et al., 1992; Ostlund et al., 1992; 
Ahmed et al., 1993). While many of the epitopes in the gC molecule are 
neutralising in vitro (Allen et al, 1988; Sinclair et al., 1989) it must be considered 
that EHV-1 can circumvent a neutralising response in vivo (Bryans. 1969; Allen 
and Bryans. 1986). A number of studies have demonstrated a role for gC in 
protecting against or reducing the severity of EHV-1 disease in animal models (Guo 
et al., 1989; Stokes et al., 1989; Guo et al., 1990). These facts favour the 
archetypal concept of immunological pressure or selection resulting in antigenic 
variation in a pathogen, in this case EHV-1. Opposition to this concept comes from 
the possibility that EHV-1 can evade the immune system of the horse thus avoiding 
immunological pressure. Firstly, the virus spreads systemically in a cell-associated 
form, potentially avoiding the initial efforts of the host's immune system to control 
its spread. Secondly, evidence suggests that the virus can suppress aspects of the 
cell mediated immune response which may also indirectly affect the humoral 
response, although this latter aspect has not been demonstrated. Thirdly, the host 
becomes susceptible to reinfection every six months, a fact especially true of 
younger horses, thereby indicating an ineffective immune response or ineffective 
immunological memory. Conversely it could be argued that reinfection may be as a 
result of an antigenic variant. Finally, the virus can establish a latent infection 
which protects it from the immune system and may be a source of rapid reinfection 
from within. In truth it is difficult to interpret how the complex biology of EHV-1 
induced disease could affect antigenic variation in particular and strain variation in 
general. Antigenic and strain variation results from random and spontaneous
mutation. The importance of any variation will depend on the advantages or
disadvantages that result from it e.g. a variant may bypass a neutralising CMI
response and reach the CNS in sufficient quantities so as to cause paralytic
disease. Although this may be initially advantageous for that particular strain it may 
result in an increase in host mortality, ultimately leading to the disappearance of 
that strain from the circulating strain population. Smith and Inglis (1987 and 
references therein) have suggested that for any virus strain variation is affected by
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a complex interplay of factors contributed by both the virus and host, the effects 
of which are difficult to predict.
Probably the most perplexing aspect of this study is that in contrast to the 
Mab typing studies performed by Allen et al (1988) inter-strain sequence variation 
was not detected, with the exception of T431, in the N-terminal coding region of 
gC. Mab typing detected antigenic variation in all the isolates analysed in that study 
which suggests that there is inter-strain sequence variation. A number of these 
isolates were assessed in this sequencing study yet no variation was detected. A 
possible explanation for this could be that the PCR/sequencing strategy adopted 
failed to detect variation because it is located in the C-terminal sequence. In an 
attempt to verify this hypothesis, and therefore resolve the discrepancies between 
the studies, further investigation of strain T373 was instigated. Strain T373 did not 
bind Mab 26A5 even though the sequence data suggested that the linear gC epitope 
that it recognises was intact in T373. It was proposed that sequence variation in 
the C-terminal region would result in the masking of this linear epitope of strain 
T373, possibly through altered conformation of gC. Site-directed mutagenesis 
studies have demonstrated that changing amino acids not directly involved in the 
formation of this epitope can reduce the efficiency of recognition by the Mab 
(Coogle et a l , 1992). Nevertheless this theory was later proven wrong as the 
entire amino acid sequence of gC of T373 is identical to that of T431 which is 
reactive with Mab 26A5.
In light of the study presented here a number of mechanisms other than 
genetic mutation of epitopes might be proposed in order to explain the differential 
reactivity of Mabs with gC of different strains. Carbohydrates can affect the 
reactivity of antisera to some glycoproteins (Alexander and Elder. 1984). Sugar 
moieties can have either a positive or negative effect on the antigenicity of peptide 
epitopes in gC of HSV-1 (Sjoblom et al, 1987). Variable glycosylation patterns of 
different strains might give rise to antigenic variation as suggested by Olofsson et 
al (1990). The tissues in which a virus has replicated can influence the 
glycosylation of viral proteins and thus give rise to antigenic variation (Datema et 
al, 1987). EHV-4 gC molecular weight varies when grown in different cell lines 
(Crabb et al, 1991). Of significance is the fact that the reactivity of anti-gC Mabs 
does not differ between EHV-4 grown in the different cell lines, although the Mab
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reactivity was determined by different methods for the different virus preparations. 
Another possible mechanism of antigenic variation is the association of an invariant 
protein with one that is widely divergent between different strains. Envelope 
glycoproteins of HCMV are known to form heterologous complexes with each other 
(see Spaete et al., 1994 and references therein). The same is true of HSV-1 for 
which it has also been found that some envelope glycoproteins associate with 
tegument proteins, with the notable exception of gC (Zhu and Courtney. 1994). It 
is not known if these associations are sufficiently intimate for one protein to affect 
the antigenicity of another.
Plasmid cloned PCR products which differed from the consensus AB-4-like 
sequence were obtained for four of the nine viruses analysed. These were initially 
considered to be Taq polymerase generated point mutations on the basis that three 
other cloned PCR products obtained from each virus had gC sequences identical to 
that of AB-4. Indeed these mutations may not have been cloned and sequenced if 
proof-reading thermostable enzymes such as Vent or PFU DNA polymerases had 
been used for PCR. These enzymes increase the fidelity of amplification. 
Furthermore, the cloning/sequencing strategy adopted results in the sampling of a 
small fraction of the PCR products generated increasing the chances of identifying 
such Taq induced mutations.
However, given that every effort was made to reduce the potential for errors 
generated by Taq, the surprising sequence bias toward AB-4 in this study and the 
direct conflict with that of Allen's, the possibility that these PCR products were 
derived from a minor variant virus in an AB-4 like population i.e. these strains 
were mixed virus populations, was given further consideration. That a given isolate 
may consist of more than one strain has been long established for RNA viruses of 
plants and animals, and is known as the quasi-species hypothesis (reviewed in 
Domingo, 1989). The mutation rates of RNA viruses are significantly higher than 
those of DNA viruses therefore DNA virus isolates are generally more 
homogeneous, although it can be inferred from studies with neutralising Mabs that 
some DNA virus isolates, including herpesvirus isolates/strains, are potentially mixed 
virus populations (reviewed in Smith and Inglis, 1987).
The potential that one of the isolates in this study consisted of a mixed virus 
population was given further credence as one of the cloned mutant PCR products
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derived from strain T373 contained a mutation (at position 587 in the gC DNA 
sequence) which lay in close proximity to the region encoding (at position 561-579 
in the gC DNA sequence) the epitope recognised by Mab 26A5 (Allen et al., 
1992). Sequencing a total of 10 cloned PCR products derived from isolate T373 
indicated that the mutant PCR product represented less than 10% of the total 
number of PCR products cloned. Did the mutant PCR product represent the first 
700bp of the gC gene of the T373 isolate originally analysed by Allen and Coogle 
(1988) and if so, how did the virus containing the AB-4 sequence become the 
predominant strain in this isolate? An AB-4 like strain may have arisen
spontaneously in the T373 stock on passage in cell culture or via contamination of
isolates. All strains were passaged no more than 3-10 times in equine cells. It
remains to be seen how this would contribute to the spontaneous appearance and 
domination of an AB-4 like virus, although extensive passage in non-equine cells 
can induce changes in the gC gene (Sugahara et al., 1994) and Mumford and co­
workers (1994) have shown that plaque purification in non-equine cells followed by 
multiple (12) passages in equine cells resulted in the production of a strain of 
EHV-1 with a markedly different pathogenic potential to that of the parent strain.
As alluded to earlier, all controls were negative using the highly sensitive 
combination of PCR and southern blot analysis. Contamination from without within 
the confines of this study was considered unlikely on this basis since these 
controls included uninfected cells which were used to propagate the viruses and 
sentinel controls used in the preparation of these viruses before and during PCR. 
However, the possibility that the viruses were contaminated prior to the onset of 
this study could not be excluded. Since these possibilities could not be totally 
discounted and given their gravity in relation to the data described in this chapter,
further investigations of the cloned mutant T373 PCR product and of a number of 
hypotheses introduced in this discussion were carried out as described in chapter 4.
Obviously this study failed to detect any inter-strain sequence variation other 
than that previously published or any marker for neurovirulence in gC of EHV-1. 
The reasons for choosing gC must be addressed in the light of these findings.
The N-terminal region of gC was shown to be highly divergent between a  
herpesviruses. This, together with the existence of inter-strain antigenic variation in 
gC of EHV-1, led to the proposal that this gene should contain sequence variation
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that may reflect the internal host environment that a given strain has encountered. 
That inter-strain antigenic variation may not necessarily reflect sequence variation has 
already been addressed. At a superficial level inter-virus sequence divergence does 
not automatically imply inter-strain divergence, although a singular study has 
demonstrated this phenomenon in gL of HSV-1 (Novotny et al., 1996). Deeper 
examination of this concept of divergence is required e.g. two closely related
viruses such as EHV-1 and -4, having relatively similar biology and infecting the 
same host but with markedly different clinical sequellae, have highly divergent gC 
N-termini so why is the same not true of EHV-1 strains? Ignoring the essential 
contribution of evolution to EHV-1 and -4 divergence a comparison of the parasite- 
host relationships of both EHV-1 and -4 reveals significant differences. Comparing 
the host-parasite relationship of different strains of EHV-1 would at first glance 
also reveal significant differences. However the factors that lead to these differences 
are not clearly understood. It is emerging that the majority of EHV-1 strains follow 
the same course of infection regardless of the clinical outcome, and therefore 
different strains of EHV-1 are not exposed to significantly different internal
environments which may explain the lack of sequence variation detected in this
study. Furthermore, Terhune and colleagues (1998) have demonstrated that for
HSV-2, replication in different organs does not lead to sequence variation in three 
glycoprotein genes gC, gB and gD.
The properties of endotheliotropism and induction of thrombosis, which were 
among the reasons for choosing gC in relation to EHV-1 induced paralysis at the 
onset of this study, are not necessarily hallmarks of EHV-1 induced paralysis alone 
but are also relevant to the pathology of EHV-1 induced abortion (Edington et al., 
1991; Smith et al, 1992 and 1993).
Indirect evidence for the involvement of EHV-1 gC in neurovirulence came 
from functional studies of the HSV-1 gC homologue. In retrospect, there is also 
evidence to suggest that the HSV-1 homologue may have conserved functions in 
vivo, and therefore at least some sequence conservation that may also be applicable 
to gC of EHV-1 which seems to be completely conserved, at least in the N- 
terminus, according to the study presented herein. gC of HSV-1 and the PRV 
homologue bind virus to heparin on the surface of cells, may have a role in 
penetration/egress, and bind complement. The relative importance of gC in the two
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former processes cannot be truly assessed since other viral proteins have similar 
functions e.g gB (Herold et al., 1991 and 1994) or also participate in these 
processes. As a result, it cannot be inferred that some sequence constraints are 
placed upon wt HSV-1 strains with regard to these functions. Indeed for PRV it 
was demonstrated that a number of distinct sites in gC could bind to heparin 
independently and exclusively of each other (Flynn and Ryan. 1996). The situation 
is different with regard to complement binding in that this function was shown to 
be conserved in low passage clinical isolates of HSV-1 (Friedman et al, 1986) and 
essential in protecting HSV-1 during the initial stages of infection. The areas not 
involved in binding C3b have been identified for HSV-1 and -2. These areas may 
be under less pressure to conserve sequence although there is a possibility that they 
are involved in other functions which require conservation e.g in HSV-1, AA 23- 
123 are not essential for complement binding but are important in binding 
properidin, a serum protein that stabilises the C3 convertase of the complement 
cascade system (Hung et al., 1994). The overall conformation of gC of HSV-1 
may be important in binding complement components (Friedman et al., 1986). 
Furthermore, some of the antigenic sites on HSV-1 gC overlap sites involved in 
complement binding (Friedman et a l, 1986) implying that there may be indirect 
conservation of antigens through conservation of function. These potential 
conservation pressures on gC of HSV-1 may also apply to the EHV-1 homologue 
since it has also been demonstrated to bind complement (Huemer et al, 1995). On 
the other hand, Huemer and co-workers (1995) have demonstrated that attenuated 
strains of EHV-1 with sequence variation in the gC gene as determined by RFLP 
analysis were able to elicit complement binding in infected cells.
The multiple outcomes of EHV-1 infection of the horse are no exception to 
the rule of the multifactorial nature of disease. For other a  herpesviruses the viral 
factors, and to a lesser extent, the host factors contributing to disease are being 
identified. Unfortunately this data is not directly transferable to EHV-1 since its 
pathogenic mechanisms seem to be unique among a  herpesviruses although they 
share many other properties. Furthermore the equid and the thoroughbred horse 
population in particular, through selective breeding, may have a limited gene pool 
compared to the hosts of other well studied herpesviruses. Therefore the apparent 
disparities between this study and others may be a reflection of the peculiar 
position that EHV-1 occupies within the a  herpesvirinae.
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4.1 INTRODUCTION
Chapter three left many interesting questions unanswered, particularly with 
regard to isolate T373 and the cloned mutant PCR products.
Mutations in the cloned PCR products could (1) be a consequence of the 
intrinsic error prone DNA synthesis of the Taq polymerase during PCR or (2) 
indicate the existence of isolates of EHV-1 that are mixed virus populations, the 
cloned mutant PCR products representing the N-terminal DNA sequence of the gC 
gene of minor strains in an isolate consisting mainly of strains with an AB-4 like 
gC DNA sequence. A mutant clone derived from a PCR with isolate T373 had 
two mutations, one of which mapped very close to the coding sequence for the 
epitope recognised by Mab26A5, previously demonstrated to be unreactive with this 
strain. This led to the hypothesis that this PCR product may have been derived 
from the isolate initially analysed by Allen which did not react with Mab26A5. 
Therefore T373 and possibly the other three isolates from which mutant PCR 
products were derived may be mixed virus populations. The possibility that mixing 
arose through contamination was considered unlikely because of the extreme care 
taken in the preparation of these viruses for PCR and the fact that they were 
supplied by two different sources. Mixed virus populations are a natural 
phenomenon and an important consideration for clinicians and basic researchers 
trying to develop effective ways of managing EHV-1 associated diseases.
Allen et al (1983b) was the first to report the isolation of two genetically 
distinct strains from a single EHV-1 isolate by plaque purification in equine cells. 
The genetic alteration was located in the repeat regions of the viral genome. It is 
widely accepted that the terminal and internal repeat regions are the source of most 
of the genetic variation identified between EHV-1 strains and by their nature are 
quite unstable. Analysis of virus isolations, taken at different time points during the 
course of an infection of a horse with a strain of EHV-1 which was not plaque 
purified, demonstrated that the viruses isolated differed from each other in these 
repeat regions (Matsumura et al, 1994). Two isolates from an outbreak of EHV-1 
associated abortion were differentiated on the basis of RFLP analysis of PCR
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products (McCann et al., 1995). It remains to be unequivocally demonstrated 
whether the initial inoculums were mixed virus populations or if the variants arose 
through in vitro or in vivo selection of offspring from the infecting virus. Indeed, 
Matsumura and co-workers (1994) have suggested that work on PRV (Mengeling et 
al., 1983; Wathen and Pirtle. 1984) indicates that the latter possibility is more 
likely.
Plaque purification followed by multiple passages in equine cells of a 
pathogenic isolate resulted in the isolation of a strain that had lost some of its 
pathogenic potential (Mumford et al., 1994; Gibson et al, 1992b). A comparison 
of this isolate with its pathogenic co-isolates has not been made in order to 
elucidate the potential mechanism resulting in altered pathogenicity. A separate study 
which may have some bearing is the demonstration that some strains consist of at 
least two viruses, one of which lacks a BamHl site residing in a coding region of 
the viral genome (Bonass et al., 1994). It is not clear whether this is a naturally 
occurring phenomenon since the viruses were propagated in non-equine cells.
It must be reiterated that for any of the aforementioned studies it is not clear 
if the infecting strain was a mixed virus population or if it spontaneously changed 
on in vivo or in vitro passage thus giving rise to a mixed virus population or 
completely new progeny. Whichever is the case, it seems certain that for the cited 
examples mixing of the virus population occurred at some stage during the infection 
process, possibly through the selection of an already existent minor population or 
the generation of new variant virus progeny. The factors which affect the 
generation of variant viruses have not been clearly defined for EHV-1. Closer 
examination of the studies mentioned in previous paragraphs reveals a role for 
external and EHV-1 encoded factors, definition of which will be of importance in 
the study of mixed virus populations in particular and strain variation in general.
Passage of EHV-1 and -4 in non-equine cells is well recognised as a means 
of generating variant viruses. Exposing a virus to a "foreign" environment forces 
the virus to change, possibly in order to adapt to the new environment. It is not 
known how strong these forces are, to what extent the virus is actually adapting 
and what their relevance is to the natural situation. Studdert et al (1986) 
demonstrated that 8-12 passages in Hamster cells were required in order to generate 
a deletion of approximately 800bp in the Us region of the EHV-1 genome which
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was quite stable on multiple passages in equine cells. Extensive passage (77) of 
EHV-1 in bovine cells resulted in two amino acid changes in gC (Sugahara et al., 
1994). In these studies it is not clear at what stage i.e. passage number, these 
changes started to occur. However, Bonass and colleagues (1994) suggest that only 
three plaque purifications in rabbit cells were needed to elicit a loss of a restriction 
site in some of the virus genomes in a given population. Further multiple passages 
in rabbit cells resulted in the progressive loss of the site in all of the viral 
genomes. These studies would suggest that passage in non-equine cells has great 
influence in selecting EHV-1 variants, but a single study has suggested that the 
genomes of EHV-1 strains are quite stable on in vitro passage in non-equine cells 
but may depend on the cell type utilised for in vitro passage (Kirisawa et al., 
1994). All of the aformentioned examples of passaging in non-equine cells are 
unique in that some of the changes in the viral genome involved, or potentially 
involved, changes in coding regions, so it seems likely that the viruses were 
adapting to their environment. However, it must be stressed that the majority of 
identified changes induced on passaging in non-equine cells involved alterations to
the copy number of repetitive elements or reiterated sequences, some of which are 
located in coding regions. In contrast, the viral genome seems to be highly stable 
on in vitro passage in equine cells. As referred to earlier, Mumford and co-workers 
(1994) demonstrated that plaque purification in non-equine cells followed by 
multiple passages in equine cells resulted in the isolation of a strain which was 
distinct from the parent virus in terms of pathogenicity. The origin of the strain
with altered pathogenicity is unknown in that it may have been present in the
original inoculum implying that the parent strain was a mixed virus population or 
that it may have arisen during replication of the parent strain. Whatever the altered 
strain's origin some unknown aspect of the handling of the parent virus resulted in 
its selection. The relevance of such in vitro changes to the natural situation was
established by the demonstration that in vivo passage of EHV-1 resulted in the 
selection or generation of variants with alterations in repetitive/reiterated sequences 
(Matsumura et al., 1994, Binns et al., 1994). Such variants were detected at 14 
days but not at 8 days post-infection (Matsumura et al., 1994). The selective 
pressures, if any, that elicit these changes are not known.
Variation within a given herpesvirus population can also occur through 
spontaneous mutation, rearrangement or recombination between different strains.
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Rearrangement of the repetitive elements of EHV-1 has been addressed already; 
however spontaneous mutation, rearrangement and recombination have not been 
studied to the same extent for EHV-1 as for HSV-1. The existence of mixed virus 
populations and the occurrence of spontaneous mutation of HSV-1 strains can be 
inferred from the selection of neutralising Mab resistance strains from within a non- 
resistant background strain population (Holland et al., 1983; Kousoulas et al., 
1984; Marlin et al, 1985; Marlin et al., 1986). The frequency with which these 
resistant strains occurred in the virus population varied over a wide range from 
approx. 10'2 to 10"^. The higher value closely correlates with the observed relative 
mutation rate of a transgene inserted into the HSV-1 genome. Unlike the Mab 
resistant phenotype, mutation of this transgene conferred no known advantageous 
phenotype on the recombinant virus, and therefore the relative mutation rate 
determined by this technique is probably a tme reflection of the natural in vitro 
mutation rate of the virus. A number of studies have also demonstrated that viral 
encoded enzymes involved in nucleic acid metabolism e.g DNA polymerase and 
thymidine kinase, can affect the relative mutation rate (Pyles and Thompson. 1994 
and references therein).
Given the possibility that some of the strains used in this study may have 
been mixed virus populations a variety of methods were employed to explore this 
possibility. Isolate T373 and the mutant PCR product cloned from it became a 
focus of attention because they offered a number of potential avenues of 
investigation. If it could be proven that the mutant PCR product did indeed 
represent the isolate initially analysed (Allen et al., 1988) then Mab 26A5 could be 
used to remove the background reactive isolate from the original isolate by a series 
of panning procedures. The purified original isolate could then be re-analysed by 
DNA sequencing and Mab typing ELISA. For the other viruses this immunological 
approach was not an option since it could not be proven that the mutations in the 
PCR products derived from these isolates could affect an antigenic site recognised 
by a Mab. Bonass and colleagues (1994) fortuitously identified mixed virus 
populations by a combined approach of RFLP and southern blot analysis. This was 
not considered to be an experimental option, mainly because the mutations in the 
PCR products did not give rise to any RFLPs but also because of the minor 
concern that the sensitivity of this combined approach for detecting mixed virus 
populations had not been assessed.
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PCR based techniques are at the core of mutation detection strategies in the 
broad areas of eukaryotic, prokaryotic and virus genetics. Two areas in particular, 
namely the genetics of cancer and RNA viruses, required the development of 
methods to detect mutant genomes in a large background of non-mutant genomes. 
A number of PCR based strategies were specifically applied in these areas. 
Examination of sequence patterns obtained from directly sequenced PCR products 
could, by virtue of parallel bands in at least two lanes of the sequencing gel, 
reveal the presence of at least two PCR product populations and therefore two 
genome populations. This was not considered an option for the purposes of this 
thesis because of the difficulties referred to in chapter three with regard to direct 
sequencing. Another option was the exhaustive cloning and sequencing of PCR 
products from a given PCR reaction, employed without success in chapter three 
and in this chapter in order to identify further clones derived from T373 with the 
same point mutation as the initial cloned mutant PCR product isolated for that 
particular isolate. The random nature of choosing clones for sequence analysis and 
the added complication of Taq-induced errors can be overcome by screening a 
library of cloned PCR products by oligonucleotide specific hybridisation with 
oligonucleotides that are specific for the mutant of interest (Grotzinger and Will; 
1992). This method will also give a reasonably accurate estimation of the level of 
a mutant genome in a particular genome population, and thus allow the prediction 
of whether or not a given mutant arose as a result of error prone DNA synthesis 
by the Taq polymerase during the PCR. This technique was not employed because 
it necessitated that large representative PCR product libraries be constructed for each 
isolate, and that highly optimised hybridisation conditions be developed for each 
mutant specific oligonucleotide probe to be used. The method chosen was Single- 
Strand Conformational Polymorphism (SSCP) analysis, initially developed by Orita 
and co-workers (1989) and subsequently used to detect mutant cancer cells against a 
non-malignant cell background in tissue biopsies (Suzuki et a l, 1990). The 
technique is based on the fact that migration of ssDNA molecules of the same size 
through polyacrylamide gels is dependent on their conformation, which in turn is 
dependent on base composition. Nucleic acids of the same size but differing at a 
single base pair can be distinguished from each other on the basis of different 
mobilities in polyacrylamide gels if a number of conditions are fulfilled. These 
conditions include the size of the nucleic acid, the location and type of base
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changes and the PAGE parameters. The refinements and the conditions necessary 
for optimal operation of the technique are reviewed by Yap and McGee (1994).
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4.2 EXPERIMENTAL APPROACH
The majority of experiments described in this chapter centre around T373 and 
the cloned PCR products derived from this isolate as described in chapter 3. For 
the purposes of this chapter the T373 derived PCR product which was identical to 
the AB-4 gC DNA sequence is referred to as the non-mutant PCR product, 
whereas the cloned PCR product that contained the two point mutations is referred 
to as the mutant PCR product.
One of the mutations in the mutant PCR product results in an amino acid 
change in the vicinity of the epitope recognised by Mab26A5. Initial experiments 
were designed which involved Mab typing of Mab26A5 using the pepscan system 
and bacterial expression of proteins encoded by the mutant and non-mutant PCR 
products. The purpose of these experiments was to determine the role of the wild- 
type residue in binding Mab26A5 to its epitope and to discover whether the 
mutation of this residue encoded by the mutant PCR product altered the reactivity 
of the Mab with its epitope.
Mutant PCR products were obtained for four isolates as described in chapter 
3. SSCP analysis was employed in order to determine if these mutations 
represented actual variant viruses i.e that the four isolates were mixed virus 
populations. The sensitivity of the SSCP technique as utilised herein for the 
detection of mixed virus populations was determined by artificially mixing two 
strains which were known to differ from each other in the region encompassed by 
a specific PCR primer pair.
Subsequently the experimental focus shifted to the actual T373 virus isolate. 
In order to unequivocally prove that the original T373 isolate was not inadvertantly 
contaminated during the course of this thesis a new isolate was requested and 
approximately 300bp of the gC gene sequenced, inclusive of the region encoding 
the Mab26A5 epitope. All experiments suggested that strain T373 had an AB-4 like 
gC DNA sequence/T431 like gC amino acid sequence. As a result, Mab typing of 
strains T373 and T431 with Mab26A5 was performed in order to determine if 
inter-strain differences in Mab reactivity are a result of a mechanism other than
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genetic mutation as discussed in chapter 3 section 3.6. Finally, a further check for 
contamination of strain T373 was made by analysing the restriction pattern of 
isolated viral DNA in order to determine if it was identical to that determined for 
this isolate by the supplier.
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4.3 MATERIALS
4.3.1 ANTIBODIES
Table 4.1 lists the antibodies used in the experimental work described in this 
chapter with a brief description of each. The anti-EHV gC antibodies were kindly 
provided by Prof. G. Allen of the University of Kentucky, U.S.A and Dr. D. 
Meredith of the University of Leeds, U.K. Those obtained from Prof. Allen were 
ascitic fluids which had been lyophilised and were therefore resuspended in 2 ml 
of water. The antibody from Leeds had not been lyophilised. All antibodies were 
divided into small aliquots and stored at -20°C. A working stock of each anti-EHV 
gC antibody containing 0.1% Sodium Azide was maintained at 4°C to avoid 
repeated freezing and thawing.
4.3.2 SSCP PRIMERS
Details of the primers used for SSCP analysis are given in table 4.2. These 
primers were obtained from Oswell DNA services, Edinburgh, U.K.
4.3.3 SOLUTIONS FOR SDS-PAGE 
See table 4.3.
4.3.4 SOLUTIONS FOR WESTERN BLOTTING/ELISA
Coupling/coating Buffer: lOmM NaHC03, ImM EGTA (pH 9.5).
Tris Buffered Saline (lx  TBS): 0.15M NaCL, 50mM Tris HCL (pH 
7.6). Tween was added at a concentration of 0.5% vol/vol to give TBST.
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Blocking solution: TBST supplemented with Marvel and goat serum at
concentrations of 2% weight/vol and 3% vol/vol respectively. This was made 
up fresh on the day of the western blot.
Phosphate buffered saline: See chapter 5.
Also see table 4.3.
4.3.5 SOLUTIONS FOR SSCP ANALYSIS
Denaturing Buffer: 500mM NaOH, lOmM EDTA.
Loading Dye: 0.5% w/v bromophenol blue and 0.5% w/v xylene cyanol in 
deionized formamide.
Mutation detection enhancement (MDEE) Gels: These were prepared 
with and without glycerol according to the manufacturer’s (Hoefer Scientific, 
U.K.) instructions.
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4.4 METHODS
4.4.1 MAPPING OF THE EPITOPE RECOGNISED BY MAB26A5
The procedure used for mapping epitopes was the Pepscan system which is 
described in detail in chapter five. Mab26A5 was assayed at a dilution of 1/1000. 
The anti-mouse y chain specific peroxidase conjugate was used at a dilution of 
1/5000. Only the EHV-1 gC domain I (see chapter 5) series of peptides were
probed with Mab26A5 since this series contains the epitope recognised by
Mab26A5 (Allen et al., 1992).
4.4.2 CLONING AND EXPRESSION OF T373 MUTANT AND NON-MUTANT 
PCR PRODUCTS IN THE pGEX BACTERIAL EXPRESSION SYSTEM
The mutant and non-mutant PCR products were amplified using primers CEX- 
1 5-GG ATCC ATGTGGTTGCCTA ATCTCGT-3 (CEX-1 contains a BamHI 
recognition site linked to the first 20bp of the EHV-1 gC coding region) and PC-7 
(see chapter 3 table 3.2). The products were subsequently cloned into the pBSTA 
cloning vector. Clones were digested with BamHI and EcoRI and the insert
directionally sub-cloned into the pGEX-2T expression vector. pGEX ligations were 
transformed into JM109 cells. The presence of mutant and non-mutant PCR 
products in the correct reading frame in pGEX-2T was confirmed by DNA 
sequence analysis. Mutant and non-mutant clones with the correct sequence and 
orientation in pGEX-2T were designated pGEX-gCM and pGEX-gCNM 
respectively.
Single bacterial colonies containing either pGEX-2T, pGEX-gCM or pGEX- 
gCNM plasmids were grown overnight in 10ml of LB-Amp. 500ul of each
overnight culture were inoculated into 4.5ml of LB-Amp and grown for 2.5hrs at 
37°C. The cultures were split in two and IPTG added to one half at a 
concentration of 0.5mM in order to induce expression of GST or GST fusion 
proteins. All cultures were incubated at 37°C for a further 2hrs.
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4.4.3 PREPARATION OF PROTEIN EXTRACTS AND SDS-PAGE
1.5ml of each culture was centrifuged at 14000rpm for 2 minutes and the 
supernatant aspirated completely. Pellets were washed by resuspension in 1ml of 
water. The bacteria were pelleted as before and resuspended in lOOul of sample 
loading buffer by vortexing. Partial denaturation of protein and shearing of high 
M.W. DNA was achieved by drawing the samples repeatedly through a small 
gauge needle. Complete denaturation was obtained by boiling the samples for 2 
minutes. Samples were centrifuged for 5 minutes and the supernatants i.e the 
protein extracts, removed for electrophoresis.
An SDS-PAGE gel was prepared as follows. Spacers, a comb and plates 
were cleaned and assembled for gel pouring. Running gel was poured to within 
1.5cm of the bottom of the comb. 200ul of water-saturated butanol was added so 
that it formed a relatively smooth layer on top of the mnning gel which was then 
allowed to polymerise. After polymerisation the butanol layer was washed away
with water. The stacking gel was then poured on top of the running gel. The
comb was removed when the stacking gel had polymerised and the gel attached to 
the buffer chambers. Wells were washed with running buffer and 20ul of each 
protein extract was loaded. A well containing Protein M.W. markers was also 
included. Electrophoresis was set at 50V and the gel allowed to run until the dye
front had reached the bottom of the gel.
After electrophoresis the glass plates were separated and the gel removed from 
the plates for visualisation of protein bands. The gel was gently agitated in a 
solution of Coomassie Blue G for one hour. The gel was then destained over a 
period of 3 hours with frequent changes of the destaining solution. When the 
desired resolution of destaining had been obtained the gel was dried overnight 
between 2 pieces of acetate paper and then photographed.
4.4.4 WESTERN BLOT ANALYSIS OF EXPRESSED PROTEINS
Protein extracts of GST, non-mutant gC GST fusion and mutant gC GST 
fusion were run in parallel on a SDS-PAGE gel as described in the previous 
section. The Biorad trans-blot electrophoretic transfer cell was used to blot the gel
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on to 0.45um nitrocellulose paper in accordance with the manufacturer's 
instructions. Transfer was allowed to proceed overnight at 30V with a current limit 
of 100mA and at a temperature of 4°C.
After transfer was completed the nitrocellulose paper was cut into strips, each 
strip containing blots of the aforementioned protein extracts. The strips were then 
incubated in blocking solution for 3hrs before being washed once in TBST. One 
strip was incubated in blocking solution containing either Mab 26A5 or 56F11 at a 
dilution of 1/5000 for lhr and then washed 3 times in TBST. Each strip was then 
incubated in blocking solution containing goat anti-mouse y-chain specific alkaline 
phosphatase conjugate at a dilution of 1/10,000 for lhr. The strips were washed 5 
times in TBST and excess liquid removed by briefly placing each strip on whatman 
filter paper. The strips were incubated in Promega protoblot substrate solution in 
the dark until bands indicating positive reactivity of the Mabs with the fusion 
proteins were clearly visible on the membranes.
4.4.5 SSCP ANALYSIS
PCR was performed on viruses and virus mixtures in order to give a product 
of approximately 150bp in size, which has been shown to be ideal for SSCP 
analysis. The primers specific for each virus or virus mixture are listed in table 
4.2. The approximate position of these primers relative to the PCR product point 
mutations in the gC gene is represented in figure 4.1. PCR was performed on 
isolate T431 diluted in isolate T632 in order to assess the sensitivity of the method 
for detecting mixed virus populations. The concentration of reactants was standard 
and the amplification conditions were 25 cycles of 95°C for lOsecs, 50°C for 
lOsecs and 72°C for 20secs. The specificity and the concentration of the PCR 
products were analysed by gel electrophoresis in a 3% metaphor gel.
The LKB macrophor system described in chapter 2 section 2.2.4 was used for 
the preparation and running of SSCP gels. Two MDEE gels were prepared, one with 
5% glycerol and one without. The macrophor system was assembled and the 
thermostatic pump set to 15°C. lul of denaturation buffer was added to 9ul of PCR 
reaction and incubated at 42°C for lOmins. lul of SSCP loading buffer was then
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added before loading 6ul of each denatured PCR product onto each gel. Undenatured 
PCR products were also loaded. Electrophoresis was conducted at a constant power of 
8W for at least 14hrs. After electrophoresis the plates were separated and the plates 
with the attached gels were immersed in an aqueous ethidium bromide solution 
(0.5ug/ml) for 10-15mins and then photographed.
4.4.6 SEQUENCE ANALYSIS OF NEW T373 SAMPLE
A cell culture supernatant of cells infected with T373 (kindly provided by 
Prof. George Allen) was sent from Kentucky and this was subjected to PCR, the 
PCR product cloned and sequenced as described in chapter 3 section 3.4.4, without 
prior passage in cells at Glasgow Vet School. 10 clones were sequenced through 
the regions where the point mutations were originally localised in one of the cloned 
PCR products derived from the first T373 isolate supplied.
4.4.7 MAB-TYPING ELISA
A clarified stock of each virus strain to be typed was prepared from ten 
175cm2 flasks infected 48hrs previously at a M.O.I of one. Partially purified 
antigen preparations were made by centrifuging the clarified stocks at 13K for 
90mins. The pellets were resuspended in 6ml of coating buffer, a small sample 
being retained for titration of virus. A checker board ELISA, the two variable 
factors being antigen/virus concentration and Mab concentration, was performed in 
duplicate as follows.
lOOul of virus, or dilutions thereof, in coating buffer was added to the wells 
of 96 well microtitre plates (Immulon I, Dynatech LTD., U.K). Control wells 
containing coating buffer without virus were included for each Mab to be assayed. 
Virus was left to adsorb overnight at 4°C. All wells were then blocked for lhr at 
room temperature with 200ul of coating buffer containing 5% v/v goat serum. The 
plates were then washed 3 times with PBST. lOOul of Mabs diluted in PBST 
containing 20% goat serum was added to the wells. After lhr the wells were 
washed 3 times with PBST and lOOul of goat anti-mouse y chain specific
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peroxidase conjugate diluted 1/5000 was added to each well. After lhr the wells 
were washed 5 times with PBST and lOOul of TMB substrate added. The substrate 
reaction was allowed to incubate for 30mins after which time the O.D495  was 
determined.
4.4.8 ISOLATION OF VIRUS DNA
An antigen preparation of each virus was made as described in section 4.4.7. 
However the virus pellet was resuspended in 400jil of T.E instead of coating 
buffer to which 50ul of Proteinase K (50mg/ml) and 50ul of 10% SDS were 
added. The resuspended virions were lysed by incubation at 37°C for 30mins 
minimum. The following steps were performed with wide bore pipette tips and all 
additions, centrifugations and mixing performed with due care to prevent shearing 
of the released virus DNA. The lysates were phenol, phenol/chloroform and 
chloroform extracted. Half a volume of 7.5M ammonium acetate and 2.5 volumes 
of 100% ethanol were then added to precipitate the virus DNA. The DNA was 
spooled on a pipette tip and washed in 70% ethanol before being allowed to dry 
briefly at room temperature and resuspended in water.
Virus DNA was digested with BamHI for 3hrs and the digest 
electrophoretically analysed on a 0 .6% agarose gel.
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4.5 RESULTS
4.5.1 EPITOPE MAP OF MAB 26A5
As can be seen from figure 4.2 the results obtained with the Pepscan system 
are identical to those obtained by Allen et al (1992) using a slightly different 
approach. KKSRRGGQ which shows peak reactivity with Mab 26A5 contains the 
minimal number of amino acids required for Mab 26A5 reactivity within the limits 
of the assay used.
4.5.2 PROTEIN EXPRESSION AND WESTERN BLOT ANALYSIS
Expression from both mutant and non-mutant PCR products derived from 
T373 in the pGEX GST fusion system resulted in the production of fusion 
proteins of the expected size i.e. 80K (see figure 4.3). Western blot analysis 
revealed that both these fusion proteins reacted with Mabs 26A5 and 56F11 (see 
figure 4.4) whereas the GST protein did not. Mab 56F11 was included as a 
positive control in that it was known to react with an epitope encoded by strain 
T373. This Mab recognises a linear EHV-1 gC (aa) epitope distinct from that 
recognised by Mab 26A5 (Allen et al, 1988; Allen et al, 1992).
4.5.3 SSCP ANALYSIS
SSCP analysis can detect single base changes in nucleic acid fragments of the 
same size. It is evident from figure 4.5 that the bands observed are single stranded 
for two reasons. Firstly, the intensities of the observed bands are quite weak, 
indicative of the weak intercalation of ethidium bromide by ss or partially denatured 
DNA. Secondly, the dsPCR products are approximately 150bp (see figure 4.6) in 
size and are run off the SSCP gel (see figure 4.5 and lanes 16, 17 and 18) 
whereas the denatured PCR products electrophorese at greater than 310bp, the 
slower migration again indicative of ssDNA.
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Mobility shifts in the PCR products derived from EHV-1 HVS25A and the 
plasmid containing the mutant PCR product derived from T373 (see figure 4.7a 
lanes 1 and 8 respectively) were detected in SSCP gels that did not contain 
glycerol. However a SSCP for T431 was not detected, therefore the sensitivity of 
the method could not be ascertained with the parameters employed. The addition of 
5% glycerol facilitated the detection of mobility shifts in all PCR products known 
to contain point mutations, including T431 (see figure 4.7b lane 2). SSCP analysis 
could detect virus at a level of 10% of the total virus population but not at 1% 
for the given viruses and mutations (see figure 4.7b lanes 2 to 6). This closely 
approximates the value of 5% reported for other types of mixed populations 
(Enomoto et al, 1994). No minor bands corresponding to the mutant PCR product 
derived from T373 could be detected in the SSCP analysis of either the old or 
new stocks of T373 virus (compare lane 8 with lanes 9 and 10 figure 4.7b). 
Similarly, no minor populations were detected in the SSCP analysis of PCR 
products derived from strains 91320 and T632, although minor bands had been 
uncovered by photography (see figure 4.5 lanes 12 and 14 compared to 11 and 13 
respectively) but were considered artifactual since they could not be seen if the gel 
was examined with the naked eye.
4.5.4 SEQUENCING ANALYSIS OF THE NEW SUPPLY OF ISOLATE T373
Partial sequence analysis of the 10 cloned PCR products derived from the 
new supply of T373 revealed that none contained the mutations initially identified in 
one of the PCR products derived from the original supply of T373. This was also 
confirmed by SSCP analysis (compare lanes 8 and 10 figure 4.7b).
4.5.5 MAB TYPING OF STRAINS T431 AND T373
T373 (original supply) and T431 show no significant difference in reactivity 
as determined by ELISA with Mab 26A5, regardless of the dilution of antigen or 
Mab. Both strains react with the conformation-dependant Mab 14H7 and neither 
react with the EHV-4 specific Mab 3C4B (see table 4.4). None of the Mabs used
78
Chapter Four: PCR generated mutations or mixed virus populations? An investigation.
in the assay reacted with wells that did not contain virus. These results can only 
be considered to be preliminary for two of reasons.
• The concentration of protein in each well was unknown although the titre 
of each virus was of the same order of magnitude.
• Although a negative control Mab was included i.e the EHV-4 specific 
antibody 3C4B which did not react with either EHV-1 strain, no virus 
negative control i.e EHV-4 antigen/virus for the EHV-1 specific Mabs 
was included.
4.5.6 RESTRICTION ENZYME ANALYSIS OF STRAINS T431 AND T373
T373 (original supply) has a BamHI restriction profile characteristic of a IB 
electropherotype whereas that of T431 is IP (see figure 4.8). This result agrees 
with Allen et al (1988). Although it is not clear from figure 4.8 the new supply 
of T373 also had a IB electropherotype.
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Figure 4.1: Position of SSCP primers.
Schematic representation of the first 700bp of the EHV-1 AB-4 gC gene 
showing the position of point mutations relative to that of SSCP primers. 
The isolates from which each mutant PCR product was derived is given 
in bold.
Figure 4.2: Mapping of the epitope recognised by Mab 26A5 by
pepscan. (A) Graphical representation of the reactivity of Mab 26A5 with EHV-1 
gC domain one pepscan peptides. The sequence of each peptide is given on the 
horizontal axis. The asteriks indicates the reactivity of the first peptide containing 
the amino acid that would be changed as a result of the expression of the mutation 
in the T373 mutant PCR product. (B) Nucleotide 587 in the T373 mutant PCR 
product results in an amino acid change in the proximity of the core epitope 
recognised by Mab 26A5. The core epitope and the affected amino acid are 
represented in bold and relief face respectively.
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Figure 4.3: Expression of EHV-1 gC in a bacterial expression
system. Coomassie blue stained denaturing polyacrylamide gel containing in 
lanes (1) and (8) Promega high range protein M.W markers (partially 
degraded), (2) protein extract from uninduced JM109 pGEX-2T, (3) protein 
extract from induced JM109 pGEX-2T, (4) protein extract from uninduced 
JM109 pGEX-gCNM, (5) protein extract from induced JM109 pGEX-gCNM, 
(6) protein extract from uninduced JM109 pGEX-gCM and (7) protein extract 
from induced JM109 pGEX-gCM. The position of the GST protein and the 
GST-gC fusion proteins and the size of the molecular weight markers are 
indicated with arrows
GST-gC Fusion
Figure 4.4: Western blot analysis of GST-gC fusion proteins.
Membranes containing immobilised fusion proteins were probed with (A) Mab
26A5 and (B) Mab 56F11. Lanes (1) GST protein, (2) GST-gCNM fusion
protein and (3) GST-gCM fusion protein. The positions of reactive full length
fusion proteins are indicated by arrows.

Figure 4.5: The entire SSCP gel. An ethidium bromide stained SSCP gel 
containing 5% glycerol. The four bands in lane (15) correspond to the four largest 
bands of the PhiX Haelll M.W marker. Note the absence of bands in lanes (16) ,  
(17) and (18) where the undenatured PCR products were loaded. (1) Denatured 
PCR products from plasmid HVS25A gC(Primers S4+S5), (2) T431
104 PFU(Primers S4+S5), (3) T431 5X103PFU:T632 5X103PFU(Primers S4+S5),
(4) T431 103PFU:T632 104PFU(Primers S4+S5), (5) T431 102PFU:T632
1 (^PFU (Primers S4+S5), (6 ) T632 104PFU(Primers S4+S5), (7 )
AHT50592(Primers S4+S5), (8) Mutant T373 clone(Primers S4+S5), (9) T373
old stock(Primers S4+S5) and (10) T373 new stock(Primers S4+S5). Note the
position of potential minor bands in lanes (12) and (14) containing denatured 
PCR products from AHT91320(Primers S2+S3) and T632(Primers S0+S1) 
respectively. (11) T431(Primers S2+S3) and (12) T431(Primers S0+S1)
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Figure 4.7: The effect of glycerol on and sensitivity of SSCP
analysis. (A) Ethidium bromide stained SSCP gel without glycerol. The contents 
of each lane are the same as those in (B). Note the lack of mobility shift for the 
denatured T431 PCR product in lanes (2), (3) and (4) relative to that obtained in 
the same lanes in (B). However mobility shifts are seen for denatured PCR
products derived from the HVS25A plasmid and the T373 mutant clone lanes (1)
and (8) respectively.
(B) Ethidium bromide stained SSCP gel containing glycerol. This figure contains a 
close-up photograph of lanes (1) to (10) of the gel in figure 4.5. Some SSCP 
bands are highlighted by arrows on the left hand side of the photograph labelled 
with the source of PCR template and the lane number(s) in brackets. Denatured 
PCR products from (1) plasmid containing EHV-1 HVS25A gC gene (Primers 
S4+S5), (2) T431 104PFU(Primers S4+S5), (3) T431 5X103PFU:T632
5X103PFU(Primers S4+S5), (4) T431 103PFU:T632 104PFU(Primers S4+S5),
(5) T431 102PFU:T632 104pFU(Primers S4+S5), (6) T632 104PFU(Primers
S4+S5), (7) AHT50592(Primers S4+S5), (8) Mutant T373 clone(Primers S4+S5), 
(9) T373 old stock(Primers S4+S5) and (10) T373 new stock(Primers S4+S5).
(A)
(B)
HVS25A (1)
Mutant T373 
clone (8)
T431
(2,3 and 4)
Figure 4.8: BamHI fingerprints of T431 and the T373 stocks. Lanes
(1) X Hindm DNA M.W marker, (4) T373 old stock DNA preparation BamHI,
(5) T373 new stock DNA preparation BamHI, (6) T431 DNA preparation BamHI 
and (7) X Hindin DNA M.W marker. Arrows indicate the differences between the 
IB and IP electropherotypes. All other lanes are empty.
1 2 3 4 5 6 7
ANTIBODY NATURE W ESTERN
BLOT
WHOLE VIRUS 
ELISA
DESCRIPTION SUPPLIER
26 A 5 Monoclonal + + Specific for EHV-1 
gC reacting with a 
linear epitope 147- 
KKSRRG-152 
(Allen et a l ., 1992)
G. Allen
5 6 F 1 1 Monoclonal + + Specific for EHV-1 
gC reacting with a 
linear epitope 40- 
PTHTTPNLTTAHG 
AGSDNTT-59 
(Allen et a l ., 1992)
G.Allen
14H 7 Monoclonal + Specific for EHV-1 
gC reacting with a 
conformation- 
dependant epitope
G. Allen
3C 4B Ascitic fluid 
from a 
hybridoma that 
was not 
monocloned
+ ND Specific for EHV-4 
gC
D. Meredith
CONJUGATE Polyclonal NA NA Anti-mouse IgG (y- 
chain specific) 
peroxidase conjugate
Sigma, UK.
Table 4.1: Characteristics of antibodies referred to in this chapter. (+)= 
reactive. (-)= not reactive. ND= experiment not performed. NA= parameters not applicable 
to particular antibody.
Primer Sequence Location (Allen 
and Coogle. 
1988)
Isolate\plasmid to be 
analysed by SSCP  
analysis
SO 5'-gaccctttggtgcatgg-3' 32-48 T632, T431
SI 5'-ctagctccagaggcataa-3' 209-192 As for SO
S2 5 '-gtatctaatctgtgccgg-3' 162-179 AHT91320, T431
S3 5 '-taccgtttgcgttagttgt-3' 313-295 As for S2
S4 5'-cataacgccaccccggat-3' 511-528 T632, T431, AHT50592, 
T373, plasmid HVS25AgC, 
and Mutant T373 clone
S5 5'-actttgtaccaccttccg-3' 661-644 As for S4
Table 4.2: Details of the PCR primers used for SSCP analysis.
SOLUTIONS FOR SDS-PAGE AND WESTERN BLOTTING
Stock Acrvlamide SDS-PAGE Running
Acrylamide 29g Gel
methylene-bisacrylamide lg Stock acrylamide 10ml
dH20  to 100ml 1M TrisHCL (pH. 8 .8) 11.2ml
dH20 8.5ml
10% SDS 0.3ml
10% APS 75ul
TEMED 20ul
SDS-PAGE Stacking SDS-PAGE Running
Gel Buffer
Stock acrylamide 1.7ml Glycine 14.4g
1M TrisHCL (pH. 6 .8) 1.2ml Tris base 3-lg
dH20 7.0ml SDS l.Og
10% SDS 0 .1ml dH20 to 11
10% APS 75ul
TEMED 8ul
SDS-PAGE Sample Coomassie Blue
Buffer Staining Solution
2.5% SDS Coomassie blue 0.5g
2.5% p-mercaptoethanol Methanol 300ml
0.1M TrisHCL (pH 6 .8) Glacial Acetic Acid 100ml
10% Glycerol dH20 to 11
0.01% Bromophenol blue
Destaining Solution Transfer Buffer
Methanol 300ml Tris Base 3.03g
Glacial Acetic Acid 100ml Glycine 14.4g
dH20 600ml Methanol 200ml
dH20 to 11
Table 4.3: Solutions for SDS-PAGE and western blotting.
Antibody Virus Dilutions of 
virus
Mab Dilutions and O.D readings
(Each column contains duplicates)
1/100 1/1000 1/10000
Neat 0.901 0.967 0.219 0.186 0.094 0.084
T373 1/10 1.262 1.089 0.212 0.232 0.101 0.105
1/100 0.596 0.614 0.203 0.222 0.108 0.109
Mab 26A5 Neat 0.823 0.864 0.218 0.222 0.106 0.085
T431 1/10 0.905 0.906 0.231 0.235 0.112 0.103
1/100 0.610 0.651 0.170 0.214 0.135 0.118
No virus Neat 0.070 0.073 0.078 0.078 0.072 0.071
Neat 0.832 0.846 0.247 0.216 0.126 0.119
T373 1/10 0.809 0.847 0.260 0.251 0.127 0.124
1/100 0.507 0.596 0.271 0.252 0.167 0.163
Mab 14H7 Neat 0.802 0.824 0.262 0.267 0.153 0.134
T431 1/10 0.892 0.879 0.276 0.281 0.153 0.142
1/100 0.603 0.644 0.319 0.304 0.166 0.176
No Virus Neat 0.070 0.077 0.086 0.079 0.074 0.075
Neat 0.076 0.086 0.082 0.085 0.075 0.066
T373 1/10 0.088 0.079 0.081 0.080 0.078 0.067
1/100 0.078 0.081 0.081 0.80 0.070 0.069
Ab C4B Neat 0.073 0.072 0.064 0.072 0.068 0.058
T431 1/10 0.077 0.080 0.066 0.072 0.067 0.059
1/100 0.089 0.084 0.072 0.072 0.073 0.064
No Virus Neat 0.072 0.082 0.088 0.089 0.077 0.069
Table 4.4: Results of antibody typing ELISA.
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4.6 DISCUSSION
The experiments described here represent a systematic attempt to solve two 
confounding results from the study described in chapter 3, namely the high 
proportion of cloned mutant PCR products and the disparity between the results 
reported here and those of Allen et al (1988), especially in relation to strain T373. 
Since both problems are not mutually exclusive, particularly with regard to T373, 
rigorous experimentation was centred around the mutant PCR product derived from 
this virus.
Pepscan analysis revealed that the amino acid changed by one of the 
mutations in the T373 PCR product was not essential for optimal binding of Mab 
26A5 to its epitope. It was, however, sufficiently close to the core epitope such 
that mutation of this residue may hinder sterically or otherwise binding of this 
Mab. To investigate this possibility the mutant and non-mutant PCR products 
derived from T373 were expressed in a bacterial system and their reactivity with 
Mab 26A5 assessed by western blotting. Both expressed proteins were reactive with 
Mab 26A5. This could not be taken as direct proof that the mutant PCR product 
was not derived from the isolate initially analysed by Allen and co-workers (1988), 
since analysis was performed with a prokaryotic version of the proteins under 
denaturing conditions. Although not performed, a more informative experiment 
would be the expression of the PCR products in a eukaryotic system followed by 
immunofluorescent analysis with Mab 26A5 and conformation-dependant anti-EHV-1 
gC Mabs (Coogle et al, 1992). Such an experiment would take into account the 
effects of conformation and of the other mutation in the PCR product derived from 
T373 which also results in an amino acid change.
Given this result it was thought prudent not to proceed with the panning 
experiment referred to in the introduction, although it might have been informative.
SSCP analysis was performed on all isolates from which a mutant PCR 
product was derived to directly assess the possibility that these viruses consisted of 
a mixed population of strains. The three mutations tested i.e those in gC of T431, 
HVS25A and the mutant T373 PCR product, were detected by SSCP analysis. One
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interesting aspect of SSCP analysis of the gC gene was the presence of three 
SSCP bands, in the absence of a dsDNA band, in all SSCP profiles associated 
with primers S4 and S5. SSCP profiles should generally contain three bands, the 
dsDNA and the two single strands. Intermediate bands however have been reported 
which are thought to correspond to partially denatured DNA. Given the high GC 
base composition of the gC gene it is not suprising that these intermediates would 
arise.
While there was no definitive evidence of mixed populations the sensitivity of 
the assay may have been increased by radioactive labelling of the PCR products, 
although this has not been found to be the case (Enomoto et a l, 1994). This 
approach, through the provision of a permanent record of the DNA bands on a 
gel, would have allowed the definitive demonstration of the presence or absence of 
SSCP bands especially in relation to the artifacts seen for T632 and 91320 SSCP 
profiles.
Although great effort was made to reduce any possibility of contamination of 
viruses, another sample of T373 was requested and sequenced to determine whether 
or not the original isolate was unwittingly contaminated during the course of this 
study. The fact that the new supply of T373 had a gC DNA sequence identical to 
AB-4 within the region analysed suggested that this was not the case. However, it 
must be said that it was assumed that the cloned mutant PCR product potentially 
represented the original isolate analysed by Allen, and therefore only the 400-500bp 
of DNA sequence encompassing the region encoding the epitope of Mab26A5 was 
determined for the new isolate.
Mab typing experiments were then performed to determine whether it was 
possible that T373 may be unreactive with Mab26A5 as determined by Allen et al 
(1988) although the sequencing data in chapter 3 suggested that it should react. 
This experiment was performed in order to see if antigenic variation of some EHV- 
1 strains is mediated by some means other than genetic mutation of the antigen 
encoding gene as discussed in chapter 3. The preliminary Mab typing experiment 
performed here suggested that T373 does indeed react with Mab 26A5. This 
directly disagrees with the results of Allen et al (1988). Two potentially significant 
differences exist between the Mab typing described here and that performed by 
Allen and colleagues (1988). Firstly, although strains in both studies were
81
Chapter Four: PCR generated mutations or mixed virus populations? An investigation.
propagated in equine dermal cells, Allen et al (1988) used KyED cells whereas this 
study used NBL6 cells. Secondly, this study used crude antigen preparations 
whereas Allen et al (1988) used purified virus particles. Of interest is a report that 
found differences in the glycoprotein content of different strains of HSV-1, and 
between virus infected cell preparations and purified particles (Al-Ahdal, 1993). It is 
not known if these differences were of significance so as to affect the assessment 
of epitope content.
Finally, restriction enzyme analysis revealed that the T373 strain analysed has 
a IB electropherotype and therefore it is likely that the same strain was used in 
both studies.
Unfortunately the results described here do not resolve the disparity between 
the DNA sequence analysis of this study and the Mab typing study of Allen et aL 
(1988). Further meticulous experimentation would be necessary to find a solution to 
this enigma, which was beyond the scope of this thesis.
Ultimately the possibility that, as first thought, these mutations are due to 
misincorporation by Taq DNA polymerase during the PCR must be addressed. The 
PCR conditions described in chapter 3 i.e. low equimolar concentrations of dNTPs, 
low number of cycles, and reduced cycling time would generally favour a high 
fidelity PCR (Ling et a l, 1991) with a few noted exceptions (for a review of 
factors affecting PCR fidelity see Eckert and Kunkel, 1991). These exceptions 
include:
• The 10-fold lower than recommended number of starting template i.e 10^ 
virus particles versus 10^ genome copies. However it is probable that this 
is an underestimation of virus genome copies present in the PCR since 
only live virus is counted by the titration methods employed.
• A two fold greater concentration of Taq was used for virus PCRs. The 
effect of Taq concentration on PCR fidelity has not been documented. 
Higher concentrations could result in the reduction of the effective 
concentration of both template and dNTPs in the PCR which could 
potentially affect fidelity.
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• Finally the addition of virus growth medium to the PCR at a 1/5 dilution 
may affect the pH of the reaction and thus fidelity.
Although the reported mutation rate of Taq polymerase varies widely, the rate 
of mutations derived from T373 at least approximates with some of the reports 
(Eckert and Kunkel. 1990; Gelfand and White. 1990) i.e 2 mutations out of a total 
of approximately 16,000bp sequenced, assuming that no other mutations occurred in 
the regions not sequenced in the 10 cloned PCR products derived from T373. It is 
possible that if more clones were sequenced for each virus mutations would be 
identified according to the calculation of the error rate.
Only two of the mutations analysed here i.e. those derived from 50592 and 
91320 are of the type most easily extended by Taq (Kwok et a l, 1990). No 
hotspots for PCR induced mutations were recognised since the five identified 
mutations were distributed across the gC encoding sequence. No mutations were 
identified in the area of the non-coding region that was sequenced but more 
extensive sequencing would have to be performed to discount this possibility.
In conclusion we cannot prove whether the mutations in the cloned PCR 
products were derived from actual viruses or whether they were PCR induced.
Although the discord between the study described in chapter three and that of 
Allen and co-workers (1988) remains unresolved this chapter revealed two pertinent 
points. Firstly, preliminary data does indeed indicate that strain T373 encodes an 
intact Mab26A5 reactive epitope and secondly, on the basis of RFLP and further 
sequencing analysis, the aforementioned strain was not contaminated during the 
course of these studies. This data supports the accuracy of the study described in 
chapter three.
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5.1 INTRODUCTION
Chapter one summarised the available methods for distinguishing between 
horses infected with either EHV-1 or -4. The majority of these tests rely on the 
direct detection of the viral antigen or nucleic acid. The major drawbacks of many 
of these techniques are that they are slow in yielding results, insufficiently sensitive 
or require very specialised techniques or equipment which are not within the 
capabilities of many clinical diagnostic laboratories.
Serological methods e.g complement fixation (CF) and virus/serum 
neutralisation (VN) tests are commonplace in the EHV diagnostic laboratory. These 
methods are not sufficiently discriminatory between EHV-1 and -4 and so require 
further confirmation by direct detection methods e.g virus isolation or indirect 
immunofluorescence (HF), that require virus to be grown. Ironically VN may have 
been a more discriminatory tool for the reasons outlined as follows. Fitzpatrick and 
Studdert (1984) in a study which was later corroborated by Edington and Bridges 
(1990) demonstrated that anti-EHV-4 serum from SPF foals could neutralise both 
virus types but that SPF foal anti-EHV-1 serum could only neutralise EHV-1. 
Unfortunately naturally infected animals experience frequent EHV-4 infections, some 
of which are subclinical which would preclude the use of the aforementioned one­
way virus neutralisation in relation to EHV-1 infections as a type-specific diagnostic 
test.
It is worth reiterating the other disadvantages associated with these serological 
tests, namely CF, VN and direct immunofluorescence (IF) as outlined in chapter 
one. Firstly further confirmation of these tests are required. Secondly paired serum 
samples are normally required from an affected animal. These samples may not 
always demonstrate an increase in antibody titre indicative of a recent infection as 
determined by the aforementioned tests. Thirdly the tests are particularly susceptible 
to problems associated with reagent variability in that a sample may be positive 
with one set of reagents but not another. Such problems may also relate to 
difficulties in detecting antibodies associated with variant strains (Thomson et al., 
1976).
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The ideal immunological assay would detect EHV type-specific antibodies in 
the serum of an infected animal. The assay could be tailored to detect the quantity 
or isotype of the type-specific antibodies in order to rapidly diagnose a recent 
infection. The development of such a test would first require the identification of a 
suitable antibody capture reagent which in this case would be type-specific epitopes 
from EHV-1 and -4. Obviously the means to initially identify such reagents would 
be to utilise serum from naturally or experimentally infected animals.
Serum from naturally and experimentally infected animals has been shown to 
cross-react with glycoproteins from both virus types, regardless of the virus with 
which the animal's immune system was initially challenged (Allen and Bryans. 
1986; Crabb and Studdert. 1990; Crabb et al., 1991; Ahmed et a l, 1993; 
McCartan et al, 1995). Crabb and colleagues (1991) cross-absorbed EHV-1 antisera 
with EHV-4 to remove cross-reacting antibody and demonstrated that all 
glycoproteins which normally elicit an immune response in affected animals were 
recognised by type-specific antibodies. Not all glycoproteins were reactive to the 
same extent with type-specific equine antibodies, and indeed the extent to which a 
given glycoprotein was recognised differed between serum from an experimental and 
natural infection. To date the antigenic sites or epitopes recognised by these type- 
specific equine antibodies have not been characterised with the possible exception of 
those reactive with gC (Crabb and Studdert. 1995). Furthermore gG, a glycoprotein 
not previously considered, was shown to be truly type-specific in that neither the 
EHV-1 nor -4 homologues contain epitopes which cross-react with monospecific 
EHV-4 or -1 antiserum respectively (Crabb et al, 1992; Crabb and Studdert. 
1993). Crabb and coworkers (1992) also demonstrated that for EHV-4 a large 
glycoprotein of 250K, which like the gG EHV-4 homologue is secreted in cell 
culture, may also be purely type-specific in terms of recognition by the equine 
immune system. Zheng et al (1995) have demonstrated that a glycoprotein in the 
EHV-4 virion, with a molecular weight corresponding to that of gp2, is recognised 
by potentially monospecific sera from animals naturally infected with EHV-4. These 
sera do not react with a similar glycoprotein in the EHV-1 virion. The former and 
latter studies did not consider gp2 to be the identity of the glycoproteins on the 
basis of slight differences in size between gp2 and the secreted glycoprotein and 
the lack of reactivity of anti-gp2 Mabs with the high M.W. glycoprotein 
respectively. Interestingly Crabb and coworkers (1991) demonstrated that much of
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the type-specific antibodies in a mare naturally infected with EHV-1 were reactive 
with gp2 and, furthermore, it has been recently shown that this glycoprotein is the 
second most divergent EHV-1 and -4 glycoprotein (Telford et al., 1998).
The linear antigenic sites on the EHV-1 and -4 gG homologues which elicit 
type-specific responses were delineated and demonstrated to be of sero- 
epidemiological value (Crabb et al., 1993; Crabb et al., 1995; Drummer et al., 
1995).
Efforts have been made to identify antigenic sites and/or epitopes of EHV 
glycoproteins because of the value of this information in the development of 
diagnostics and vaccines. A number of techniques are available for this purpose and 
have been applied to EHV diagnosis. The application of some of these techniques 
continue to aid the characterisation of some of the epitopes type-specifically 
recognised by the EHV - affected equine immune system. This should allow the 
physical separation of cross-reactive from type-specific epitopes, an obvious 
prerequisite in the development of a type-specific serological assay.
The development and application of Mabs against EHV-1, particularly the 
work performed by Allen's group, has achieved much in extending knowledge of 
the EHVs in general. These Mabs have been used to probe Xgtll expression 
libraries of both EHV-1 and -4 in order to identify genes and the epitopes they 
encode (Allen and Yeargen. 1987; Whittaker et a l, 1991; Cullinane et al., 1993). 
Wilson and colleagues (1994) have taken this approach a step further by screening 
an EHV-4 expression library with serum from naturally infected equids in order to 
identify naturally important epitopes. Serum from convalescent animals identified 
recombinant phage expressing regions of the EHV-4 gB and gG genes. Indeed a 
number of groups have developed Mabs against EHV-1 and -4, some of which are 
type-specific. The relative importance of the epitopes recognised by these Mabs in 
the equine immune response to the EHVs has been assessed by competitive 
ELISAs where the horse serum, if reactive with a given epitope, will competitively 
inhibit the binding of a Mab specific for that epitope (Ostlund et al, 1992; Sinclair 
et al, 1993b). Ostlund and colleagues (1992) demonstrated that for gC, three out 
of five previously characterised Mab binding domains (Allen et a l, 1992) were 
either only weakly recognised by horse sera, four weeks post an experimental 
EHV-1 infection, or were not recognised at all. The two EHV-1 gC Mab binding
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domains that were marginally recognised were conformation-dependant. Conversely 
for gB, three out of five previously identified Mab binding domains were 
recognised, two strongly and one moderately. All three domains contain linear
epitopes on the basis of western blot reactivity (Allen et al, 1992). An increase in
the antibody titre between paired acute and convalescent serum samples to an 
epitope recognised by a conformation-dependant cross-reactive anti-gC Mab, 
developed by Sinclair and co-workers (1993b), was detected in six out of seven 
horses naturally infected with either EHV-1 or -4. This epitope was conformation- 
dependant whereas an anti-gC Mab which recognised a linear epitope was not 
competitively inhibited by naturally infected horse sera.
All or portions of specific EHV glycoprotein genes have been expressed in 
bacteria as GST fusion proteins. Antigenic sites in the EHV-1 and -4 gG 
homologues (Crabb and Studdert. 1993), EHV-1 gB (Sinclair et al., 1993a) and 
EHV-1 gC (Crabb and Studdert. 1995) have been characterised in this way and 
their diagnostic potential assessed. The C-terminus of the EHV-1 and -4 gG
homologues contain only type-specific epitopes (Crabb and Studdert. 1993) and 
these have been exploited for the development of an invaluable diagnostic test as 
alluded to earlier. A GST fusion protein containing the first 50 amino acids of 
EHV-1 gB cross-reacts with serum from EHV-1 and -4 affected animals. Reactivity 
with EHV-4 antisera was 10-fold less than that with EHV-1. Although it cannot 
be used as a type-specific diagnostic reagent the authors have shown that when 
used as an antibody capture reagent in an end-point titration ELISA, the fusion 
protein consistently demonstrated recent infection with either virus when acute and 
convalescent serum samples were compared (Sinclair et al., 1993a). Crabb and 
Studdert (1995) demonstrated the presence of cross-reactive epitopes in amino acids 
107-275 of EHV-1 gC, and pointed to the existence of potentially useful EHV-1 
gC type-specific epitopes in amino acids 152-275 on the basis of analysing the
somewhat fortuitous occurrence of breakdown products of a gC-GST fusion 
protein.
Immunofluorescence analysis, with conformation dependant Mabs, of mutants 
of the EHV-1 gC homologue generated by PCR based site-directed mutagenesis and 
expressed in eucaryotic cells allowed the complex analysis of conformational 
epitopes to be addressed (Coogle et al., 1992).
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Linear antigenic domains of EHV-1 gC and gB have also been defined using 
a strategy whereby multiple overlapping peptides representing the primary structure 
of these glycoproteins were synthesized, and their reactivity with Mabs and 
naturally infected animal sera assessed by ELISA (Allen et al., 1992; Ostlund et
al, 1992). Pepscan analysis of EHV-1 gB and EHV-1 gC with nested sets of
peptides 20 amino acids in length and overlapping by 10 amino acids, representing 
the entire amino acid sequence of these glycoproteins, was performed. Linear 
epitopes on gC, corresponding to amino acids 140-159 and 40-59, and on gB, 
corresponding to amino acids 106-125, were identified when glycoprotein specific
Mabs were used as probes. The gC epitopes were not strongly recognised by 
convalescent equine sera whereas the gB epitope was. Furthermore an epitope 
corresponding to amino acids 306-325 which was not recognised by gB specific
Mabs was identified using convalescent equine sera as probe.
Comparison of the EHV-1 gD sequence with that of HSV-1 led to the 
identification of a region homologous to a HSV-1 neutralising epitope. Subsequent 
development of anti-serum to a peptide representing this region of EHV-1 gD i.e. 
amino acids 4-22, confirmed the hypothesis that this region of EHV-1 also contains 
a complement independent neutralising epitope (Flowers and O'Callaghan. 1992). 
Anti-serum raised against a peptide representing amino acids 267-285 of EHV-1 gD 
was non-neutralising in vitro but did react with virion gD.
88
Chapter Five: Serological analysis o f EHV-1 and-4 infections with the Pepscan system
5.2 EXPERIMENTAL APPROACH
Many of the studies referred to in the introduction to this chapter did not 
examine the responses of naturally/experimentally infected horses to the linear 
antigenic domains identified, or did not specifically localise the antigenic sites under 
study. This chapter describes attempts to localise more precisely previously 
described linear antigenic domains using sera from experimentally and naturally 
infected equids and thus assess their importance, if any, in natural infection. The 
amino acid sequence of many EHV-1 and -4 glycoproteins has been elucidated and 
this data was used to identify regions which were potentially antigenic and/or 
variable between EHV-1 and -4 that could also be included in these experiments. 
The ultimate aim of this work was to identify peptides that could be utilised in a 
type-specific serological assay.
The approach used was to obtain overlapping peptides, synthesized by the 
Geysen method (Geysen et al, 1984 and 1987) representing the regions of interest. 
The Geysen method involves the synthesis of peptides attached to a solid support 
i.e a pin made of polystyrene material. The advantages of the system are:
1. very small peptides can be synthesized on the surface of the pins at very 
high effective concentrations without problems of solubility,
2. The peptides are synthesized such that they are accessible to antibody and
3. antibody can be removed from the peptides and the pins reused a number 
of times without affecting the integrity of the peptides.
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5.3 MATERIALS
5.3.1 PEPTIDES
94 peptides were ordered from Cambridge Research Biochemicals, Cheshire, 
U.K. Peptides were synthesized onto a solid support or pin according to the 
method of Geysen and colleagues (1984). A block of peptides was constructed by 
inserting 96 pins into a rectangular plastic platform in an arrangement such that the 
head of each pin could be inserted into the well of a 96 well microtitre plate (see 
figure 5.1a and b). The peptides were synthesized onto the head of each pin. A 
positive and negative control peptide was synthesized in parallel with every batch of 
94 peptides and tested in-house by the company to quality control peptide 
synthesis. The 94 peptides ordered were synthesized in duplicate therefore two
blocks of peptides were supplied. Each block consisted of 47 test peptides in 
duplicate and a positive and negative control (see figure 5.1b for the arrangement 
of pins containing positive and negative control peptides and duplicate test
peptides). All peptides were acetylated at the N-terminus and linked through the C- 
terminus to the polystyrene support via a spacer region (see figure 5.1c).
The details of the 94 peptides synthesized are given in table 5.1.
5.3.2 SERA AND ANTIBODIES
Field sera from horses associated with EHV-1 and -4 outbreaks (see table 
5.2) were generously supplied by Dr. R. Sinclair of the Animal health Trust,
Newmarket, U.K. and Dr. A. Cullinane of the Irish Equine Centre, Co. Kildare, 
Rep. of Ireland. Primary sera and plasma samples from experimentally infected 
specific pathogen free foals were a gift from Dr. J. Gibson, Cambridge University, 
U.K (see table 5.3).
A control murine monoclonal antibody, which reacts with the positive but not 
the negative control peptide referred to in section 5.3.1, was obtained from 
Cambridge Research Biochemicals, Cheshire, U.K. The lyophilised antibody was
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reconstituted in 500ul of sterile distilled water. 3ml of PBS were added to the 
reconstituted antibody and this working stock solution was stored at 4°C.
Goat anti-Horse IgG (y chain specific) Peroxidase conjugate obtained from 
Dynatech Ltd., U.K. was developed by Kirkgaard-Perry, the Netherlands and 
maintained at 4°C.
Rabbit anti-Horse IgG (whole molecule) Peroxidase conjugate was obtained 
from Sigma, U.K. and stored at 4°C.
Goat anti-Mouse IgG (y chain specific) Peroxidase conjugate was obtained 
from Sigma, U.K. and stored at 4°C.
5.3.3 RECIPES
See table 5.4.
5.3.4 PLASTICWARE
Immulon I microtitre dishes were obtained from Dynatech Ltd. These plates 
were used throughout the pepscan experiments.
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5.4 METHODS
5.4.1 CRITERIA FOR CHOOSING PEPTIDES
Peptides were chosen from regions of EHV-1 and -4 glycoproteins associated
with:
(1) antigenicity as determined by reactivity of said regions with Mabs or
experimentally/naturally infected animal sera.
(2) potential antigenicity as predicted by computer algorithms.
(3) divergent sequence relative to the heterologous virus type.
EHV-1 and 4 gC peptides
Domain One: Peptides encompassing this region in EHV-1 were reactive with 
horse sera (Ostlund et al, 1992). This region was proposed for extensive pepscan 
analysis, mainly for two reasons. (1) the degree of EHV-1 vs. 4 sequence 
divergence in this domain (see figure 5.2) and (2) the fact that an epitope for a 
type specific Mab (26A5) was localised in this region (Allen et al., 1992). 27 
peptides 8aa in length and overlapping by 7aa encompassing the epitope recognised 
by Mab26A5 were chosen. The homologous region of EHV-4 was similarly 
analysed as peptides from this region were immunogenic in hamsters (Stokes et al., 
1991) (Table 5.1).
Domain Five: This domain was shown to be weakly antigenic in the horse 
and potentially type specifc (Ostlund et al., 1992; Allen et al., 1992). Three 
peptides 12aa in length and overlapping by 5aa were chosen to represent the EHV- 
1 sequence.
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EHV-1 and -4 gB peptides
AHT Domain: The corresponding EHV-1 and -4 regions were represented by 
8mers overlapping by 7. These regions are quite divergent (figure 5.3) and for 
EHV-4 at least, are potentially antigenic (figure 5.4). Furthermore, EHV-1 fusion 
proteins encompassing this region react with both EHV-1 and -4 infected animal 
sera (Sinclair et al, 1993a).
Misc peptides: 8mers overlapping by 4 were chosen to represent the EHV-1
gB sequence (aa255-270) and the homologous EHV-4 region. This region is
divergent (figure 5.3) but is not predicted to be antigenic (figure 5.4). Single 
peptides representing gB of EHV-1 (aa512-520) and -4 (aa508-514) were included 
as this region is quite divergent and potentially antigenic. A peptide from EHV-1 
gB (aa526-537) was also included for pin system analysis since it was potentially 
antigenic (figure 5.4).
Miscellaneous gH peptides
12mers overlapping by 6 representing amino acids 16-39 and 22-45 of EHV-
1 and -4 respectively were included given the low identity between the EHV-1 and
-4 sequences in this region (see figure 5.5). These regions were not predicted to 
be antigenic. Single peptides representing EHV-1 and -4 gH aa274-285 and 282- 
293 were selected on the basis of their potential antigenicity (see figure 5.6)
Miscellaneous gplO peptides
Three peptides representing isolated divergent regions of EHV-1 gplO were 
included (see figure 5.7).
gD peptides
Flowers and O'Callaghan (1992) demonstrated that an EHV-1 peptide 
homologous to a HSV-1 gD neutralising domain injected into rabbits induced anti-
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EHV-1 neutralising antibodies. Another peptide from EHV-1 gD did not induce 
neutralising antibodies in immunised animals but did induce gD reactive antibodies. 
The EHV-1 and homologous EHV-4 regions are each represented by three 12mers 
overlapping by five for pepscan analysis (see table 5.1 and figure 5.8).
Note added in proof
All the EHV-4 peptides used in this chapter were aligned with translations of 
the recently published DNA sequences of the respective glycoproteins from EHV-4 
strain NS80567 (Telford et a l, 1998). All alignments revealed 100% identity 
between the peptide and glycoprotein amino acid sequences (Data not shown).
5.4.2 PREPARATION AND HANDLING OF ANTI-SERA
Sodium azide 1% w/v was added to equine serum which was divided into 
aliquots and stored at -70°C until required. A working stock of serum was stored 
at 4°C. Serum was centrifuged at 14000rpm for 5 minutes before use in an 
ELISA. This procedure removed any serum constituents which may have 
precipitated during long-term storage of the sera, and may have interfered with the 
ELISA assay.
5.4.3 DERIVATION OF SERUM SAMPLES FROM PLASMA
Equine plasma was stored at -70°C until required. After thawing the plasma, 
thrombin was slowly added at a concentration of 50units/ml of plasma. The plasma 
was gently agitated during addition of thrombin and this agitation was maintained 
for 30 minutes after addition. The clot formed in the plasma was removed by 
centrifugation at 14000rpm for 10 minutes. Sodium Azide was added to the 
retained supernatant at a concentration of 0 .1% w/v and the serum stored in small 
aliquots at -70°C. A working aliquot was kept at 4°C and handled according to 
section 5.4.2.
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5.4.4 ELISA ANALYSIS WITH THE PIN TECHNOLOGY SYSTEM
The pins were used according to the manufacturer's instructions but with 
some minor modifications. All incubation steps were carried out in lids of pipette 
tip boxes (one block of pins/lid) unless stated otherwise. All washes were 
performed in enzyme boxes (one block of pins/box).
Blocking step
Non-specific binding sites on each of the two blocks of pins were blocked 
by incubating each block in 30ml of pre-coat buffer for 1 hour at room 
temperature on a rotary platform, set at a speed such that the buffer repeatedly 
washed completely over the pin heads.
Primary antibody incubation
The pins were then removed from the pre-coat buffer momentarily and horse 
serum was added to the pre-coat buffer to give a dilution of 1/1000 (unless 
otherwise stated). At this stage the control peptide pins were removed from the 
blocks and placed in the wells of a microtitre dish that contained 175ul of the 
control antibody. The blocks containing the experimental peptide pins were returned 
to the diluted serum. The primary antibody incubation step was performed overnight 
at 4°C with gentle agitation.
W ashes
The control pins were reattached to the blocks and excess diluted anti­
serum/antibody was flicked from the pins which were then washed four times. A 
single wash involved agitating the pins in 500mls of wash buffer for 10 minutes. 
Clean buffer was used for each wash.
Conjugate reaction
Following removal of excess wash buffer the control pins were again 
removed from the blocks and placed in the wells of a microtitre dish containing 
175ul of the working solution of Goat anti-Mouse IgG (y chain specific) 
Peroxidase conjugate. Blocks containing the experimental pins were placed in the 
lids of pipette tip boxes containing 30ml of a Rabbit anti-Horse IgG (whole
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molecule) Peroxidase conjugate diluted 1/5000 in conjugate diluent. The pins were 
gently agitated in the diluted conjugates for 1 hour at room temperature.
Substrate reaction
Each block of pins was washed as described and in the meantime 200ul of 
fresh substrate were added to each well of two 96 well microtitre plates. The 
plates were marked according to the block of pins that was to be inserted into 
them. Each block was positioned over the corresponding plate so that each of the 
96 pins were immersed in substrate in each of the 96 wells. The 
orientation/position of each well and the pin it contained was noted relative to the 
position of the wells containing the control pins. The reaction was incubated for 45 
minutes. The reaction was stopped by removing the pins from the wells. The 
microtitre plates were agitated for a further 10 minutes to ensure complete mixing 
of the colour that had developed in the substrate. The O.D405nm of each well was 
measured using an automatic plate reader.
Results were processed with particular attention being paid to the results for 
each duplicate of a peptide and graphs drawn using a Microsoft Excel 4.0 package.
5.4.5 REMOVAL OF PIN/PEPTIDE BOUND ANTIBODY
Standard procedure
A sonication bath was rinsed with distilled water. 4 litres of antibody removal 
buffer was placed in the bath and allowed to reach a temperature of 60°C. After the 
substrate reaction was complete (see section 5.4.4) the pins were immersed in the 
buffer and sonicated for 15 minutes (unless otherwise stated) and then rinsed twice 
with distilled water, pre-heated to 60°C, for 30 seconds. The pins were then 
placed in a bath of distilled water initially at a temperature of 60°C for at least 30
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minutes with agitation. Excess water was removed from the pins which were then
immersed in boiling methanol for 15 seconds. The pins were air dried for 15
minutes after which time they were either re-used or stored at 4°C in an air-tight
container containing silica powder to absorb excess moisture.
During the course of this thesis two other antibody removal procedures were 
adopted.
Universal buffer procedure
The first involved incubation of the pins in universal buffer for 10 minutes at 
room temperature prior to following the above procedure. The low pH of this 
buffer is effective at disrupting antibody-antigen interactions in the pin system 
(Davis et a l, 1993).
Urea based procedure
The second was essentially the same as the manufacturer's procedure except 
that 8M Urea containing 1% v/v of 1-mercaptoethanol was used instead of antibody 
removal buffer. This is an effective procedure for denaturing proteins attached to 
the pin-bound peptides which remain intact (G. Tribbick, Chiron Mimitopes, 
Australia., Personal communication).
5.4.6 CONTROL REACTIONS
The effectiveness of the pin-bound antibody removal procedure and that of the 
binding of conjugate in the absence of primary antibody was tested by performing 
an ELISA on the pins, using the aforementioned procedure but omitting the primary 
antibody incubation step. Two conjugates, a Goat anti-Horse IgG (y chain specific) 
peroxidase conjugate and a Rabbit anti-Horse IgG (whole molecule) peroxidase 
conjugate, both diluted 1/5000 were assayed in this manner prior to assaying sera 
with the pin system.
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5.5 RESULTS
5.5.1 CONJUGATE CONTROL REACTION
A goat anti-equine y chain specific peroxidase conjugate was shown to react 
weakly with some peptides in the absence of primary antibody. The peptides 
recognised by the conjugate were PASTQSAK, ASTQSAKT and STQSAKTV from 
the EHV-4 gB AHT domain series (see figure 5.9). Rabbit anti-horse IgG(whole 
molecule) and goat anti-mouse y chain specific horseradish peroxidase conjugates 
did not react with these EHV-4 gB AHT domain peptides or any of the other 
peptides. These conjugates were therefore routinely used in the Pin system ELISA 
assays described.
5.5.2 REMOVAL OF PIN BOUND ANTIBODY
Initially two blocks of peptides were obtained from the manufacturer. These 
blocks were initially assayed with serum 94538 at a dilution of 1/100. A conjugate 
control reaction performed post 94538 indicated that the peptide reactive antibodies 
in this serum were not removed by the manufacturer's antibody removal protocol. 
The manufacturer's parent company (Chiron Mimitopes, Australia) indicated that the 
serum had stuck to the pins, possibly because of concentrated antibodies of very 
high affinity in the very low dilution of serum utilised. The manufacturer's protocol 
recommends a dilution of 1/1000 for naturally infected animal sera. Standard 
antibody removal buffer was replaced by 8M Urea in the antibody removal protocol 
on the parent company's recommendation, however this also failed to remove the 
serum. A search of the literature revealed that pins could be subjected to a low pH 
buffer in order to elute reactive antibodies from the pins without having any 
apparent adverse effects on the peptides (Davis et al., 1993). Acid elution in 
association with the standard antibody removal procedure was attempted without 
success. Extending the length of any of the procedures up to one hour was equally 
unsuccessful. A second set of blocks (which differed from the first set of blocks 
in terms of peptide content) were ordered and assayed with serum 94538 at a 
dilution of 1/5000. Although this is the manufacturer's recommended dilution for
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hyperimmune animal sera, serum 94538 stuck to the new set of pins. In order to 
define conditions for the removal of this serum the old set of pins were sonicated 
for three hours using standard antibody removal buffer. A conjugate control reaction 
indicated that the O.D values of all 94538 reactive peptides had dropped by 30%. 
On this basis the old pins were sonicated for 10 hours. The temperature of the 
antibody removal buffer at the end of this extended sonication period was 80°C. A 
conjugate control reaction determined that the O.D values had returned to those seen 
for the conjugate control performed prior to the use of any sera. The new blocks 
of pins were subjected to sonication for 10 hours in standard antibody removal 
buffer which resulted in the removal of serum 94538 reactivities from these pins. 
Table (5.5) summarises the main steps taken to remove serum 94538 and their 
efficacy. Although no serum was stuck to the control pins these were also treated 
in the same way in order to ascertain if any of the aforementioned procedures 
could be potentially damaging to the peptides. After each variation of the antibody 
removal procedures the reactivities of the control antibody with (1) the control pins 
which were subjected to the altered antibody removal procedure and (2) control 
pins subjected to the standard procedure only were compared and found to be 
identical.
The new blocks of pins were used for all subsequent experiments during the 
course of which all other sera and control antibodies were removed by the 
manufacturer's recommended protocol.
5.5.3 REACTIVITY OF CONTROL ANTIBODY WITH CONTROL PEPTIDES
The O.D405nm values for the reactivity of the control antibody with the 
positive and negative control peptides were in the region of 1.100 and 0.15 
respectively. There was no significant inter-assay variation in these values between 
assays performed at different times.
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5.5.4 REACTIVITY OF EQUINE SERUM WITH PIN BOUND PEPTIDES
SPF foal preinfection sera
All preinfection sera were taken from animals 2 days prior to primary 
infection. Preinfection serum (Foal identity unknown) which was obtained directly 
from Cambridge did not react with any of the peptides. All O.D values for this 
serum were less than 0.25, the average being 0.17.
F I2 and FI 3 preinfection serum extracted from plasma at Glasgow Vet school 
reacted strongly and specifically with some of the peptides (see figure 5.10). These 
assays were repeated with the same results. A conjugate control was performed 
between these repetitions and proved negative, suggesting that the reactivities were a 
property of the sera being analysed and not a residual reactivity remaining on the 
pins after prior analyses.
Subsequent experiments with the pin system were performed with serum 
samples from experimentally or naturally infected animals which had been obtained 
directly from the sources listed in section 5.3.2 and were not derived from plasma 
at Glasgow Vet school by the procedure described in section 5.4.3.
Background reactivity for immune sera
Sera having an O.D value greater than 0.5 with a given peptide were 
generally considered to be reactive with that peptide.
EHV-1 gC domain one (137-170) Figure 5.11
At least three different antigenic regions corresponding to peptides 3-7, 10-15 
and 18-23 were defined by probing these peptides with serum from naturally and 
experimentally infected horses. This is most clearly illustrated by the reactivity 
profile of foal 6 . However, all sera did not have the same epitope specificity 
within these regions and it could be said that all peptides, with the exception of
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peptides 1 and 2 , gave an above background reactivity with at least some of the 
sera. Anti-EHV-4 sera tended to exhibit consistently better reactivities especially 
from peptide 17 onwards, the sequences of which are 100% homologous between 
EHV-1 and -4 (Nicolson and Onions, 1990). It is notable that F12 and 14 sera 
reacted, albeit weakly, with peptide 12 which contains an epitope recognised by an 
EHV-1 type-specific Mab (Allen et al., 1992). This is of interest since both 
animals had been infected with EHV-4 and at the time when serum samples were 
collected had never been infected with EHV-1. Serum 94538 reacted strongly with 
this epitope. EHV-4 had been isolated from horse 94538 at the time of serum 
sampling. Sera from the same outbreaks/experimental infections generally gave 
comparable results e.g 21196 vs 22460 vs 21546. However there were a few 
notable exceptions, especially with regard to sera associated with EHV-1 e.g 32474 
vs 30645. It is noteworthy that the two latter sera reacted with single peptides as 
did 84568. Horse 7 and 84694 did not react with any of these peptides which, in 
the case of 84694 could have been due to the dilution factor of 1/2500 used.
EHV-4 gC domain one (154-187) Figure 5.12
The results of this peptide series were generally similar to that of the EHV-1 
series. Overall three regions were recognised peptides 2-5, 7-15 and 18-23. SPF 
12 reacted with peptides in all three of these regions. Most of the sera with the 
exceptions of 84694 (dilution factor), 84568 and 32474 reacted with at least one 
of these regions. All of the aforementioned sera are derived from animals 
associated with outbreaks of EHV-1. A comparison of the SPF foal sera shows 
that F12, but not F14, both of which had been infected with EHV-4, reacted with 
some of peptides 2-5 whereas sera from EHV-1 associated foals did not show 
appreciable reactivity. However two factors are worth noting with regard to the 
reactivity of field sera with peptides 2-5. EHV-1 associated field sera 84890 and 
30645 reacted with peptides 2-5 whereas EHV-4 associated field sera 22460, 94538 
and horse 7 did not react with these peptides. Of interest is the reaction of Horse 
7, which was thought to have only a potential association with EHV-4 infection, 
with this series. This serum reacted with peptides 9-11 in the EHV-4 gC domain 
one series which align with the region of EHV-1 gC that contains an epitope for 
an EHV-1 specific Mab. Horse 7 serum did not react with the EHV-1 gC domain
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one peptides. This situation is similar to that of sera 84568 which reacts with the 
EHV-1 series but not the EHV-4 gC domain one series in this region. 30645 again 
reacts with a single peptide homologous to the 30645 reactive peptide in the EHV- 
1 series. The O.D reading for the EHV-4 peptide is greater than that for the EHV- 
1 peptide.
EHV-1 gB AHT domain (95-112) Figure 5.13
It is difficult to discern peaks of reactivity with this peptide series e.g.
21196, 32474, 84568 and 30645. This is due mainly to either high background 
activity e.g. 21196 or marginal peak reactivities e.g. 84568 and 30645. All the 
SPF foals seemed to recognise some of the peptides no. 8-11. Sera 21546, 21196 
and 22460 are from the same outbreak and reacted with some of these peptides. 
EHV-1 associated sera from the same outbreak i.e. 32474 and 30645 reacted with
peptide 6 , albeit marginally. Peptides 1-2 and 5-11 were recognised by some sera
e.g. 84890 and 21196 and 32474, 21546 and 21196 respectively.
EHV-4 gB AHT domain (93-108) Figure 5.14
Peaks were most frequently obtained with peptides 4-7. All SPF sera reacted
with some of the peptides no. 4-7. An EHV-1 associated serum 84568 reacted
strongly with peptide 7. Peptides 2-3 and 8-9 were not as frequently recognised as
peptides 4-7. A comparison of sera from the same outbreaks revealed the
following. Serum 21546 reacted with peptides from 2-3, 4-7 and 8-9 whereas
serum 21196 reacted with peptides 3 and 9, and 22460 reacted with peptide 6 .
Serum 30645 reacted with peptides 2-3 and 6-9 whereas serum 32474 did not react
appreciably with any of the peptides in this series.
Miscellaneous gH peptides Figure 5.15
All sera with the exceptions of 94538, 32474, and 84694 show similar 
reactivities with these peptides. 84694 did not react with any of the miscellaneous
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gH peptides whereas sera 32474 and 94538 did not react with any of the peptides 
in the EHV-4 gH aal6-39 series. The reactivities of all reactive sera with the 
EHV-1 gH aa 16-39 peptides were practically identical in that peptide 2 of this 
series was consistently recognised. On the other hand reactivities with the 
homologous EHV-4 region were not as consistent among the reactive field sera 
whereas the SPF foal sera had similar reactivity patterns with this peptide series. 
Three sera, namely 94538, F I3, and F I2, reacted with both EHV-4 gH peptide 
282-293 and its EHV-1 homologue. EHV-4 sera from the same outbreak had 
identical reactivity patterns with the three different peptide series but of different 
intensities i.e. peak O.D for 21196>21546>22460. EHV-1 sera from the same 
outbreak differed in their reactivity with the first two gH peptide series but do not 
react with peptides representing regions 274-285 and 282-293 of EHV-1 and -4 gH 
respectively.
Miscellaneous peptides Figure 5.16
EHV-1 gC domain 5 peptides: Four EHV-1 associated sera i.e 30645, 84890,
F I3 and F6 were reactive with these peptides. Other sera from different horses
from the same outbreaks/infections were not reactive. Two EHV-4 associated sera 
from the SPF foals were weakly reactive.
EHV-1 gplO peptides: Sera from Foals 6 , 12, 14 and horse 30645 reacted
with these peptides whereas other animals had a borderline reactivity or were not
reactive.
gB peptides ("1)255-270 and (41252-267: Sera 94538 and F I2 reacted quite 
strongly with at least one peptide from each of the EHV-1 and -4 series. F14 and 
84890 reacted with only one peptide in the EHV-4 series. Some sera e.g 30645 
and 21196 had borderline reactivities with both series.
gB peptides (T^511-520 and (4-1507-514: Two EHV-1 associated sera i.e 
84558 and 84694 reacted specifically with the EHV-1 peptide. EHV-4 sera 94538 
and F12 reacted with both EHV-1 and -4 peptides. 21196 reacted with the EHV-4 
peptide only whereas 21546 had a borderline reactivity with the EHV-4 peptide but 
reacted strongly with EHV-1 peptide.
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EHV-1 gB peptide (526-537): Serum 21196 reacted with this peptide. Other 
sera had borderline reactivity with this peptide.
EHV-1 gD neutralising and non-neutralising domain peptides and the 
EHV-4 homologues Figure 5.17
Seven of the sera did not react with the neutralising domain peptides. Of
those that did react, most reacted with both EHV-1 and -4 peptides (e.g. 32474, 
94538 F I3, and F12). Serum 84694 is interesting in that although it is EHV-1 
associated it reacted with an EHV-4 peptide. All EHV-4 sera from the same 
outbreak had marginal reactivity with these peptides. A comparison of sera from the 
same EHV-1 outbreak reveals that serum 32474 reacted with peptide 2 from the 
EHV-1 and -4 gD neutralising domain peptides whereas 30654 did not react with 
any of these peptides. Although F I3 was infected with EHV-1 its sera had 
antibodies against the EHV-4 peptide homologous to the EHV-1 neutralising 
domain. This is interesting since it has been demonstrated that sera from EHV-1 
infected foals do not neutralise EHV-4 in vitro (Fitzpatrick and Studdert 1984; 
Edington and Bridges 1990).
Both F6 and F13 reacted with peptide 2 of the EHV-1 gD non-neutralising 
domain. Both foals had been infected with EHV-1. The EHV-4 associated foals 
F12 and F14 had only marginal reactivity with these peptides. Of the EHV-4
associated field sera only those from the same outbreak i.e. 21196, 22460 and
21546 reacted with the EHV-1 gD non-neutralising peptides and with a specificity 
(peptide 1) different to that of the EHV-1 associated SPF foals (peptide 2). Some 
EHV-1 associated field sera e.g. 32474 and 84694 did not react with these 
peptides. All the SPF foal sera with the possible exception of F I3 reacted strongly 
with peptide 2 from the EHV-4 gD non-neutralising domain. Some EHV-4 
associated field sera e.g. horse 7 and 21546 reacted with EHV-4 peptide 2; 
however sera 21196 and 22460 had only marginal reactivity and 94538 did not 
react with either peptide 1 or 2. Three EHV-1 associated field sera 84890, 84568 
and 30645 reacted strongly with peptide 1 but not peptide 2 from the EHV-4
neutralising domain.
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Figure 5.1: Schematic representation of the Pin/Pepscan system.
(A) Side view of the Pepscan system system
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(B) Plan view from the bottom of the system showing numbering system
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(C) Magnification showing the Pin surface environment interface
Domain Five
EHV-1 MWLPNLVRFV AVAYLICAGA ILTYASGASA SSlSQSTPATP T-----------HTTl 44
EHV-4 MGLVNIMRFI TFAYIICGGF ILTRTSGTSA SASPATPTTN TGEGTSSPVT 50
C o n s e n s u s  M .L .N ..R F . . .A Y .IC .G . IL T ..S G .S A  S .S . .T P .T .  T  T 50
Domain Five contd.
EHV-1 IPNLTTA HGAGSDNlirN ANGTEST--------------HSHETTI TCTKSLISVP 84
EHV-4 PTYTTSTDSN NSTATNNSTD VNGTEATPTP SHPHSHENTI TCTNSLISVP 100
C o n s e n s u s  P . .T T  N .T . .NGTE.T................... HSHE.TI TCT.SLISVP 100
EHV-1 YYKSVDMNCT TSVGVNYSEY RLEIYLNQRT PFSGTPPGDE ENYINHNATK 134
EHV-4 YYTSVTINCS TTVSVNHSEY RLEIHLNQRT PFSDTPPGDQ ENYVNHNATK 150
C o n s e n s u s  Y Y .SV ..N C . T.V .VN.SEY RLEI.LNQRT PFS.TPPGD. ENY.NHNATK 150
___________Domain One__________
EHV-1 DdTLLLFSTA ERK-KSRRGG QLGVIPDRLP KRQLFNllPLH TEGGTKFPLT 183
EHV-4 DOTLLLFSTA HSSAKSRRVG QLGVIPDRLP KROLFNllPAH TNGGTNFPLN 200
C o n s e n s u s  DQTLLLFSTA  KSRR.G QLGVIPDRLP KRQLFNLP. H T .G G T.FPL. 200
EHV-1 IKSVDWRTAG IYVWSLYAKN GTLVNSTSVT VSTYNAPLLD LSVHPSLKGE 233
EHV-4 IKSIDWRTAG VYVWYLFAKN GSLINSTSVT VLTYNAPLMD LSVHPSLKGE 250
C o n s e n s u s  IKS.DWRTAG .YVW.L.AKN G.L.NSTSVT V.TYNAPL.D LSVHPSLKGE 250
EHV-1 NYRATCWAS YFPHSSVKLR WYKNAREVDF TKYVTNASSV WVDGLITRIS 283
EHV-4 NHRAVCWAS YFPHNSVKLR WYKNAKEVDF TKYVTNASSV WVDGLITRIS 300
C o n s e n s u s  N.RA.CW AS YFPH. SVKLR WYKNA.EVDF TKYVTNASSV WVDGLITRIS 300
EHV-1 TVSIPVDPEE EYTPSLRCSI DWYRDEVSFA RIAKAGTPSV FVAPTVSVSV 333
EHV-4 TVS IPADPDE EYPPSLRCSI EWYRDEVSFS RMAKAGTPSV FVAPTVSVNV 350
C o n s e n s u s  T V SIP .D P.E  EY.PSLRCSI .WYRDEVSF. R . AKAGTPSV FVAPTVSV.V 350
EHV-1 EDGDAVCTAK CVPSTGVFVS WSVNDHLPGV PSQDMTTGVC PSHSGLVNMQ 383
EHV-4 EDGAAVCTAE CVPSNGVFVS WWNDHLPGV PSQDVTTGVC SSHPGLVNMR 400
C o n s e n s u s  EDG.AVCTA. CVPS.GVFVS W.VNDHLPGV PSQD.TTGVC .SH.GLVNM. 400
EHV-1 SRRPLSEENG EREYSCIIEG YPDGLPMFSD TWYDASPIV EDRPVLTSII 433
EHV-4 SSRPLSEENG EREYNCIIEG YPDGLPMFSD SWYDASPIV EDMPVLTGII 450
C o n s e n s u s  S . RPLSEENG EREY.CIIEG YPDGLPMFSD .WYDASPIV E D .P V L T .II 450
EHV-1 AVTCGAAALA LWLITAVCF YCSKPSQAPY KKSDF 468
EHV-4 AVTCGAAALA LWLITAVCF YCSKPSQVPY KKADF 485
C o n s e n s u s  AVTCGAAALA LWLITAVCF YCSKPSQ.PY KK.DF 485
Figure 5.2: Alignment of EHV-1 and -4 gC amino acid sequences.
Boxes outline regions chosen for pepscan analysis.
EHV-1 gB 
EHV-4 gB
Consensus
EHV-1 gB 
EHV-4 gB
Consensus
EHV-1 gB 
EHV-4 gB
Consensus
MSSGCRSVGG STWGNWRGDG GDLRQRRVLS PVCSAPAAGS 
MSTCCRAICG PQRCYWRRDC GNLRQRRVLA SIHRTPAAGS
MS..CR. . . G  WR.D. G . LRQRRVL...... PAAGS
NLLATPHPLG KPASSRVGTI VLACLLLFGS CWRAVPTTP 
NLPATSPMSK DSTSLGVRTI VIACLVLLGC CIVEAVPTTP
WIGSQLGNVG
WLWSQLGNV-
W..SQLGNV.
AHT
SPPTSTPTSM
SSOPSTPA—
NL.AT........ S..V.TI V.ACL.L.G. C.V.AVPTTP S...STP...
Domain
STHSHGTVDP
STOSAKTVDO
TLLPTETPDP LRLAVRESGI LAEDGDFYTC 
TLLPTETPDP LRLAVRESGI LAEDGDFYTC
PPPTGSTWR
PPPTGSTWR
ST.S..TVD. TLLPTETPDP LRLAVRESGI LAEDGDFYTC PPPTGSTWR
50
49
50
100
97
100
150
147
150
EHV-1 gB IEPPRTCPKF DLGRNFTEGI AVTFKENIAP YKFRANVYYK DIWTRVWKG 200
EHV-4 gB IEPPRSCPKF DLGRNFTEGI AVIFKENIAP YKFRANVYYK DIWTKVWKG 197
Consensus IEPPR.CPKF DLGRNFTEGI AVIFKENIAP YKFRANVYYK DIWT.VWKG 200
EHV-1 gB YSHTSLSDRY NDRVPVSVEE IFGLIDSKGK CSSKAEYLRD NIMHHAYHDD 250
EHV-4 gB YSHTSLSDRY NDRVPVSVEE IFTLIDSKGK CSSKAEYLRD NIMHHAYHDD 247
Consensus YSHTSLSDRY NDRVPVSVEE IF.LIDSKGK CSSKAEYLRD NIMHHAYHDD 250
EHV-1 gB 
EHV-4 gB
C o n s e n s u s
EDEVELDLCR PSLQLRGARA 
EDElELDLVP SKFATPGARA
WQTTNDTTSY VGWMPWRHYT STSVNCIVEE 
WQTTNDTTSY VGWMPWRHYT STSVNCIVEE
EDEVELDL........ GARA WQTTNDTTSY VGWMPWRHYT STSVNCIVEE
300
297
300
EHV-1 gB VEARSVYPYD SFALSTGDIV YASPFYGLRA AARIEHNSYA QERFRQVEGY 350
EHV-4 gB VEARSVYPYD SFALSTGDIV YTSPFYGLRS AAQLEHNSYA QERFRQVEGY 347
Consensus VEARSVYPYD SFALSTGDIV Y .SPFYGLR. AA..EHNSYA QERFRQVEGY 350
EHV-1 gB RPRDLDSKLQ AEEPVTKNFI TTPHVTVSWN WTEKKVEACT LTKWKEVDEL 400
EHV-4 gB QPRDLDSKLQ AGEPVTKNFI TTPHVTVSWN WTEKKIEACT LTKWKEVDEL 397
Consensus .PRDLDSKLQ A.EPVTKNFI TTPHVTVSWN WTEKK.EACT LTKWKEVDEL 400
EHV-1 gB VRDEFRGSYR FTIRSISSTF ISNTTQFKLE SAPLTECVSK EAKEAIDSIY 450
EHV-4 gB VRDEFRGSYR FTIRSISSTF ISNTTQFKLE DAPLTDCVSK EAKDAIDSIY 447
Consensus VRDEFRGSYR FTIRSISSTF ISNTTQFKLE .APLT.CVSK EAK.AIDSIY 450
EHV-1 gB KKQYESTHVF SGDVEYYLAR GGFLIAFRPM LSNELARLYL NELVRSNRTY 500
EHV-4 gB RKQYESTHVF SGDVEFYLAR GGFLIAFRPM ISNELARLYL NELVRSNRTY 497
Consensus .KQYESTHVF SGDVE.YLAR GGFLIAFRPM .SNELARLYL NELVRSNRTY 500
EHV-1 gB 
EHV-4 gB
Consensus
DLKNLLNPNA
DLKNLLNPNA
RSLLdvPEPO PTODGVijREO ILHRLHKRAV 550
RSLLSIPEPT PTQESLHREQ ILHRLHKRAV 545
DLKNLLNPNA N. . .NT.R.R RSLLS.PEP. PTQ. . .HREQ ILHRLHKRAV 550
NNNNNTTRRR 
NH— NTNRTR
EHV-1 gB EATAGTDSSN VTAKQLELIK TTSSIEFAML QFAYDHIQSH VNEMLSRIAT 600
EHV-4 gB EAANSTNSSN VTAKQLELIK TTSSIEFAML QFAYDHIQSH VNEMLSRIAT 595
Consensus EA...T.SSN VTAKQLELIK TTSSIEFAML QFAYDHIQSH VNEMLSRIAT 600
Figure 5.3: Alignment of EHV-1 (1-600) and -4 (1-595) gB amino acid sequences.
Boxed regions were chosen for pepscan analysis.
Figure 5.4: Chou-Fasman prediction of antigenic regions of (A)
EHV-4 and (B) -1 gB homologues. Regions surrounded by hexagons are 
potentially antigenic.
(A)
A n l iq p n . In d c n  >* 1.6
NH2
300
400
tea
850
(B)
750
800
350
950
HOOC
EHV-1 gH 
EHV-4 gH
Consensus
MLQPYKKMLI FAWIVAFAM AVWSTPVPAT PSG- -V GNATW^VNNS-
MSQPYLKIAI LVAAHIVSAI PVWTTPVSTS PPOOTKLHYV GNGTWHNNT 
M.QPY.K..I ___ T...A. .VW.TPV. . . P....... V GN.TW. .N. .
43
50
50
EHV-1 gH FNITRYDKIT MGQVYSNTSN SPIFFWISE RNFRIVNTPL GASVFWIPKG 93
EHV-4 gH FNVTRYDRIT MEPVYNNNLS STTFFVAISE RNFRTVNTPL GASVFWILKS 100
Consensus FN.TRYD.IT M..VY.N... S..FFV.ISE RNFR.VNTPL GASVFWI.R. 100
EHV-1 gH AMNPPQHQPC VANGPEPGDP RGPCVNSTVS LLFNENVEPF LMSKNLLEFE 143
EHV-4 gH ALNPPKHQPC IANVPEPGDP RGPCVNSTVS LFFNDNLEPF LMTKNLLEFE 150
Consensus A.NPP.HQPC .AN.PEPGDP RGPCVNSTVS L.FN.N.EPF LM.KNLLEFE 150
EHV-1 gH 
EHV-4 gH
Consensus
VLPDTYITGW TFERSKTATT KSNPVGWLS PPRGSPSANT TIRDDGGPKK 
VLPDNYITGW TFERSKTVAT KGNPVGWLS PPRTSPDVNN TIRDDGTPKQ
VLPD.YITGW TFERSKT..T K.NPVGWLS PPR.SP..N. TIRDDG.PK.
193
200
200
EHV-1 gH PLSIIDEYTT LVADLQNFTM TLTYISPFAA VWPIEAFQTG ITVMGCDTTQ 243
EHV-4 gH HLSIIDEHTT FVLDLQNFTK TLTYISPFAA VWPITAFHAG ITVMGCDTTQ 250
Consensus .LSIIDE.TT .V.DLQNFT. TLTYISPFAA VWPI.AF. .G ITVMGCDTTQ 250
EHV-1 gH 
EHV-4 gH
Consensus
WAYLGHGFM GLQISSVNNP PLEMIWPND \
AIAYLGNGFM GLQISSVNNP PLEMIVAPND URARIVNRLP PRHRLEPPGP
SARILNRRP SRI RLEPPGP
..AYLG.GFM GLQISSVNNP PLEMIV.PND V.ARI.NR.P .R .RLEPPGP
293
300
300
EHV-1 gH HAGPIYKVYV LSDGNFYLGH GMSRISREVA AYPEESLDYR YHLSLANLDT 343
EHV-4 gH YAGPIYKVYV LSDGNFYLGH GMSRISREVA AYPEESLDYR YHLSLANLDT 350
Consensus .AGPIYKVYV LSDGNFYLGH GMS.ISREVA AYPEESLDYR YHLSLANLDT 350
EHV-1 gH LAMLAELSSG KSTDVSYYMY RIVARLAVAT FSLAEVIRLS DYMLLQEAID 393
EHV-4 gH LAMLAELSSG KSKDVSYYLY RIIARLAVAT FSLAEVIRLS DYMLLQEAID 400
Consensus LAMLAELSSG KS.DVSYY.Y RI.ARLAVAT FSLAEVIRLS DYMLLQEAID 400
EHV-1 gH VDMNLRLIVP LVMKYAAGGA ADSSYTSSDV AMDQFDVAQS QIEKIVSDIN 443
EHV-4 gH VDINLRLIVP LVMKYAAGGT ADSSYTSSDV AMDQFEVAQA QIEKIVADIN 450
Consensus VD.NLRLIVP LVMKYAAGG. ADSSYTSSDV AMDQF.VAQ. QIEKIV.DIN 450
EHV-1 gH VEAELRKPMY EHRSLLRSVY AYSRKPLPNA VALADRLILA MYKEAIKDRI 493
EHV-4 gH IENELRKPMY EHRSLLRSVY AYSRRPLPNA VSFANRLITA MYREAIRDRI 500
Consensus .E .ELRRPMY EHRSLL.SVY AYSRRPLPNA V ..A .RLI.A MYREAIRDRI 500
EHV-1 gH TWNSTMREVL FFAVGAAAGS HVILTDEPEP GAPAHRDASL FLSLNRNILL 543
EHV-4 gH TWNSTMREVL FFAVGAAAGS HVILTDGPDL GLHAHRDSSM FLSLNRNILL 550
Consensus TWNSTMREVL FFAVGAAAGS HVILTD.P.. G..AHRD.S. FLSLNRNILL 550
EHV-1 gH LCTAMCTASH AVSAGLRLEE VMAGLVAGGV QFSLLEVFSP CMASTRFDLA 593
EHV-4 gH LCTAMCTASH AVSAGVRLEE VMAGLIAGGV QFSLLEVFSP CMASARFDLA 600
Consensus LCTAMCTASH AVSAG.RLEE VMAGL.AGGV QFSLLEVFSP CMAS.RFDLA 600
Figure 5.5: Alignment of EHV-1 and -4 gH amino acid sequences.
Boxed regions were chosen for pepscan analysis.
Figure 5.6: Chou-Fasman prediction of antigenic regions of (A)
EHV-4 and (B) -1 gH homologues. Regions surrounded by hexagons are 
potentially antigenic.
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EHV-1 gplO MDQHHGARGG APIRRPRRSI ESRSHPFRAT GNTQRTYSTP RLSYRDGLSG 50
EHV-4 gplO MDQHHGVRGG APIRRPRRSI ETRSHPFRAA GNTQRTYSTP RLSYRDGLSG 50
Consensus MDQHHG.RGG APIRRPRRSI E .RSHPFRA. GNTQRTYSTP RLSYRDGLSG 50
EHV-1 gplO RTASRDPQEQ ASNQDESSNP STSNAQQSTS FWGYLRRVFS DDVPAQPQAP 100
EHV-4 gplO RASSLEPGGQ AHDQNESSTQ STSNNQPSTS FWGYLRRVFS DDAPAQPQAP 100
Consensus R..S..P..Q A..Q.ESS.. STSN.Q.STS FWGYLRRVFS DD.PAQPQAP 100
EHV-1 gplO RPRADFAPPA GEESSSEEEE EEGPAQAPLD EEDQLMYADQ YSVGDSSDEJn| 150
EHV-4 gplO RSRADFAPPP EEDSSSEEED EEGPSQAPLD EEDQLMYADQ YSVGNSSDDN 150
Consensus R .RADFAPP. .E.SSSEEE. EEGP.QAPLD EEDQLMYADQ YSVG.SSD.N 150
EHV-1 gplO IDEEEDPRLGS E|YPTSAESSE YHDHGEMVAG AGAESESETD I^AEEEEEDDl 200
EHV-4 gplO -EEDYLQPEV EYPTSAESGE YHNSG-MFAE EEPESESESD M ENYE 193
Consensus .EE YPTSAES.E YH. .G.M.A. . . .ESESE.D ...... E. . . 200
EHV-1 gplO lEDCkDDMEVI RDESYRLPRT WLDKSIRLMD EALAQSSELS KAITKSTRSL 250
EHV-4 gplO TYEENDTEVI SDDSHRLTRT WLDRSIRLMD DALAQSSEIS KAITKSTRRL 243
Consensus ...E.D.EVI .D.S.RL.RT WLD.SIRLMD .ALAQSSE.S KAITKSTR.L 250
EHV-1 gplO YDSQFAPGGR GYTQTATPSR RLVQLSRAGM YDSDKIVMTG DYMEVDDDPD 300
EHV-4 gplO YDSQFTPGGR GYKQTETPSQ RLVHLSRAGM YDSDEIVMTG DYMEVDDDPN 293
Consensus YDSQF.PGGR GY.QT.TPS. RLV.LSRAGM YDSD.IVMTG DYMEVDDDP. 300
EHV-1 gplO SAYQSWVRAI RHPLAMNPSW EETISNHTNP SFSTDIDYDI DELIEKNLAR 350
EHV-4 gplO SAYQSWVRAI HHPVAMNPSW EETISNHTNT SFSADIDYDI DELIEMNLAR 343
Consensus SAYQSWVRAI .HP.AMNPSW EETISNHTN. SFS.DIDYDI DELIE.NLAR 350
EHV-1 gplO TPPVFEGLLD SAEFFYKLPM LYTYATITQD EAYEERLAWS NTQALHGHEQ 400
EHV-4 gplO TPPVFEGLLD SADFFYRLPM LYTYATITQD EAYEERQAWS NTQALHGHEQ 393
Consensus TPPVFEGLLD SA.FFY.LPM LYTYATITQD EAYEER.AWS NTQALHGHEQ 400
EHV-1 gplO SSWQALLVYY SRGGMYVSPT QEPRGIWRRA LKQAMALQLK MCVLGLSDW 450
EHV-4 gplO SSWPALVSDY SKGGMYVSPT QEPRGIWRRA LKQAMALQLK LCVLGLTEFV 443
Consensus SSW.AL...Y S.GGMYVSPT QEPRGIWRRA LKQAMALQLK .CVLGL...V 450
EHV-1 gplO TKQNATHHHA AVTFLVDALL RTARNCYLAS RLLVFAWERR RETGAKRPAE 500
EHV-4 gplO TKRELTQHHS AVTFLVDSLL RTAKNCYLAS RLLVFAWERR RETGVRRPAE 493
Consensus TK...T.HH. AVTFLVD.LL RTA.NCYLAS RLLVFAWERR RETG..RPAE 500
EHV-1 gplO PLIALSGVTL LQPLPPEVSE LLEQRTFDIG LRTPNSAVFR AFFGSLVYWA 550
EHV-4 gplO PLIALSGVTL LQPLPPEVSE LLEQRTFDIG LRTPQSGVFR AFFGPLVYWA 543
Consensus PLIALSGVTL LQPLPPEVSE LLEQRTFDIG LRTP.S.VFR AFFG.LVYWA 550
EHV-1 gplO ELRLALRDPA SINCRYVGFH LQTSEIYLLA RAHSASPGYT KEELVAMEAI 600
EHV-4 gplO ELRRALRDPA AINCRYVGFH LQTSEIYLLA RAHSASPGYT KEELVAMEAT 593
Consensus ELR.ALRDPA .INCRYVGFH LQTSEIYLLA RAHSASPGYT KEELVAMEA. 600
Figure 5.7: Alignment of the first 600AA of the EHV-1 and -4 gplO homologues.
Boxed regions were chosen for pepscan analysis.
Cleavage site
EHV-4 gD 
EHV-1 gD
Consensus
MSTFKPMMNG CLVFAAIITL LSFMLSLGT 2 ENYRRWRGN QNQRPEFPPP 
MSTFKLMMDG RLVFAMAIAI LSWLSCGT1 EKAKRAVRGR QDRPKEFP ?P
MSTFK.MM.G .LVFA..I.. LS..LS.GTC E...R.VRG. Q  EFPPP
50
50
50
EHV-4 gD RYNFTIVTTY NETSLPSPFI NDQVKIVDVR TVAATRPCEM IALIAKTNVD 100
EHV-1 gD RYNYTILTRY NATALASPFI NDQVKNVDLR IVTATRPCEM IALIAKTNID 100
Consensus RYN.TI.T.Y N.T.L.SPFI NDQVK.VD.R .V.ATRPCEM IALIAKTN.D 100
EHV-4 gD 
EHV-1 gD
Consensus
SIIKELDAAH KTYSARLTWF KITPTCATPI HDWYMKCNP KLLFGMCDER 
SILKELAAAQ KTYSARLTWF KIMPTCATPI HDVSYMKCNP KLSFAMCDER
SI.KEL.AA. KTYSARLTWF KI.PTCATPI HDV.YMKCNP KL.F.MCDER
150
150
150
EHV-4 gD SNILWLNSLI TTAAETDDEL GLVLASPAHS YSGLYRRVIQ IDGRRIYTDF 200
EHV-1 gD SDILWQASLI TMAAETDDEL GLVLAAPAHS ASGLYRRVIE IDGRRIYTDF 200
Consensus S.ILW..SLI T .AAETDDEL GLVLA.PAHS .SGLYRRVI. IDGRRIYTDF 200
EHV-4 gD SVTIPSSHCP LSFEQNFGNP DRCKTPEQYS RGEVYTSRFL SEFNYRQGVH 250
EHV-1 gD SVTIPSERCP IAFEQNFGNP DRCKTPEQYS RGEVFTRRFL GEFNFPQGEH 250
Cons ensus SVTIPS. . CP ..FEQNFGNP DRCKTPEQYS RGEV.T .RFL .EFN..QG.H 250
EHV-4 gD 
EHV-1 gD
C o n s e n s u s
LAWVKHWFVQ DGGNLPVQFY EAQAFARPVP PDNHPGFDSV E£ EITQNKTN 
MTWLKFWFVY DGGNLPVQFY EAQAFARPVP PDNHPGFDSV E£ EITQNKTD
.W.K.WFV. DGGNLPVQFY EAQAFARPVP PDNHPGFDSV ESEITQNKT.
300
300
300
EHV-4 gD 
EHV-1 gD
Consensus
PKQEQASPKP NPPFKWPSIK QLAPRIDEVD NAKEITTKKP PASNSNSTFI 
PKPGQADPKP NQPFKWPSIK HLAPRLDEVD EVIEPVTKPP KTSKSNSTFV
PK..QA.PKP N.PFKWPSIK .LAPR.DEVD ...E..TK.P ..S.SNSTF.
350
350
350
EHV-4 gD GWIGLGWG LISVGAILYV CWRRRKSQNK SEKNGSPSLR STFKDVKYTQ 400
EHV-1 gD GISVGLGIAG LVLVGVILYV CLRRKKELKK SAQNGLTRLR STFKDVKYTQ 400
Consensus G...GLG..G L..VG.ILYV C.RR.K...K S..NG...LR STFKDVKYTQ 400
EHV-4 gD 
EHV-1 gD
Consensus
LP
LP
LP
402
402
402
Figure 5.8: Alignment of the EHV-1 and -4 gD homologues.
Boxed regions were chosen for pepscan analysis. Peptides representing these regions 
were numbered from the proposed cleavage site.
(A) Rabbit anti-horse IgG H+L chain specific HRP conjugate.
(B) Goat anti-horse y-chain specific HRP conjugate.
F igure 5.9: Conjugate control reactivities with the EHV-4 gB AHT 
domain peptides. The peptides in this series are listed on the horizontal axes. 
The vertical axis are labelled O .D ^ ^  x 1000.
Figure 5.10: Reactivity of Preimmune SPF foal 12 and 13 plasma
derived sera with pepscan peptides. (A+H) EHV-1 gC domain one
peptides, (B+I) EHV-4 gC domain one peptides, (C+J) EHV-1 gB AHT domain
peptides, (D+K) EHV-4 AHT domain peptides, (E+L) Miscellaneous gH peptides,
(F+M) Miscellaneous gB, gplO and gC peptides and (G+N) EHV-1 and -4 gD 
neutralising and non-neutralising domain peptides. The maximum O.D reading and 
the unit length of the vertical axis for each peptide series is given at the top and 
towards the bottom of each vertical axis respectively. Reactivities of preimmune 
SPF foal 12 and 13 are illustrated in graphs A to G and H to N respectively.
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Figure 5.11: Reactivity of sera with EHV-1 gC domain one. Serum 
numbers are in bold face and the associated virus types in relief face. The 
horizontal axes are labelled with the pepscan numbers. Note the differences in 
scale of the vertical axis (O .D ^^  xlOOO) for each graph.
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Figure 5.12: Reactivity of sera with EHV-4 gC domain one. Serum 
numbers are in bold face and the associated virus types in relief face. The 
horizontal axes are labelled with the pepscan numbers. Note the differences in 
scale of the vertical axis (O.D405nm xlOOO) for each graph.
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Figure 5.13: Reactivity of sera with EHV-1 gB AHT domain. Serum 
numbers are in bold face and the associated virus types in relief face. The 
horizontal axes are labelled with the pepscan numbers. Note the differences in 
scale of the vertical axis (O .D ^^  xlOOO) for each graph.
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Figure 5.14: Reactivity of sera with EHV-4 gB AHT
numbers are in bold face and the associated virus types in 
horizontal axes are labelled with the pepscan numbers. Note 
scale of the vertical axis (O .D ^ ^  xlOOO) for each graph.
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Figure 5.15: Reactivity of sera with miscellaneous gH peptides.
Serum numbers are in bold face and the associated vims types in relief face. The 
horizontal axes are labelled with the pepscan numbers where applicable. Graphs A 
and B show the identity of the peptide series on the horizontal axes. The 
positions of these identified series/peptides are conserved in the other graphs 
which are not labelled in this manner. Juxtaposed EHV-1 and -4 reactivities are 
labelled at the top of each bar with a number indicating the vims type. Note the 
differences in scale of the vertical axis (O .D ^^  xlOOO) for each graph.
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Figure 5.16: Reactivity of sera with miscellaneous gC, gplO and
gB peptides. Serum numbers are in bold face and the associated virus types in
relief face. The horizontal axes are labelled with the pepscan numbers where
applicable. Graphs A through to F show the identity of the peptide series. The 
positions of these identified series/peptides are conserved in the other graphs 
which are not labelled in this manner. Juxtaposed EHV-1 and -4 reactivities are 
labelled at the top of each bar with a number indicating the virus type. Note the
differences in scale of the vertical axis (O .D ^^  xlOOO) for each graph.
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Figure 5.17: Reactivity of sera with gD neutralising and non­
neutralising domain peptides. Serum numbers are in bold face and the 
associated vims types in relief face. The horizontal axes are labelled showing the 
positions of the different peptides and their pepscan numbers. EHV-1 and -4 
reactivities are labelled at the top of each bar with a number indicating the vims 
type. Note the differences in scale of the vertical axis (O.D405nm xlOOO) for each 
graph.
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Table 5.1: Details of peptides chosen for pepscan
analysis. PSN refers to the pepscan number used to label, where 
applicable, the horizontal axis of the graphs presented in the results 
section of this chapter. The position in the native glycoprotein 
sequence of the first and last amino acid in each peptide series is 
indicated by a number at the beginning and end of each peptide 
series. NA indicates that there is only one peptide in this series.
PSN EHV-1 gC Domain 1 Virus PSN EHV-4 gC Domain 1 Virus PSN EHV-1 gC Domain 5 Virus
1 137-TLLLFSTA 1 154-LLLFSTAH 1 33-SQSTPATPTHTT
2 LLLFSTAE 2 LLFSTAHS 2 PTHTTPNLTTAH EHV-1
3 LLFSTAER 3 LFSTAHSS 3 LTTAHGAGSDNT-58
4 LFSTAERK 4 FSTAHSSA
5 FSTAERKK 5 STAHSSAK PSN EHV-1 misc gplO Virus
6 STAERKKS 6 TAHSSAKS 1 52-TASRDPQEQASN-63
7 TAERKKSR 7 AHSSAKSR 2 150-NDEEEDPRLGSD-161 EHV-1
8 AERKKSRR 8 HSSAKSRR EHV-4 3 192-DAEEEEEDDEDD-203
9 ERKKSRRG EHV-1 9 SSAKSRRV
10 RKKSRRGG 10 SAKSRRVG PSN EHV-1/4 misc gB Virus
11 KKSRRGGO 11 AKSRRVGQ 1 255-ELDLCRPS
12 KSRRGGQL 12 KSRRVGQL 2 CRPSLQLR EHV-1
13 SRRGGQLG 13 SRRVGQLG 3 LQLRGARA-270
14 RRGGQLGV 14 RRVGQLGV
15 RGGQLGVI 15 RVGQLGVI 1 252-ELDLVPSK
16 GGQLGVIP 16 VGQLGVIP-187 2 VPSKFATP EHV-4
17 GQLGVIPD 3 FATPGARA-267
18 QLGVIPDR P SN EHV-4 gB Dom. AHT Virus
19 LGVIPDRL 1 93-PSTPASTQ NA 512-NNNNTTRRR-520 EHV-1
20 GVIPDRLP 2 STPASTQS NA 508-HNTNRTR-514 EHV-4
21 VIPDRLPK 3 TPASTQSA
22 IPDRLPKR 1/4 4 PASTQSAK EHV-4 NA 526-VPEPQPTQDGVH-537 EHV-1
23 PDRLPKRQ 5 ASTQSAKT
24 DRLPKRQL 6 STQSAKTV PSN EHV-1/4 neut gD Virus
25 RLPKRQLF 7 TQSAKTVD 1 4-CEKAKRAVRGRO EHV-1
26 LPKRQLFN 8 QSAKTVDQ 2 VRGRQDRPKEFP-22
27 PKRQLFNL-170 9 SAKTVDQT-108
1 4-CENYRRVVRGNO EHV-4
P SN EHV-1 gB Dom. 
AHT
Virus PSN EHV-1/4 misc gH Virus 2 VRGNQNQRPEFP-22
1 95-STPTSMST 1 16-VAFAMAVWSTPV
2 TPTSMSTH 2 VW STPVPATPSG EHV-1 PSN EHV-1/4 non-neut gD Virus
3 PTSMSTHS 3 PATPSGVGNATW-39 1 267-EITQNKTDPKPG EHV-1
4 TSMSTHSH 2 PKPGQADPKPNQ-286
5 SMSTHSHG EHV-1 1 22-VWTTPV STSPPQ
6 MSTHSHGT 2 STSPPQQTKLHY EHV-4 1 267-EITQNKTNPKQE EHV-4
7 STHSHGTV 3 QTKLHYVGNGTW-45 2 PKQEQASPKPNP-286
8 THSHGTVD
9 HSHGTVDP NA 274-RARIVNRLPPRR-285 EHV-1
10 SHGTVDPT NA 282-S ARILNRRPSRL-293 EHV-4
11 HGTVDPTL-112
Serum CF Titre* Description Supplier
21196 (1) 5 
(4) 10
EH V-4: Convalescent 
serum from a horse in­
contact with a mare with 
EHV-4 respiratory disease
AHT
21546 (1) 40 
(4) 160
EHV-4: cohort serum of 
21196,22460 and 21179
AHT
22460 (1) 640 
(4) 640
EHV-4: cohort serum of 
21196, 21179 and 21546
AHT
94538 No details EHV-4: serum from a 
horse from which EHV-4 
was isolated.
IEC
Horse 7 (1) 5 
(4) 40
EH V-4: presumed 
exposure to EHV-4.
IEC
30645 (1) 160 
(4) 80
EHV-1: convalescent 
serum from a horse in­
contact with a mare which 
aborted an EHV-1 positive 
foetus.
AHT
32474 (1) 640 
(4) 320
EHV-1: cohort serum of 
30645.
AHT
84890 High titre 
No details
EHV-1: serum from 
horse which had been 
vaccinated after contact 
with horses with EHV-1 
induced paralysis.
IEC
84568 (1) 80: (4) 40 EHV-1: No details. IEC
84694 (1) 80: (4) 20 EHV-1: No details. IEC
Table 5.2: Details of naturally infected animal sera. *In some
cases the precise CF titre was not given by the supplier. In the CF titre 
column the numbers in brackets refer to EHV-1 or -4. AHT= the Animal 
Health Trust, Newmarket, UK. IEC= the Irish Equine Centre, Kildare, 
Ireland.
Serum Titre Description Supplier
SPF Foal 6 No details EHV-1: serum taken from 
animal 102 days after 
primary experimental 
infection with EHV-1.
CU
SPF Foal 13 No details EHV-1: serum taken from 
animal 82 days after 
primary experimental 
infection with EHV-1
c u
SPF Foal 12 No details EHV-4: serum taken from 
animal 82 days after 
primary experimental 
infection with EHV-4
CU
SPF Foal 14 No details EHV-4: serum taken from 
animal 82 days after 
primary experimental 
infection with EHV-4
c u
Preimmune
sample
No details Negative: serum taken 
from SPF foal (Identity 
unknown) 2 days before 
been experimentally 
infected for the first time.
c u
SPF foal 
12+13
No details Negative: serum derived 
at Glasgow vet school 
from plasma taken from 
animals at Cambridge 2 
days prior to their first 
contact with either EHV-1 
or -4.
c u
Table 5.3: Details of sera from experimentally infected SPF  
foals. CU= Cambridge University veterinary college.
IPX PBS
Na2HP04 42.8g
NaH2P04.2H20 15.6g
NaCl 340g
The salts were dissolved in 
41 of hot dH20. The 
solution was allowed to 
cool to room temperature 
and the pH adjusted to 7.2 
with 50% NaOH.
Conjugate diluent
IX PBS
1% v/v sheep serum 
0.1% w/v Casein 
0.1% Tween 20
Universal Buffer
1M Citric Acid 
1M Phosphoric Acid 
1M NaOH 
0.1M HCL
57mM Orthoboric Acid 
The above is the final 
concentration of buffer 
components mixed in water. 
The pH of the buffer was 
2.5.
Precoat buffer
IX PBS
0.1% v/v Tween 20 
0.1% w/v Sodium Azide 
2% w/v BSA
Wash buffer
IX PBS
0.5% v/v Tween 20
Substrate
One phosphate-citrate buffer tablet (Sigma) was 
dissolved in 100ml of water yielding a 0.05M 
phosphate citrate buffer, pH 5.0. One ABTS tablet 
(Sigma) was dissolved in 100ml of this buffer. 25ul 
of 30% H2O2 was added immediately prior to use.
Ab removal buffer
N a^P O , 1.07kg
NaH2P 0 4.2H20  390g
SDS 250g
The above components were dissolved in 51 of hot 
dH20. The temperature was allowed to equilibrate to 
60°C at which point the pH of the solution was 
adjusted to 7.2 with 50% NaOH. This solution was 
brought to a volume of 201 with dH2 0  providing 
sufficient buffer for 5 removal procedures. 5ml of 2- 
mercaptoethanol was added to 51 of the buffer 
immediately prior to use.
Table 5.4: Solutions for the Pin system.
Removal Procedure % reduction in 
94538 signal
Post reactivity o f  
control pins
Normal 0% 100%
8M Urea 0% 100%
Universal buffer 0% 100%
Normal + 3hrs. 30% 100%
Normal + lOhrs. 100% 100%
Table 5.5: Antibody removal procedures and their effectiveness.
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5.6 DISCUSSION
The Pin system was chosen because it allows a large number of potentially 
antigenic sites to be characterised in detail with regard to their epitope content
without the problems associated with the use of small free peptides. However the 
system proved to be problematic.
Firstly, a goat anti-equine IgG (y chain specific) peroxidase conjugate reacted 
weakly with some of the EHV-4 gB AHT domain peptides. This serum was 
prepared from pooled immune goat sera. It is possible that some of the animals
utilised to prepare the pool could have been infected with EHV since cross-species 
EHV infection has been documented (Montali et al., 1985; Rebhun et a l, 1988). 
Two other potential alternatives are anti-goat herpesvirus serum cross-reacting with 
EHV epitopes or a fortuitous reaction of the goat sera with EHV epitopes.
However this conjugate was used routinely without problem for ELISA analysis of 
gG peptides (see chapter 6).
The second major problem to be encountered with this system involved the 
apparent inability of the recommended serum removal procedure to remove reactive 
antibodies in serum 94538 from the pin system. The recalcitrance of this serum 
seems to defy established facts about protein chemistry. The harsh regimes
necessary to remove this serum cannot simply be justified by the presence of high
affinity antibodies in the semm, although similar problems have been encountered in
removing high affinity antibodies from affinity columns. Throughout the initial 
extremely harsh and extended removal procedures the reactivity pattern of the serum 
with the different epitopes was maintained i.e. peptides either side of a peak
reactivity in an extended series still maintained the same O.D after the various
antibody removal procedures initially employed. These peptides only contain part of 
the core epitope, therefore it is assumed that antibodies within the serum would not 
have the same affinity for them as for the core epitope. On the basis of 
conservation of these non-core epitope-antibody interactions after the different 
removal procedures, one could surmise that irreversible binding was a general 
property of the serum and not confined to specific high affinity antibody-paratope 
interactions. This suggests that the inability to remove these antibodies was not due
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to their affinity, assuming that non-core epitope peptides were not also reacting
with high affinity antibodies that may have been present in the serum in low but
detectable amounts. Furthermore serum 94538 was assayed at a dilution of 1/5000 
which was recommended for hyperimmune animal sera that may contain high 
affinity antibodies. An alternative explanation for the irreversible binding of the
serum may have been the presence of highly reactive chemical groups that were 
used in the synthesis of the peptides and which had not been sufficiently blocked 
by the manufacturer of the pins and by the blocking reagents used herein for 
ELISA with the Pin system. The high concentration of amine groups in the serum 
available for covalent reaction with the aforementioned groups on the pins, relative 
to the low concentration in the highly dilute positive control Mab, may explain why 
irreversible binding of this serum was detected whereas the Mab seemed to be
efficiently removed. Be that as it may it still remains to be understood why the
serum survived the harsh denaturing antibody removal conditions. The supplier of
this serum did not indicate anything unusual about this serum or the animal it was 
derived from, indeed other sera obtained from the same supplier were easily
removed from the pins.
Given the harsh treatment of the pin-bound peptides it must be considered 
whether or not the peptides suffered damage which may have affected subsequent 
analysis of sera. The control peptides were not noticeably damaged by the treatment 
regimes. Chapter 3 contains the reactivity profile of Mab 26A5 with the EHV-1 gC 
domain one series. This result, as already stated, compares favourably with
previously published data suggesting that the core epitope recognised by this Mab 
survived the antibody removal regime. Finally duplicate peptides consistently gave 
similar results. It seems likely that the peptides were not detectably damaged. On 
the other hand, given the high density of the peptides on each pin it is possible 
that a percentage of the peptides were damaged and that the degree of damage was 
not detected by the procedures employed here, but may have ultimately affected the 
useful life of the pins. Another possibility is that some peptides may be more 
liable to damage and would remain undetected if they had not previously been 
identified as being antigenic.
The third problem with the utilisation of the pin system involved the 
reactivities of preinfection sera derived from plasma at Glasgow that were similar in
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strength and specificity to the reactivities of immune sera. Plasma samples were 
brought from Cambridge but had been labelled on the day of sampling i.e. prior to 
infection of any animals involved in the SPF foal study and before transport to 
Glasgow. It is therefore unlikely that these preinfection samples had been confused 
with post-infection plasma samples. Furthermore these samples were negative for 
EHV-1 and -4 antibody in a gG ELISA (see chapter 6), however the senstivity of 
this assay was not determined. These sera did however react marginally with 
peptide 15 (Stokes et al., 1991) representing the EHV-4 amino acid sequence 
homologous to the EHV-1 gC domain one epitope (see chapter 6). Preinfection 
serum supplied directly by Cambridge did not react with any of the Pin system 
peptides. It was not determined if the Glasgow and Cambridge serum derivation 
procedures differed significantly. The possibility exists that the plasma was not 
completely coagulated using the Glasgow procedure since it was assumed that the 
plasma had already being citriated prior to its arrival in Glasgow. That the plasma 
had been citriated may not have been the case, therefore plasma proteins may have 
still been present in the serum prepared at Glasgow in sufficient concentrations to 
interfere with the pin system ELISA.
The fourth problem concerned the decision of what was to be considered the 
background for these ELISA assays. If the maximun O.D value obtained with 
preinfection serum supplied by Cambridge was considered background then many of 
the immune sera would have been shown to react with most of the peptides. There 
was a wide variation between different sera in terms of background reactivity with 
specific peptide series and between different peptide series with a given serum. 
These differences were probably due to the different anamnestic responses within 
each serum tested. Since these assays were mainly qualitative in nature an O.D 
value of < 0.5 units was therefore empirically considered to be background 
reactivity.
Allen and co-workers (1992) characterised a linear epitope in an area they 
designated EHV-1 gC domain one. This study agrees with theirs in that not all 
EHV-1 infected horses recognised this epitope. They defined this epitope as being 
type-specific but this study found that both naturally and experimentally EHV-4 
infected horses react with this epitope i.e peptide 12 representing amino acids 148- 
155 of EHV-1 gC. The reactivity of sera from horses naturally infected with EHV-
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4 could be due to a prior EHV-1 infection, however this does not explain the 
reactivity of EHV-4 infected SPF foal sera. Crabb and Studdert (1995) found that 
fusion proteins containing this region reacted with both anti-EHV-1 and -4 serum. 
Likewise, Stokes et al (1991) found that anti-peptide antibodies to the homologous 
EHV-4 region were not type-specific but this may be due to other epitopes which 
are cross-reactive contained within the peptide used for immunisation in that study. 
Furthermore, the SPF foals infected with EHV-1 show reactivity with peptide 15 
(Stokes et al., 1991), which contains the EHV-4 amino acid sequence homologous 
to the EHV-1 domain one epitope used in the aforementioned study (see chapter 
6). The apparent disparity between this study and that of Allen's can be justified 
by clarification of the definition of a type-specific epitope e.g the epitope is type- 
specific with regard to murine Mabs but is not with regard to serum from infected 
animals. The most obvious explanation for the lack of specificity in the equine sera 
is the polyclonality of the sera which probably contain antibodies with relaxed 
specificities which can recognise both homologues of this epitope.
Both the EHV-1 and -4 gC domain one regions contain previously 
uncharacterised epitopes although they may represent the epitopes recently localised 
in these regions, as alluded to earlier (Crabb and Studdert. 1995). One enigmatic 
aspect is that these epitopes were not identified by a previous study (Allen et al., 
1992). The entire EHV-1 gC amino acid sequence was represented by a set of 
overlapping peptides 20 amino acids in length. Each peptide overlapped the next 
peptide in the series by 10 amino acids. It is possible that this context in which 
the peptides were presented did not represent all serologically reactive linear 
epitopes e.g. it is likely that the first peptide in the series represented amino acids 
1-20 of the EHV-1 gC sequence; however if Allen and colleagues started the 
peptide series at any of the amino acids from 2-20 then each series would contain 
20mer peptides of different sequence. The context of the peptide series has been 
shown to be an important consideration when designing pepscan studies. Peptides 
with the maximun amount of overlap are likely to represent all linear epitopes in a 
given amino acid sequence (Geysen et al., 1987).
Allen and co-workers (1992) however did suggest that this region may 
contain multiple overlapping epitopes and certainly the clustered reactivity of some 
serum samples around groups of peptides suggests that this might be the case.
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Pepscan analysis of this region with shorter overlapping peptides with maximum 
overlap between subsequent peptides i.e each peptide in the series differs from the 
subsequent peptide by one amino acid, as in this study, should unveil the existence 
of overlapping epitopes.
Peptides 17-27 in the EHV-1 gC domain one series represent a region, 
aal53-170, which has an identical counterpart, aal70-187, in the EHV-4 gC amino 
acid sequence. Peptides from this region are the most frequently recognised by the 
EHV-1 and -4 associated sera tested. It would be interesting to assess the 
neutralising ability of antibodies directed against this region in order to determine 
what role, if any, these epitopes play in the relationship of both viruses with their 
host.
Peptides 2, 3 and 4 from the EHV-4 gC domain one sequence (aal55-162) 
could be reactive with potentially EHV-4 type-specific antibodies since these 
peptides are not recognised by EHV-1 associated SPF foal sera. Peptide 2 differs 
at only 2 amino acids when compared to the homologous EHV-1 peptide. Dolter et 
al (1992) demonstrated by site-directed mutagenesis of HSV-1 or -2 gC 
homologues that single amino acid changes result in recognition of the virus by 
type-specific Mabs against the other virus type. Therefore a peptide which differs at 
just two amino acids between the virus types might be recognised by type-specific 
antibodies However the potential diagnostic usefulness of these peptides is 
questionable given that some EHV-1 associated sera react with it, possibly because 
of prior contact with EHV-4 and more importantly, not all EHV-4 associated sera 
react with peptide 2 .
The results obtained with both EHV gB series of peptides are extremely 
difficult to interpret. Since gB was demonstrated to be the major target of the 
equine humoral immune response (Allen et al., 1992), it is possible that this region 
is saturated with linear epitopes which are recognised with varying specificities by 
different sera that could cause difficulties in defining peak reactivities in reactive 
sera.
The peptides included under the umbrella title of miscellaneous gH peptides 
were included in this analysis because they were potentially antigenic on the basis 
of computer predictions. The peptides corresponding to regions 16-39 and 22-45 of
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EHV-1 and -4 gH homologues respectively are adjacent to the signal sequence 
cleavage site. These peptides contain previously unidentified linear gH epitopes and 
therefore merit further investigation. Peptides which are most homologous between 
the virus types are the most frequently recognised — however there is one notable 
exception i.e 32474 which, although associated with an EHV-1 infection, reacts 
with an EHV-4 peptide which contains very little intertypic homology. This may be 
due to a recent exposure to EHV-4. Why the EHV-1 series seems to be more 
readily recognised than its EHV-4 counterpart could be due to many reasons, the 
most likely being that the EHV-4 epitope was fragmented or misrepresented by the 
chosen context of the peptide series or that it was less immunogenic than the 
EHV-1 epitope.
The other two peptides in this group corresponding to amino acids 274-285 
and 282-293 in EHV-1 and -4 gH homologues respectively have previously been 
shown to induce anti-EHV-1 and -4 antibodies when injected into hamsters (Onions 
et a l, 1992). In this study only one serum from a naturally infected animal, 
94538, reacted significantly with these peptides. SPF foals 12 and 13 also showed 
appreciable reactivity. As with the hamster study, where anti-EHV-4 peptide 
antibodies reacted with both virus types, the horse serum recognised both virus 
peptide homologues which, when given the level of homology, is not suprising.
Reactivity with the EHV-1 gC domain five peptides is confined mainly to 
sera derived from horses associated with EHV-1 outbreaks, although some 
associated with EHV-4 show weak reactivity. Mabs reacting with this epitope have 
been shown to be type-specific (Allen et a l, 1992). Some sera show reactivity 
with the variety of peptides chosen from EHV-1 gplO and from EHV-1 and -4 
gB. The EHV-4 gB peptide (aa508-514) does not react with EHV-1 associated 
sera, however not all EHV-4 sera recognise this peptide. These potentially represent 
previously unidentified linear epitopes.
The EHV-1 neutralising and non-neutralising peptides were previously shown 
to be antigenic in mice by Flowers and O'Callaghan (1992). Here these regions 
and their EHV-4 homologues are also shown to be immunogenic in some horses. 
Unfortunately, it was not possible to correlate the presence of neutralising 
antibodies with clinical symptoms or time of sampling. Notably, there is a striking 
consistency with which homologous peptides are recognised and this might explain
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why some SPF foals e.g. 12 and 13, recognise epitopes from a virus that has not 
been encountered before. However it must be said that some sera e.g. F6 , that 
recognise one peptide do not recognise the homologous peptide from the other 
virus. EHV-1 infected SPF foals do not contain EHV-4 neutralising antibodies yet 
FI 3 recognises an EHV-4 peptide homologous to a peptide from EHV-1 gD that 
induces EHV-1 neutralising antibodies in mice. It is possible that the antibodies 
reacting with the EHV-4 peptides are not neutralising i.e. aa4-22 of EHV-4 gD do 
not represent an EHV-4 neutralising domain. There is only 50% homology between 
the EHV-1 and -4 in this region.
Peptide 2 of the EHV-1 gD non-neutralising domain reacts with the EHV-1 
SPF sera but has only marginal reactivity with EHV-4 sera. This peptide represents 
amino acids 275-286 of EHV-1 gD and has 75% homology with the peptide 
representing EHV-4 gD amino acids 275-286. It is possible that this epitope binds
to EHV-1 type-specific antibodies in equine sera. Its diagnostic potential may be
limited since EHV-4 field sera from the same outbreak recognise a partially 
overlapping peptide and not all EHV-1 associated sera react with peptide 2 of the 
EHV-1 gD non-neutralising domain.
Overall, it remains to be seen if the analysis of the pin peptides with sera 
from naturally and experimentally infected animals identifed any peptide or peptide 
combination which could be useful for distinguishing between EHV-1 and -4 
infected horses. Certainly the peptides from the EHV-4 gC domain one series, the 
EHV-4 gB peptide (aa508-514) and the EHV-1 gD non-neutralising domain peptide 
series merit further investigation. The use of slightly larger peptides containing the 
EHV-4 gC domain one peptides and a more thorough pepscan analysis of the 
EHV-1 gD non-neutralising domain may result in the identification of peptides in
each case that may be recognised by more sera and that still retain their type-
specificity in relation to SPF foal sera.
That more potentially useful peptides were not identified may be due mainly 
to the fact that no consistent relationship could be found between infection with a 
given virus and reactivity with a given peptide. A number of factors could have 
contributed to this, namely the pre-EHV infection history of the naturally infected 
animals, the strain of the pre- and present infecting viruses, and qualitatively or 
quantitatively different immunological responses of different animals. The
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involvement of some of these factors in the unresponsiveness of the host to some 
epitopes has been suggested (Sinclair et al, 1993b).
Differences in the epitope content of different strains and also strain variation 
in the ability to augment the immune response may have been contributory factors. 
The extent of strain variation in the EHV virus population has been the subject of 
discussion elsewhere in this thesis — suffice to say that it has not been 
unequivocally proven that sufficient variation exists in the virus population to elicit 
differences between the immune responses of animals infected with different strains 
of the same virus. Consistent with this view in this study is the differences seen 
between SPF foals infected with the same virus and between animals from the 
same natural outbreak, although the latter may be affected by pre-infection history 
and by the fact that more than one strain may be present during an outbreak.
Insufficient data exists to comment on the effects of prior EHV infection on 
the initial aim of this study. Such data if it did exist would probably be extremely 
difficult to interpret in relation to reactivity with type-specific epitopes given the 
relative frequency of infection of horses, especially with regard to EHV-4.
It has been demonstrated that different horses respond differently to the same 
antigen but these studies were examining all or nothing responses or responses to a 
given epitope (Ostlund et al., 1992; Bodo et al, 1994). In this study responses to 
peptides overlapping epitopes were examined, and differences between animals 
infected with the same virus varied from differences with regard to epitope fine 
specificity to recognition or lack of recognition of an epitope. The latter could have 
been due to the insufficient overlap between peptides such that the epitope 
recognised by an animal's serum was not adequately represented. This is especially 
true for gH, gB, gplO and gD peptides. An alternative explanation may reside in 
studies with the pepscan system which have shown that closely related strains of 
mice and rabbits can differ with regard to the gross and fine specificity of epitopes 
that they recognise. Such differences are determined to some extent by genetic 
factors (Schwab et al, 1993; Su and Caldwell. 1993; Cason et a l, 1993; Qu et 
al, 1994). A similar situation might therefore extend to the thorough-bred horse 
population. However, Ostlund et al (1992) have suggested that variation between 
horses in response to a given epitope of EHV-1 is not due to similar factors e.g 
genetic, implicated in the aforementioned strain differences, but rather is an inherent
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property of the immune response of the equine population in general to EHV-1 
infection.
Although this study did not yield a desirable conclusion with respect to 
identification of type-specific linear epitopes, it did reveal valuable information with 
regard to previously identified epitopes and points to the existence of epitopes 
previously unidentified.
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Chapter Six: Evaluation of peptides representing EHV-1 and -4 gG epitopes as type.
6.1 INTRODUCTION
Of the 12 known herpes simplex virus glycoproteins only one, the HSV-2 
gG homologue, is known to be secreted. Likewise the PRV homologue gX is also 
secreted. Furthermore of all the HSV glycoproteins the intertypic differences in 
electrophoretic mobility and amino acid homology are greatest for the gG 
homologues.
A glycoprotein of 63K was initially identified in the cell culture supernatant 
of EHV-4 infected cells. This glycoprotein was detected by monospecific anti-EHV- 
4 sera from SPF foals but not by monospecific sera from EHV-1 infected SPF 
foals. This glycoprotein was assumed to be the EHV-4 gG homologue since the 
only a  herpesvirus glycoprotein homologues known to be secreted are HSV-2 gG 
and the PRV homologue gX. The gG gene was located in the Us region of the 
EHV-4 genome, the DNA sequence determined and shown to have limited 
homology with the PRV gX gene. The entire gene was expressed as a prokaryotic 
fusion protein that, like the secreted glycoprotein, reacted with EHV-4 but not 
EHV-1 monospecific antisera (Crabb et al, 1992).
Comparison of the HSV-1 and -2 gG homologues revealed that the amino 
acid identity between the glycoproteins is 45%. HSV-2 gG contains a unique 
region of 526 amino acids whereas HSV-1 has 42 unique amino acids in the same 
region (McGeoch et al, 1987). These glycoproteins have formed the basis for the 
development of a number of different serological assays to distinguish HSV-1 and - 
2 infections in humans (reviewed by Bergstrom and Trybala, 1996).
Likewise Crabb and Studdert (1993) compared translations of the EHV-4 and 
-1 (Telford et al, 1992) gG genes and found an overall identity of 56%. However 
comparison of a divergent region in the C-terminal region of the EHV-1 and -4 gG 
homologues revealed a level of identity of 21% (see figure 6.1). These regions 
representing amino acids 288-350 and 287-382 in EHV-1 and -4 gG repectively 
were expressed as prokaryotic fusion proteins and shown to react monospecifically 
with SPF foal sera. The power of these fusion proteins as antibody capture 
reagents for the serological analysis of EHV-1 and -4 epidemiology was
114
Chapter Six: Evaluation o f peptides representing EHV-1 and -4 gG epitopes as type.
demonstrated by a number of studies performed by Studdert's group. Firstly, the 
presence of EHV-1 in the Australian equine population 10 years prior to the first 
confirmed case of EHV-1 associated abortion was inferred from the demonstration 
of EHV-1 type-specific antibodies in a few horses at that time by a single-dilution 
type-specific ELISA with the aforementioned antibody capture reagents (Crabb and 
Studdert, 1993). This ELISA consistently detected the presence of EHV-1 antibodies 
after natural and experimental infections with very few exceptions. The long-term 
persistence of equine anti-EHV-4 gG antibodies relative to EHV-1 antibodies was 
thought to reflect the relative rates of reinfection/reactivation of each virus in the 
equine population (Crabb et al, 1995). Finally, a singular study demonstrated the 
clinical usefulness of the gG assay in that it was used to separate EHV-1 antibody 
positive from antibody negative mares at the onset of an abortion storm which
resulted in a significant reduction in the number of abortions in the ensuing storm
(Drummer et al, 1995).
The initial observations of Crabb and co-workers (1992) may not have been 
possible but for the availability of monospecific antisera. The sources of such sera
are maternal colostrum deprived specific pathogen free (SPF) foals. EHV-1 free
ponies were initially developed by Fitzpatrick and Studdert (1984). These animals 
offer the potential to study EHV-1 and -4 infections without the complications or 
doubt associated with the interpretation of data from non-SPF equids in which the 
effects of preinfection history are difficult to define. Studies performed with SPF 
foals and the reagents thus derived/developed continue to clarify and extend data 
concerning the immunology, latency/reactivation, diagnosis, pathogenicity and 
treatment of EHV-1 and to a lesser extent EHV-4.
SPF foals are an invaluable source of unquestionably monospecific antisera, 
the usefulness of which has already been discussed for the identification of type- 
specific epitopes.
The humoral immune response to EHV-1 in SPF foals has received much 
attention.
Two independent studies have demonstrated that antibodies of the IgM class 
are the first detected after EHV-1 infection in SPF foals and reach a peak 10-18 
days post infection (dpi) after which time IgM levels steadily decrease (Chong and
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Duffus, 1992; Gibson et a l, 1992a). IgG levels peak later than IgM levels i.e. 
after 26d.p.i and remain at very high levels. Secondary EHV-1 infection of EHV-1 
infected animals 61d.p.i did not result in changes in the levels of IgG or IgM 
detected pre-secondary infection. Virus neutralising (VN) and complement fixing 
(CF) antibodies rise in parallel with IgG levels (Gibson et al., 1992a). However 
levels of CF antibodies will begin to fall 60d.p.i (Tewari et al., 1993) unless 
restimulated by secondary infection (Gibson et al., 1992a; Tewari et al., 1993). 
Generally all foals in these studies had very little cross reactive anti-EHV-4 
antibodies, as determined by VN, CF or western blotting.
A singular study of a primary EHV-4 infection of one SPF foal demonstrated 
both weak CF and VN responses. However when this animal was infected with 
EHV-1 84 days later there was a concomitant rise in CF and VN titres to both 
virus types. Glycoproteins were only weakly labelled in western blots with sera 
obtained 15d.p.i with either EHV-1 or -4. Positive western blot staining was 
detected 82d.p.i and there was significant levels of cross reactive antibodies in the 
EHV-4 sera relative to the EHV-1 sera, as determined by western blotting (Tewari 
et al., 1993).
The SPF foal system has been central to the demonstration of changes in 
aspects of the cellular immune response to EHV-1 infection. Deficits in neutrophil 
function (Chong and Duffus, 1992) and levels (Gibson et a l, 1992a) have been 
observed. Lunn and colleagues (1991) have demonstrated a drop in the equine 
lymphocyte population that contains the cytotoxic and suppressor T lymphocytes 
upon EHV-1 infection of SPF foals. These factors may partly contribute to the 
non-specific immunosuppression seen following EHV-1 infection.
SPF foals exhibit most of the clinical signs indicative of a recent EHV-1 
infection. EHV-1 associated abortigenic disease has not been demonstrated for 
obvious reasons. Furthermore, the paralysis associated with EHV-1 infection has 
not been demonstrated in SPF foals, although pathological changes in the retina 
which may be related to the neurological manifestation of EHV-1 disease were 
detected in some animals but only after secondary infection caused by virus 
reactivation (Gibson et al, 1992a).
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Although the SPF foal system will continue to be of value a number of 
questions concerning the real value of this system remain as yet unanswered. 
Firstly it may be an oversimplification of the natural situation in that most naturally 
infected animals have the added complication of previous EHV infections. Indeed 
controversy has arisen, as referred to in chapter one, with regard to the study of 
latency in SPF foals vs. animals that may have been or may be infected with a 
number of EHVs. Secondly the system suffers from the not insurmountable 
problems of being unable to reproduce the two most important aspects of EHV-1 
induced disease, namely abortion and paralysis.
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6.2 EXPERIMENTAL APPROACHi
!
i
This chapter describes experiments designed to identify peptides which 
represent and further delineate the EHV-1 and -4 gG epitopes localised by Crabb 
and Studdert (1993). The identification of such peptides would preclude the need 
for synthesis of fusion proteins. These peptides would allow the assessment of the 
EHV-1 and -4 gG epitopes with sera from naturally infected horses from the U.K. 
and Rep. of Ireland, countries that significantly differ from Australia in terms of 
the epidemiology of EHV-1 and to a lesser extent EHV-4.
Two sets of overlapping peptides of 20 amino acids in length spanning the 
EHV-1 and -4 gG type-specific domains identified by Crabb and Studdert (1993) 
were chosen. The overlap between subsequent peptides in each series was 10 
amino acids.
Two peptides from EHV-4 gC were also included in this study. Hamsters 
immunized with these peptides were shown to contain antibodies to both EHV-1 
and -4 (Stokes et al., 1991). One of these peptides, peptide 15, was recognised by 
sera from naturally and experimentally infected horses whereas the other peptide, 
peptide 14, was not reactive with the limited number of sera tested (Unpublished 
observations). Peptides 15 and 14 were therefore included in this study as it was 
thought that these peptides might represent positive and negative peptide controls, 
respectively.
All peptides were probed with SPF foal and naturally infected animal sera. 
SPF foals were subjected to a primary and secondary EHV-1 infection or a 
primary EHV-4 followed by a secondary EHV-1 infection. Serum samples were 
from defined days post primary or secondary infection. These samples allowed the 
EHV-1 and -4 gG peptides to be assessed under conditions which had not been 
clearly addressed by the studies performed by Studdert's group.
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6.3 MATERIALS
6.3.1 SERA AND PLASMA
The sera and antibodies listed in tables 6.1 and 6.2 were obtained from the 
same sources as listed in Chapter 5 section 5.3.
6.3.2 PEPTIDES
The peptides illustrated in figure 6.2 were synthesised by Alta Biosciences, 
University of Birmingham as free acids. Peptides were supplied lyophilised.
6.3.3 REAGENTS AND PLASTICWARE
See chapter 4 for recipes for coupling/coating buffer and TBS.
Superblock in TBS was obtained from Pierce Chemical Co., UK.
ELISA wash buffer was TBS containing 0.5% Tween 20.
The ELISA substrate was stabilised TMB from Sigma.
Immulon 1 and 2 microtitre dishes were obtained from Dynatech LTD., U.K.
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6.4 METHODS
6.4.1 SOLUBILISATION OF FREE PEPTIDES
Free peptides were supplied in solid form by the manufacturer. 500ul of 
sterile distilled water was added to each peptide. Solutions containing insoluble 
peptides were incubated at 55°C for 30 minutes and agitated from time to time. 
Those peptides which were water insoluble were subjected to the solubilisation 
procedure outlined in the applied biosystem's flow chart for peptide solubilisation 
(Figure 6.3)
All peptides were brought to a final volume of 1.0ml with water.
6.4.2 ESTIMATION OF PEPTIDE CONCENTRATION
Peptide concentration was estimated by two methods. Peptide gC 15 had been 
produced in milligram quantities so it was possible to prepare from it a standard 
solution containing a precise amount of peptide.
All peptides were diluted 1/100 in 500ul of water and the O.D280nm measured 
with a UV spectrophotometer which had been calibrated with water.
The Pierce BCA protein assay kit was also used to assess peptide solubility. 
The standard protocol provided by the manufacturer was followed.
Peptide gC15 was used as the standard and serial dilutions ranging in 
concentration from 100ug-0. lug/ml were made. Neat and 1/500 dilutions of all 
other peptides were assayed. Reactions were carried out in a 96 well microtitre 
plate. 200ul of freshly prepared working reagent was added to lOul of each peptide 
and the dilutions thereof. A blank consisting of water was also included. The plate 
was then incubated at 37°C for 30 minutes with gentle agitation. At the end of the 
incubation period the plate was equilibrated to room temperature and the O.D562nm 
of each well measured.
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6.4.3 PEPTIDE ELISA
0.5ul of each peptide >500ng in lOOul of coating buffer was added to each
well of immulon 2 microtitre plates. This was performed in duplicate for each
peptide. Plates were incubated overnight at 4°C.
After washing the plates three times with wash buffer using an automatic 
plate washer, blocking was performed with Superblock in TBS according to the 
manufacturer's instructions. The plates were washed once as before.
Equine serum was diluted 1/100 in Superblock containing 0.5% tween 20 and 
lOOul was added to each well. Plates were then incubated at room temperature for 
1 hour.
After washing the plates 6 times lOOul of goat anti-equine IgG (y chain 
specific) peroxidase conjugate diluted 1/5000 in Superblock containing 0.5% tween 
20 was added to each well and the plates incubated for 1 hour at room 
temperature.
The plates were washed 6 times. lOOul of TMB substrate was then added to
each well and the substrate reaction was allowed to proceed for 15-45 minutes at
room temperature with gentle agitation. The O.D650nm of each well was monitored 
over a 45 minute period with an automatic plate reader. Each serum was analysed 
twice in this manner. The results were processed and graphs drawn with the aid of 
a Microsoft Excel 2.0 package.
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! 6.5 RESULTS
6.5.1 SOLUBILISATION AND ESTIMATION OF CONCENTRATION OF FREE 
gG PEPTIDES
Peptides showed a varying degree of solubility as determined visually. In 
some cases an insoluble residue remained even after taking all possible steps to 
effect solubilisation. All peptides gave an absorbancy reading at U.V. 280nm, equal 
to or better than the standard. A similar result was obtained with the BCA protein 
assay kit although there was not a direct correlation between the two tests. On this 
basis it was assumed that the concentration of each peptide was > lug/ul (see table 
6.3).
6.5.2 REACTIVITY OF SPF FOAL SERA WITH gG PEPTIDES
Although there was excellent agreement between duplicate values of each 
peptides reactivity with a given serum and between ELISA analysis of each sera 
performed on different days, there was a wide variation between different sera in 
terms of background reactivity. As with the pepscan analysis described in Chapter 
5, preimmune SPF foal sera could not be used as a background standard as this 
would imply that most immune sera analysed were reactive with all peptides. 
Secondly, although gC peptide 14 was considered to be a negative peptide control 
one serum actually reacted with this peptide. These differences were probably due 
to the different anamnestic responses within each semm tested and in this respect 
some preimmune SPF foal sera showed appreciable reactivity with gC peptide 15. 
The majority of data interpretation is thus qualitative and quantitative comparisons of 
different sera are tentative.
F l l  and F6 (see figure 6.4): On day 0 i.e. 2 days prior to primary 
infection, foal 11 did not react with any of the gG peptide series, although it did 
give an above background reactivity with the gC peptide 15 control. On day 11, 
post EHV-1 infection, it is obvious that the animal reacted with gC peptide 15 but 
it is very difficult to discern any specific reaction with the gG peptide series
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despite an increase in background reactivity. During the course of these animal 
experiments F l l  was replaced by F6 . 102 days after primary infection i.e. 2 days 
before secondary infection, F6 exhibited a strong reaction with the EHV-1 peptide 
series only. 26 days after secondary infection with EHV-1 F6 still reacted strongly 
with the EHV-1 series. However there was also an increase in the reactivity of this 
serum with some of the peptides from the EHV-4 gG series.
F13 (see figure 6.5). This foal had a day 0 reaction similar to that of 
F l l .  79 days after primary infection with EHV-1 i.e 2 days before secondary 
infection, F I3 reacted specifically with peptides of the EHV-1 series. 2 days after 
secondary infection with the same strain of EHV-1 there seemed to be a 30 to 
50% drop in the reactivity with the reactive EHV-1 gG peptides and with gC 
peptide 15. 26 days after secondary infection reactivity increased although, as with 
foal 6 , there was also an increase in the non-specific background reactivity with the 
EHV-4 series.
F12 (see figure 6.6): This foal had a typical day 0 reaction. 79 days 
after primary EHV-4 infection or 2 days before secondary infection with EHV-1 it 
reacted with the EHV-4 peptide series only. 4 days after the 79th day post primary 
infection and 2 days after an EHV-1 challenge there was a significant drop in 
reactivity with these peptides. 10 days later the reactivity with these peptides had 
increased but there was no reactivity with the EHV-1 series, indicative of a recent 
EHV-1 infection. 26 days after secondary infection there was again a slight 
decrease in the reactivity with the EHV-4 peptide series and again no reactivity 
with the EHV-1 gG series.
F14 (see figure 6.7): This foal had a day 0 reaction almost identical to 
that of F l l ,  F I3 and F I2. 79 days after primary EHV-4 infection and 2 days 
before secondary infection with EHV-1, F14 reacted with peptides from the EHV-4 
series but also reacted with one peptide from the EHV-1 series. 12 days after 
secondary infection with EHV-1 this foal still showed reactivity with the EHV-4 
series which seemed stronger than the reactivity of the serum sampled 14 days 
earlier. A similar increase in reactivity with the EHV-1 peptide 2 was also seen. 
This foal did not demonstrate any reactivity similar to that of other animals 
experimentally infected with EHV-1 in this study.
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6.5.3 REACTIVITY OF FIELD SERA WITH gG PEPTIDES
22460 (see figure 6.8): This serum showed a reactivity typical of an 
animal which had a prior EHV-4 infection. The serum was derived from an animal 
in-contact with a mare suffering from respiratory symptoms indicative of an EHV-4 
infection.
21196 (see figure 6.8): This horse was a cohort of 22460. Its serum 
reacted similarly to that derived from 22460. Interestingly, this serum also reacted 
with gC peptide 14 which was considered to be a negative control.
21179 (see figure 6.8): This serum was from an animal in-contact with 
the same mare as 21196 and 22460. It reacted with the EHV-4 gG peptide series 
but also with EHV-1 gG peptide 7, an interesting result considering its C.F. titre is 
greater for EHV-1 than -4.
21546 (see figure 6.8): This serum does not react with any of the gG 
peptides but does react with gC peptide 15. It is a serum from an animal in­
contact with EHV-4 respiratory diease.
94538 (see figure 6.8): This serum was derived from a horse from 
which EHV-4 had been isolated. It shows a reactivity profile indicative of contact 
with EHV-4.
30645 (see figure 6.9): This serum was obtained from a horse in-contact 
with a mare which had aborted, the likely cause being EHV-1. The semm reacted 
strongly with peptide 6 indicative of contact with EHV-1. However, unlike the SPF 
foals, it did not react with peptide 3 in the EHV-1 gG peptide series. It also 
demonstrated a strong anti-EHV 4-like reactivity.
32474 (see figure 6.9): This horse was in-contact with the same mare as 
30645. It had a higher C.F titre than 30645. It seemed to have a slightly different 
EHV-1 peptide specificity than 30645 and like 30645 reacted with the EHV-4 
peptide series.
84568 and 84890 (see figure 6.9): These horses were in-contact with 
horses suffering from the neurological form of EHV-1 disease. After confirmation 
of EHV-1 infection all horses were vaccinated with Pneumabort. Although both
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horses show evidence of contact with EHV-4 it is very difficult to discern if the 
sera reacted with the EHV-1 gG peptide series. 84568 also does not react strongly 
, if at all, with gC peptide 15 which is in agreement with the EHV-4 gC pepscan 
results for this serum (see chapter 5).
84694 (see figure 6.10): This animal was associated with EHV-1 but, 
like 84588 and 84890, it is difficult to decide if its serum reacted with EHV-1 
peptides although it reacted strongly with the EHV-4 gG peptide series. This sera 
reacts with gC peptide 15 in contrast to the pepscan results for this serum. 
However, a lower dilution (1/100) of this serum was used for assaying gC peptide 
15 than was used for pepscan (1/2500).
83451A and 83643C (see figure 6.10): These are paired acute and 
convalescent serum samples from a horse in-contact with animals suffering from 
EHV-1 induced neurological symptoms. The acute sample had a low C.F titre 
whereas the convalescent sample had a high titre. Both samples gave a similar 
reactivity pattern which was comparitively weak. There was no discernible pattern 
indicative of EHV-1 infection although both samples were weakly reactive with 
peptide 2, not unlike SPF foal 14.
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EHV-4 gG MLAVGATLCL LSFLTGATGR LAPDDLCYAE PRKTGPMPRS KPKHQPLLFE 50
EHV-1 gG MLTVLAALSL LSLLTSATGR LAPDELCYAE PRRTGSPPNT QPERPPVIFE 50
Consensus ML.V.A.L.L LS.LT.ATGR LAPD.LCYAE PR.TG..P.. .P...P..FE 50
EHV-4 gG APKVALTAES KGCQLILLDP PIDMGYRLED KINASIAWFF DFGNCRMPIA 100
EHV-1 gG PPTIAIKAES KGCELILLDP PIDVSYRRED KVNASIAWFF DFGACRMPIA 100
Consensus .P..A. .AES KGC.LILLDP PID..YR.ED K.NASIAWFF DFG.CRMPIA 100
EHV-4 gG YREYYDCVGN AIPSPETCDG YSFTLVKTEG WEFTIVNMS LLLQPGIYDS 150
EHV-1 gG YREYYGCIGN AVPSPETCDA YSFTLIRTEG IVEFTIVNMS LLFQPGIYDS 150
Consensus YREYY.C .GN A .PSPETCD. YSFTL..TEG .VEFTIVNMS LL.QPGIYDS 150
EHV-4 gG GSFIYSALLD MDVLTGRVIL NVENDTNYPC GMTHGLTADG NINVDET-TH 199
EHV-1 gG GNFIYSVLLD YHIFTGRVTL EVEKDTNYPC GMIHGLTAYG NINVDETMDN 200
Consensus G.FIYS.LLD_____TGRV.L .VE.DTNYPC GM.HGLTA.G NINVDET... 200
EHV-4 gG TTPHPRAVGC FPELINFDAW ENVTFEEMGI PDPNSFLDDE SDYPNTMDCY 249
EHV-1 gG ASPHPRAVGC FPEPIDNEAW ANVTFTELGI PDPNSFLDDE GDYPNISDCH 250
Consensus ..PHPRAVGC FFE.I...AW .NVTF.E.GI PDPNSFLDDE .DYPN..DC. 250
EHV-4 gG 
EHV-1 gG
Consensus
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Figure 6.1: Alignment of EHV-1 and -4 gG homologues.
Boxed regions were chosen for pepscan
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Solubility in Water
Attempt to solubilise peptide initially in water.
Insoluble in water
Calculate total charge on each peptide
Assign a -1 to each acidic residue (Asp, Glu and 
C-terminal -COOH)
Assign a +1 to each basic residue (Arg, Lys, His and 
N-terminal -NH2)
The remaining groups are neutral and therefore have a 0 
charge
Overall charge of peptide 
a positive number
Overall charge of peptide 
a negative number
Overall charge of peptide 
is zero
Add Acetic acid up to a concentration of 10%
Acid insoluble
If peptides are insoluble in water or acidic solution, centrifuge and remove solution 
which will be added as diluent in the following solubilisation procedures. Freeze 
dry the insoluble precipitate._________
Add TFA (<50ul) and 
dilute to 1ml with diluent
Add NH40H (<50ul) and 
dilute to 1ml with diluent.
Add acetonitrile and if
soluble slowly add diluent 
to 1ml adding more solvent 
if required______________
Figure 6.3: Peptide solubilisation flow chart
Adapted from the Applied Biosystems peptide synthesizer mauual
Figure 6.4: Reactivity of SPF foals 6 and 11 sera with gG and
gC peptides. The vertical axes are labelled O.D650nm xlOOO. The horizontal axes
are labelled in bold face according to the position of each peptide series and in
standard face according to the pepscan number of each peptide. Above each
graph; the foal number and the day of sampling of plasma relative to the day of 
primary or secondary (S) challenge are in bold followed by the virus type used 
for primary (P) or secondary (S) challenge in relief face. + = no. of days after, 
- = no. of days before infection.
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Figure 6.5: Reactivity of SPF foals 13 sera with gG and gC
peptides. The vertical axes are labelled O.D650nm xlOOO. The horizontal axes are
labelled in bold face according to the position of each peptide series and in
standard face according to the pepscan number of each peptide and this labelling 
is conserved for all graphs. Above each graph; the foal number and the day of 
sampling of plasma relative to the day of primary or secondary (S) challenge are 
in bold followed by the virus type used for primary (P) or secondary (S)
challenge in relief face. + = no. of days after, - = no. of days before infection.
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Figure 6.6: Reactivity of SPF foals 12 sera with gG and gC
peptides. The vertical axes are labelled O.D650nm xlOOO. The horizontal axes are
labelled in bold face according to the position of each peptide series and in
standard face according to the pepscan number of each peptide and this labelling 
is conserved for all graphs. Above each graph; the foal number and the day of 
sampling of plasma relative to the day of primary or secondary (S) challenge are 
in bold followed by the virus type used for primary (P) or secondary (S)
challenge in relief face. + = no. of days after, - = no. of days before infection.
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Figure 6.7: Reactivity of SPF foals 14 sera with gG and gC
peptides. The vertical axes are labelled O.D650nm xlOOO. The horizontal axes are
labelled in bold face according to the position of each peptide series and in
standard face according to the pepscan number of each peptide and this labelling 
is conserved for all graphs. Above each graph; the foal number and the day of 
sampling of plasma relative to the day of primary or secondary (S) challenge are 
in bold followed by the virus type used for primary (P) or secondary (S)
challenge in relief face. + = no. of days after, - = no. of days before infection.
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Figure 6.8: Reactivity of field sera from animals associated with
EHV-4 with gG and gC peptides. The vertical axes are labelled O.D650nm 
xlOOO. The horizontal axes are labelled in bold face according to the position of 
each peptide series and in standard face according to the pepscan number of each 
peptide and this labelling is conserved for all graphs. The serum number and 
associated virus type are positioned above each graph in bold and relief face 
respectively.
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Figure 6.9: Reactivity of field sera from animals associated with
EHV-1 with gG and gC peptides. The vertical axes are labelled O.D650nm 
xlOOO. The horizontal axes are labelled in bold face according to the position of 
each peptide series and in standard face according to the pepscan number of each 
peptide and this labelling is conserved for all graphs. The serum number and 
associated virus type are positioned above each graph in bold and relief face 
respectively.
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Figure 6.10: Reactivity of paired acute and convalescent field sera 
from animals associated with EHV-1 with gG and gC peptides. The
vertical axes are labelled O.D650nm xlOOO. The horizontal axes are labelled in bold 
face according to the position of each peptide series and in standard face 
according to the pepscan number of each peptide and this labelling is conserved 
for all graphs. The serum number and associated virus type are positioned above 
each graph in bold and relief face respectively.
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Table 6.1: Details of the SPF foal plasma used in this study.
SPF foal Time course o f 
experimental infection
Primary
challenge
virus
Secondary
challenge
virus
Samples analysed 
(Abbreviation)
11 Initially infected with 
EHV-1
EHV-1 ND Day 0: 2 days prior to 
primary infection (DO). 
Day 11: 11 days after 
primary infection (D ll)
6 Initially infected with 10^ 
PFU of EHV-1 strain 
AB-4. Received 3 
dexamethasone injections 
(2mg/Kg) over the course 
of the first 3 days of 
infection. Foal challenged 
with 107PFU of EHV-1 
strain AB-4 104 d.p.i
EHV-1 EHV-1 2 days before secondary 
infection (DS-2).
26 days after secondary 
infection (DS+26).
13 This foal had the same 
infection schedule as foal 
6 with the exceptions that 
dexamethasone was not 
administered and 
secondary challenge 
commenced 84 d.p.i.
EHV-1 EHV-1 Day 0 (DO).
2 days before secondary 
infection (DS-2).
2 days after secondary 
infection (DS+2).
26 days after secondary 
infection (DS+26)
12 Foal initially infected with 
107PFU of EHV-4 strain 
MD. Challenged with 
10^ PFU of EHV-1 strain 
AB-4 84 d.p.i.
EHV-4 EHV-1 Day 0 (DO).
2 days before secondary 
infection (DS-2).
2 days after secondary 
infection (DS+2).
12 days after secondary 
infection (DS+12).
26 days after secondary 
infection (DS+26).
14 Infection schedule identical 
to that of foal 12
EHV-4 EHV-1 Samples from the same 
days as those for foal 12 
were analysed.
Serum Titre Description Supplier
21179 (1) 640 
(4) 80
EHV-4: Convalescent serum from a 
horse in-contact with a mare with EHV-4 
respiratory disease.
AHT
21196 (1) 5: (4) 10 EHV-4: cohort serum of 21179, 22460 
and 21546.
21546 (1) 40 
(4) 160
EHV-4: cohort serum of 21196,22460 
and 21179
AHT
22460 (1) 640 
(4) 640
EHV-4: cohort serum of 21196, 21179 
and 21546
AHT
94538 No details EHV-4: serum from a horse from which 
EHV-4 was isolated.
IEC
30645 (1) 160 
(4) 80
EHV-1: convalescent serum from a horse 
in-contact with a mare which aborted an 
EHV-1 positive foetus.
AHT
32474 (1) 640 
(4) 320
EHV-1: cohort serum of 30645. AHT
84890 High titre EHV-1: serum from horse which had 
been vaccinated after contact with horses 
with EHV-1 induced paralysis.
IEC
83451A Low titre EHV-1: Acute sample from horse 
involved in an outbreak of EHV-1 
paralysis
EEC
83643C High titre EHV-1: Convalscent sample taken from 
horse from which sample 83451 was 
derived
IEC
84568 (1) 80: (4) 40 EHV-1: No details. IEC
84694 (1) 80: (4) 20 EHV-1: No details. IEC
Figure 6.2: Details of sera from naturally infected animals. IEC= the 
Irish Equine Centre, Kildare, Ireland. AHT= the Animal Health Trust, 
Newmarket, UK.
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6 .6  DISCUSSION
This study has further delineated the epitopes identified and located by Crabb 
and Studdert (1993) on EHV-1 gG homologue. There are at least two regions of 
the EHV-1 homologue that are consistently recognised and may contain one or 
more epitopes. Pepscan analysis as utilised herein may allow further definition of 
the epitopes contained within these regions.
Telford and colleagues (1998) have recently brought to attention the errors in 
the DNA sequence of the EHV-4 gG gene determined by Crabb et al (1992), the 
translation of which was utilised in this thesis for the selection of peptides for 
analysis. An alignment of the translations of the correct and incorrect sequences 
demonstrates that many of the peptides supposedly representing the EHV-4 gG 
peptide sequence of the region under scrutiny are incorrect (see figure 6.11). The 
region encompassing peptides 10 to 14 of the EHV-4 gG peptide series contains 
the most errors. It follows that these peptides do not accurately represent the EHV- 
4 gG peptide sequence and may have precluded the identification of epitopes 
contained within the correct EHV-4 gG peptide sequence. On the other hand, 
relatively short stretches of amino acids are required for the formation of linear 
epitopes and in some cases a certain degree of variation from the consensus epitope 
sequence can be tolerated (Geysen et al., 1987). There are short regions of 
consensus between the correct and incorrect sequences. Synthesis of a new EHV-4 
gG peptide series based on the correct sequence would resolve these issues.
Two peptides from the EHV-4 gG peptide series were consistently reactive 
with anti-EHV-4 sera: peptide 16 which contains no errors and peptide 13 which 
contains 8 errors out of a total of 20 amino acids. Interestingly these two peptides 
contain a core sequence (M-K-N-N-P-V/I-Y-S-E) which could represent an epitope 
recognised by anti-EHV-4 sera. Phage encoding this core sequence were purified 
using immune horse sera from an expression library of EHV-4 DNA (Wilson et 
a l, 1994).
In agreement with the study of Crabb and Studdert (1993) it was found that 
with the SPF foals, responses to the primary challenge virus seemed to drop
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iniially on secondary challenge with the heterologous but also the homologous 
vims. Whether this is due to non-specific virus induced immunosuppression, as 
previously documented for EHV-1, remains to be proven.
The ability of the gG system as utilised here to consistently diagnose EHV-1 
infection is questionable. In some experimental and naturally infected animals it was 
no possible to detect an expected reactivity with EHV-1 peptides. Similarly one 
anmal associated with EHV-4 did not react with any peptides in the gG series. 
Tvo possible reasons were initially considered; firstly, the signal to noise ratio was 
qute low in many of these cases which may have precluded the identification of 
weakly positive samples and secondly, the time at which sampling occurred may 
no: have been ideal for the detection of anti-EHV-1 reactivity. In the case of the 
anmal associated with EHV-4 it may be reactive with a peptide which was not 
accurately represented by the EHV-4 gG peptide series as alluded to earlier.
With regard to the problem of signal to noise ratio, further dilution of the 
sen in question or monitoring of the ELISA substrate reaction as it proceeded did 
no reveal positivity in any samples which were negative under the standard 
coiditions employed. Many factors have been implicated in low signal to noise 
ratos in antibody capture ELISAs. These include the overall charge of the antibody 
capture system (Pesce et al, 1986; Graves. 1988a) and non-specific binding of 
inmune complexes to the plastic surface (Cafruny et al, 1986). The contribution of 
caionic peptides to the high background observed herein was not investigated, but 
it may have been pmdent to include an anionic matrix coat to reduce non-specific 
biiding of serum to cationic peptides (Graves. 1988b). Notably, the majority of 
peptides in the EHV-1 gG series are anionic in terms of overall charge. Of 
paticular note in the gG ELISAs was the increased background reactivity in SPF 
foil sera that reacted strongly with peptides diagnostic for infection. Although 
supposition, this may reflect the development of immune complexes. Immune 
complexes have been demonstrated in animals suffering from the paralytic form of 
EIV-1 induced disease (Edington et al, 1986). The microtitre plates used in the 
gO ELISAs were shown to bind immune complexes (Cafruny et al, 1986). To 
cicumvent the potential contribution of immune complexes in the equine sera 
diferent plates, namely immulon I, were used and Tween 20 was added to all 
diuted antibodies at a concentration of 0.5%, as was EDTA and EGTA, both at a
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concentration of 7.5mM. These latter two precautions have been shown to reduce 
non-specific binding of serum proteins in ELISAs (Cafruny et al, 1986; Nielsen et 
al, 1994). None of the precautions taken made a significant difference to the 
overall results. A point of potential relevance was the demonstration that preimmune 
SPF foal sera prepared in Glasgow Vet school from plasma supplied by Cambridge 
Vet school reacted strongly with all pepscan peptides (see chapter 5) but not with 
the gG peptides. It seems likely that the procedures used in Glasgow did not 
efficiently remove many of the clotting factors which could have decreased the 
signal to noise ratio or masked potentially weak reactivity with the EHV-1 gG 
series. Crabb et al (1995) demonstrated that positive sera and plasma from a given 
horse gave identical results in the gG fusion protein ELISA.
Those SPF foals which were positive for EHV-1 were sampled 79 days after 
primary infection and unfortunately, earlier samples were not analysed which may 
have shed light on the problem. In this respect foal 11 was analysed 11 days post 
infection and foals 12 and 14 were tested 2, 12 and 26 days after secondary 
infection. It is possible that in the case of foal 11 and foal 12 and 14 on days 2 
and 12 postinfection that these animals had not yet seroconverted. Seroconversion 
in general occurs 14d.p.i in EHV-1 infected SPF foals (Gibson et a l, 1992a; 
Tewari et a l, 1993). The majority of animals which were EHV-1 gG antibody 
negative at the time of diagnosis of the index case in an EHV-1 associated abortion 
storm had not seroconverted by day 13 post index case but were positive 54 days 
later (Drummer et a l, 1995). Seroconversion may have been detected earlier if 
samples were available or alternatively, these animals may not have necessarily been 
infected at the exact time of the index case. During an abortion storm EHV-1 
antibodies were detected in mares 2 days prior to the index case but it is not 
known when these animals developed an active infection. Notably 7/31 in-contact 
mares in that outbreak remained seronegative for EHV-1 as determined by gG 
ELISA (Drummer et al., 1995). On the other hand EHV-1 gG antibodies were 
detected in sera from experimentally infected animals as early as 21 days post 
infection (Crabb et al., 1995). In the case of animals that were initially infected 
with EHV-4 it is possible, given the lower sensitivity of the assay for detecting 
EHV-1 antibodies (as determined by lower peak O.D values), that EHV-1 gG 
antibodies may not be detected in dual infected animals, as was suggested for gG 
serodiagnosis of dual HSV-1 and -2 infections in humans (Ho et al, 1993).
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Detection of EHV-1 antibodies in an SPF foal 3-5 months after primary EHV-4 
infection, 1-2 months after secondary EHV-1 infection, was not problematic (Crabb 
and Studdert, 1993). In contrast a recent evaluation of different gG diagnostic 
systems for the herpes simplex viruses of humans has demonstrated that some 
individuals who were initially seropositive can become seronegative over time. There 
was very little agreeement between the different systems concerning an individuals 
shift from seropositivity to seronegativity. Furthermore, the results, as yet , have 
only been demonstrated for a defined group of individuals (Schmid et al., 1999).
Both Crabb and Studdert (1993) and this study imply that infection with 
either EHV-1 or -4 can suppress the immune response to gG epitopes. Given that 
the responses to the EHV-1 gG peptide series were relatively weak it is possible 
that during the initial stages of infection the weak response is suppressed to levels 
not detected by ELISA. It has been suggested that the problem of weak or false 
positives be addressed by the utilisation of a western blot system based on gG 
(Crabb and Studdert. 1993).
Another valid reason which was discussed in chapter 5 in relation to the 
pepscan system is that the epitopes recognised by these sera are not adequately 
represented in the peptide set.
Some EHV-1 associated field sera did not react appreciably with the EHV-1 
series. Again many of the reasons proposed for the unresponsiveness of the SPF 
foal sera are also applicable to the field sera. Field sera reactivity may also be 
influenced by the possible existence of EHV-1 gG strain variants. However, in 
Australia at least, this does not seem to be the case for either EHV-1 or -4, as 
inferred from the consistent serological reactivity of sera from different outbreaks 
with the gG fusion protein. This however does not preclude the possibility that 
specific epitopes within the fusion protein are strain specific. If there are strain- 
common epitopes on the fusion protein then most, if not all, strains will be 
detected.
Another worrying factor with regard to the use of this system as a diagnostic 
aid was the spurious reaction of F14 with an EHV-1 peptide which was recognised 
by only one EHV-1 infected animal, 83451. This may be an inherent reactivity 
within the serum not associated with an encounter with EHV-1. Alternatively, this
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could be the converse example of the relatively rare anti-EHV-4 gG cross reactivity 
in anti-EHV-1 sera (Crabb et al., 1995).
Many of these problems, particularly with regard to field sera, could also 
conceivably relate to the different epidemiology of EHV-1 in the British Isles 
compared to that of Australia. EHV-1 has been present in these islands significantly 
longer than in Australia. The immune response of horses from the British Isles 
could have evolved such that some animals do not recognise these linear EHV-1 
gG epitopes.
The acid-test which would address many of the aforementioned problems 
would be to subject the sera utilised herein to the system developed by Crabb and 
Studdert (1993) to ascertain if the peptides do not contain the epitopes, or do not 
contain them in the correct context, and if the spurious reactions and unreactivities 
were unique to the peptide system.
This study successfully identified peptides representing EHV-1 and -4 type- 
specific gG epitopes. The identification of these peptides represents the first step in 
making the EHV-1 and -4 type-specific serological test developed by Crabb and 
colleagues easily available. However a number of problems must be addressed 
before the peptides could be employed in routine diagnosis of EHV-1 and -4 
infections.
130
Chapter Seven
General Discussion and Concluding Remarks
Chapter Seven: General discussion and concluding remarks
7.1 DISCUSSION
The two main aims of the research described in this thesis were to identify a 
virus encoded marker for neurovirulence in EHV-1 isolates and a serological test 
that could definitively distinguish between EHV-1 and -4 infected horses. 
Unfortunately these aims were not realised but nonetheless the research dictates 
further studies and points to future directions in order to solve these perplexing 
challenges in the study of EHV biology.
The sequence analysis of the N-terminal coding region of the gC gene of 
nine epidemiological distant isolates of EHV-1 revealed total inter-strain conservation 
in the glycoprotein amino-acid sequence. This conflicting result was further 
confused by the fact that at least one isolate, namely T373, was expected to 
contain sequence variation on the basis of Mab typing studies (Allen et al., 1988) 
but did not. A number of possible reasons were put forward in chapter three but 
were not proven by the research described in chapter four. Resolution of this issue 
will first require the repetition of the Mab typing of T373 as described by Allen et 
al (1988) and an extension of the gC study.
Extension of the gC study would require the analysis of a large number of 
EHV-1 isolates. Given the relatively low level of inter-strain variation reported in 
this thesis and described recently by others using RFLP analysis of different 
regions of the EHV-1 genome, DNA sequencing would become a cost ineffective 
method of defining variation. The introduction of a pre-screening method to first 
identify the presence of a mutation in a PCR product derived from an isolate, 
followed by sequencing if differences were detected, would be a more economic 
approach. SSCP analysis as described in chapter four is one possible approach, 
however it would require the amplification of the region of interest in small 
overlapping sections to allow an optimal mutation detection rate. Alternatively the 
combined use of SSCP and RFLP analysis of larger fragments is a feasible option. 
In recent years with the development of PCR a variety of mutation detection 
methods have been utilised to detect mutations in PCR products. Some of these, 
particularly denaturing gradient gel electrophoresis (DGGE) (Sheffield et al., 1989)
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and enzymatic methods (Myers et al, 1985; Ganguly and Prockop. 1990; Ellis et 
al, 1994), are well suited for the analysis of EHV-1 gene size PCR products. 
DGGE and the similar temperature gradient gel electrophoresis (TGGE) have not 
been widely adopted as mutation detection systems because of the necessity to 
specially adapt pre-existing electrophoresis equipment. Wider application of these 
techniques may be seen with the introduction of the first commercially available 
system from Biorad. Herpesviruses such as EHV-1 and -4 and their genes may be 
particularly suited to these mutation detection systems because of their relatively 
high GC base composition. One relatively simple system which seems to have gone 
unrecognised by the wider scientific community is known as low-stringency single 
specific primer PCR (LSSP-PCR). The system developed by Pena and co-workers 
(1994) involves subjecting a PCR product or DNA fragment of interest to a PCR 
which contains high concentrations of a single specific oligonucleotide primer and 
of Taq DNA polymerase and involves thermal cycling with relatively low annealing 
temperatures. Analysis of the PCR should reveal a complex banding pattern or 
fingerprint that will differ between templates with only single base differences.
The serological studies were not unlike the preceding gC study with regard to 
odd results, the most enigmatic being that of serum 94538. A complete chemical 
and physical analysis of this serum and its individual constituents may give clues 
as to its bizarre properties. One possible approach would be to study the interaction 
of this serum with appropriate antigens utilising plasmon surface resonance 
technology. Biosensors based on this technology allow the rapid determination of 
many of the parameters governing antibody antigen interactions in real time (Morgan 
et al, 1998 and references therein), however it remains to be seen if these systems 
will be suitable for the detailed analysis of polyclonal antiserum.
The failure to identify a suitable diagnostic peptide or peptide combination
was tempered by the identification of previously unknown linear epitopes and the
confirmation that previously identified epitopes are also recognised by sera from
affected animals. That these epitopes are specific for either EHV-1 or -4 will
require further confirmation since the pepscan method can give rise to spurious 
results. Indeed all the pepscan results ideally should have been confirmed by 
repeating the analysis of each serum after it had been pre-adsorbed with the virus 
antigen with which it is associated (Schwab et al, 1993). Further confirmation and
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an extension of the findings of the pepscan analysis would be achieved by 
synthesizing a more representative set of peptides for those regions that gave 
extremely variable results or in the case of newly identified epitopes, the synthesis 
of fusion proteins encompassing the regions in which the peptides are located. 
These approaches might eventually lead to the detection of reactivity in animal 
serum previously not shown to react with the peptides derived from these regions. 
Furthermore the assessment of the importance of these new epitopes with regard to 
host control of infection would be of interest.
The gG diagnostic system is certainly of great retrospective epidemiological 
value. Its usefulness in a clinical laboratory remains unclear. The study described in 
this thesis dictates that a detailed analysis of the time course of the immune 
response to the EHV-1 peptides of serum from experimentally infected animals 
needs to be addressed. If this yields negative results then a more extensive set of 
peptides representing the EHV-1 region will have to be synthesized and assessed. 
Alternatively, proteins closely matching the native EHV-1 and -4 gG glycoproteins 
could be expressed and purified from the Baculovirus (Sanchez-Martinez et al., 
1991) or Yeast (Scorer et al., 1993) based expression systems such that the type- 
specific conformational epitopes referred to by Crabb and Studdert (1993) might 
become available for assessment as clinical diagnostic tools. Diagnosis may be 
further enhanced if the detection of type specific IgM responses to these proteins 
were identified and analysed as has been described for HSV-2 (Ho et al., 1992). 
Although not documented in this thesis one attempt was made at identifying IgM 
responses in SPF foals to the EHV-1 and -4 gG peptide series albeit without 
success.
In conclusion, there may be some overlap between the gC sequencing and the 
pepscan studies which may be of significance in relation to the biology of EHV-1 
in particular. Horses are generally susceptible to reinfection six months after a 
previous episode of EHV-1 infection. The studies described here show that different 
horses, even those that are blood relatives and infected with the same strain, show 
qualitative and quantitative variability in the fine specificity of the epitopes that their 
serum recognises. Whether this is also tme of conformational epitopes remains to 
be proven. However it might be postulated that given the relative weakness and 
inconsistency of the equine immune response to EHV-1 that, contrary to accepted
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concepts for other host-virus relationships, EHV-1 is not under immunological 
pressure to evolve. Therefore there is little if any inter-strain variation in these 
viruses, gC being a case in point. Indeed the recent discovery that EHV-1 encodes 
a VHS protein which does not function in vivo (Feng et al., 1996) may provide 
the answer as to why this is so. This discovery presents the possibility that host 
enzymes may still be available to correct errors made during the replication of 
EHV-1 DNA, thus leading to a lower virus mutation rate.
Given that the differences between strains of EHV-1 are relatively small it is 
likely that the viral determinants of whether a given strain will give rise to the 
paralytic syndrome characteristic of some EHV-1 infections are probably very 
elusive indeed. It is now recognised that there is probably a spectrum of 
pathogenicity in the natural EHV-1 and -4 strain populations. The two extremes of 
this spectrum, namely low and high pathogenic isolates, will probably form the 
basis of the most constructive means of identifying the virus determinants of 
pathogenicity in general and neurovirulence in particular. Molecular methods are 
already at hand to dissect these isolates e.g. by the deletion of specific genes and 
the interchange of genomic regions between isolates of well defined, albeit greatly 
different, pathogenic potential (Van Zijl et al., 1988). The introduction of these 
mutant and chimeric viruses into the natural host and other model systems should 
yield valuable data. These approaches will most likely identify the regions of the 
virus genome involved in determining a viruse's pathogenicity but this will 
ultimately have to be extended to the general strain population. An approach similar 
to that outlined earlier for the extension of the gC study i.e the prescreening of 
regions of interest from different strains for the presence or absence of mutations 
would be applicable.
An alternative approach to identifying strain specific markers of neurovirulence 
which does not rely on prior knowledge of the genes that are potentially involved 
is to fingerprint a large number of isolates using the new generation of 
fingerprinting techniques. These techniques include the widely used random 
amplified polymorphic DNA (RAPD) analysis system (Williams et al., 1990) and 
the combined RFLP/SSCP approach referred to earlier. Such systems could be used 
in combination with XL PCR (Barnes. 1994) to exclude regions of the virus 
genome which are inherently unstable i.e. the repeat regions that may provide
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undue interference in such analyses. This is not to say that the repeat regions do 
not play an important role in the determination of a viruses pathogenicity. These 
areas tend to have complex transcriptional activity and also may affect viral 
replication.
Recent advances in DNA chip technology (for a review see Lipshutz et al., 
1999) might permit the identification of all types of genomic polymorphisms within 
the genome of any EHV-1 strain. This would involve the production of DNA chips 
containing the entire prototypic EHV-1 genome represented as small oligonucleotide 
sequences. High stringency hybridisation of these chips with a probe representing 
the entire genome of any strain should reveal polymorphisms within that strain 
relative to the prototypic virus. A comparison of the hybridisation pattern of probes 
generated from different strains would allow the identification of regions of the 
EHV-1 genome that are particularly polymorphic that have yet to be identified by 
current technologies.
In the age of molecular biology the power of basic techniques tends to be 
overlooked. An interesting yet to be published experiment would be to assess the 
yield of different EHV strains of varying pathogenicity from various cell types in 
order to achieve some idea of their relative replication rates. This alone may have a 
major influence on whether a virus reaches a particular tissue in sufficient quantities 
to exert its pathogenic effect. A more advanced version of this experiment would 
be to fingerprint e.g. by differential display reverse transcriptase PCR (ddRTPCR), 
a variety of different cell types infected by a variety of EHV isolates of varying 
pathogenicity to elucidate what effects, if any, different strains have on transcription 
in different cell types and vice-versa. The findings of this study could then be 
extended to the natural host via in situ PCR or hybridisation studies. ddRTPCR 
has recently been used for the preliminary characterisation of changes in cellular 
gene expression on infection with PRV (Hsiang et al, 1996).
The viral determinants of pathogenicity have been a focus of this thesis but 
host factors cannot be excluded. Although there may be a spectrum of pathogenic 
potential in the natural virus population it is likely, given that recent studies have 
found little variation at the molecular level in the virus population, that the majority 
of viruses have roughly equal pathogenic potential and in most cases that it is the 
interplay between virus and host that determines the outcome of a given infection.
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Two independent studies have indicated that pregnancy may predispose mares 
to the paralytic syndrome associated with EHV-1 infection. The factors e.g. 
hormonal control of immune responses, that may be at work here and how they 
may relate to the same syndrome in affected non-pregnant mares and stallions 
remain elusive. The inference of the involvement of the immune response gains 
further support from the idea that damage to nervous tissue may be elicited by 
immune effector mechanisms e.g. immune complexes. Furthermore it has been 
demonstrated that at least one cytokine, namely TGF-6 , is directly involved in the 
immunosuppression induced by EHV-1 (Charan et al, 1997). It follows that some 
animals, that may have genome encoded anomalies in related aspects of the 
cytokine network, may be more or less susceptible to EHV-1 induced disease. A 
recent study of HSV-1 in an animal model system has suggested that the antibody 
response to virus has a major influence on the ensuing pathology of a HSV-1 
infection. In this case the immune system controlled the spread of virus to the 
sites where the virus would normally cause damage rather than playing an active 
positive role in the generation of pathology (Mitchell and Stevens. 1996). It 
remains to be seen whether it is the infecting strain, the host or both that 
determines the effect of the immune response. Indeed, results in this thesis suggest 
that there are differences between the antibody response of different yet related 
animals infected with the same strain of virus. One possible approach to further 
investigate this problem would be to use expression or random peptide libraries 
(Cwirla et al, 1990; Scott and Smith. 1990) to establish a large bank of epitopes 
recognised by pools of animal serum, then to utilise these banks to establish 
epitope profiles of sera from animals associated with different manifestations of 
EHV-1 infection. Incidently, this technology could also be employed to identify 
peptides or epitopes useful for the differentiation of EHV-1 from EHV-4 infected 
horses.
The advance of the human genome project has spawned many studies 
investigating the genetic susceptibility to infectious diseases. These studies by their 
very complex nature require very dense genetic maps (Dib et a l, 1996). The 
equine research community has already taken the first steps in identifying some 
genetic markers based on micro- and mini-satellite repeat sequences (Van Haeringen 
et a l, 1998; Coogle et a l, 1996 and references therein) which may eventually
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provide some evidence for the involvement of genetic factors in determining the 
outcome of an EHV-1 infection.
Finally most of the possible avenues described above will be of no use if 
detailed epidemiological data is not available to complement such studies. In a 
recent review Powell (1992) called for a more structured approach to 
epidemiological studies of equine infectious diseases. He states that:
"The recognition of the frequent multifactorial nature of disease aetiology, the 
significance of subclinical disease as it affects performance and the need to 
understand the methods by which pathogens are disseminated have increased 
the necessity for epidemiological studies.”
This sentiment is particularly true of the studies of EHV-1 and -4 especially with 
regard to their involvement in the development of unusual or relatively rare diseases 
in the equine.
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